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CHAPTER I 
Introduction 
 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder 
affecting about 4 million people worldwide, which is expected to double by 2030 
(Dorsey et al. 2007). The neuropathological hallmark of PD involves the loss of 
dopaminergic neurons projecting from the substantia nigra pars compacta (SNc) to 
the striatum resulting in a depletion of striatal dopamine (DA) (Ehringer and 
Hornykiewicz 1960). The emerging cardinal motor features in patients suffering from 
PD are characterised by resting tremor, bradykinesia, rigidity, postural instability, 
“freezing” as well as loss of postural reflexes (Fahn 2003). 
The primary therapeutic treatment strategy involves the restoration of dopaminergic 
neurotransmission in the basal ganglia motor loops. Many dopaminergic drugs are 
currently available but L-3,4-dihydroxyphenylalanine (L-DOPA) continues to be the 
most effective pharmacological treatment strategy, which counteracts all major 
symptoms of PD. However, L-DOPA therapy often has to be curtailed due to the 
development of debilitating treatment limiting side effects such as wearing off 
phenomena and other motor complications such as dyskinesia. L-DOPA-induced 
dyskinesia is characterised by abnormal involuntary movements mainly comprising 
an idiosyncratic mixture of choreic and dystonic movements. Dyskinesia is developed 
progressively over time and 40 % of PD patients are adversely affected by dyskinesia 
within 4 – 6 years following initiation of L-DOPA treatment (Ahlskog and Muenter 
2001). Dyskinesia was found to be associated with a substantial increase of health 
care costs in PD patients, rising from !11 412/year in patients with no dyskinesia to 
!24 990/year in those with severe dyskinesia (Pechevis et al. 2005). The costs were 
more pronounced for non-medical costs (e. g. social and carer services) rather than 
for medical costs. Induction of L-DOPA-induced dyskinesia is mainly associated with 
risk factors such as the degree of dopaminergic neurodegeneration within the basal 
ganglia motor loops, which is equivalent to the severity of the disease (Obeso et al. 
2000b), the dose and beginning of L-DOPA therapy (Rascol 2000) as well as the 
young onset of PD (Kumar et al. 2005).  
L-DOPA-induced dyskinesias can be classified into three different patterns (Obeso et 
al. 2000a): 1) The most common form called peak-dose or “on”-period dyskinesia 
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most severely occurs during the two hours following exogenously applied L-DOPA 
reflecting the maximum plasma and brain levels of L-DOPA, which in parallel results 
in a drug-induced relief in motor response (Nutt 1990). 2) Diphasic dyskinesia mainly 
comprises stereotypic movements of the lower extremities and tends to appear both 
prior to the maximum L-DOPA response as well as when the therapeutic effect of L-
DOPA wears off. 3) “Off”-period dystonia consists of painful dystonic muscle cramps 
affecting different segments of the body such as feet, arms and face and can result in 
a sustained abnormal posture. 
Alternative pharmacological approaches to the use of L-DOPA for the treatment of 
PD patients include administration of DA agonists and compounds affecting the 
enzymatic metabolism of DA such as monoaminoxidase (MAO)-B or catechol-O-
methyltransferase (COMT) inhibitors. However, none of these drugs has surpassed 
the therapeutic benefit derived from the gold standard L-DOPA. Moreover, 
monotherapy with DA agonists can also induce dyskinesia in PD patients, albeit with 
a reduced incidence of motor complications (Rascol et al. 2000). 
At present, the glutamatergic non-competitive NMDA antagonist amantadine is the 
only compound which is used to alleviate L-DOPA-induced dyskinesia in patients 
suffering from PD. However, amantadine is not registered for the treatment of L-
DOPA-induced dyskinesia, this is rather an off-label use. Pharmacotherapy with 
amantadine is limited due to the development of central side effects including 
dizziness, confusion and hallucinations. There is a controversy in the literature 
concerning the duration of amantadine’s antidyskinetic effect. Stocchi et al. (2008) 
reported that the effect of amantadine is often transient and lost within 1 year, 
whereas Verhagen Metman et al. (1999) showed that amantadine’s effect on motor 
response complications is maintained for at least 1 year after treatment initiation. 
Non-pharmacological approaches for the treatment of L-DOPA-induced dyskinesia 
involve surgical interventions such as deep brain stimulation (DBS) targeting the 
globus pallidus internus (GPi) and the subthalamic nucleus (STN). The STN seems 
to be the preferred target in PD since a relief of tremor, bradykinesia, rigidity, “off” 
time as well as dyskinesia is provided (Fahn 2008). A meta analysis of the outcome 
of STN-DBS comprising 921 PD patients revealed a decrease in Unified Parkinson’s 
Disease Rating Scale (UPDRS) motor scores of 28 % (Kleiner-Fisman et al. 2006). 
Average reduction in L-DOPA equivalents and dyskinesia scores were observed to 
be 56 % and 69 %, respectively. However, alleviation of dyskinesia due to stimulation 
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of the STN is thought to simply result from the reduction of daily L-DOPA dosage 
(Follett 2004), but it is also possible that DBS of the STN provides antidyskinetic 
efficacy on its own (Fahn 2008). This is supported by a case report of Figueiras-
Mendez et al. (1999), who demonstrated a substantial improvement of dyskinesia 
following bilateral STN stimulation without a reduction of L-DOPA dosage. Surgical 
procedures are generally subjected to patients suffering from intermediate or 
advanced PD, who respond well to L-DOPA but develop severe debilitating motor 
fluctuations and dyskinesia. Only a small percentage of PD patients undergo DBS 
since neurosurgeries are associated with a substantial risk of adverse events, are 
expensive and require regular follow-up adjustments of the stimulator to maintain the 
best outcome. 
 
Animal models of L-DOPA-induced dyskinesia 
Different animal species such as monkeys, rats and mice are used to investigate 
abnormal involuntary movements or dyskinesia, which to a greater or lesser extent 
mimic dyskinetic movements demonstrated in PD patients. Peak-dose dyskinesia is 
the one subtype which is closely modelled in animals, whereas the two other forms 
are rarer or not at all represented. 
Non-human primate models show dyskinetic behaviour closely resembling that 
observed in humans. The most commonly used monkey model for L-DOPA-induced 
dyskinesia is generated by systemic administration of the neurotoxin 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) to achieve dopaminergic 
neurodegeneration and subsequent treatment with L-DOPA to induce dyskinetic 
movements (Bedard et al. 1986; Clarke et al. 1987; Pearce et al. 1995). However, 
ethical, logistical and financial considerations limit the abundant employment of 
primate models in preclinical studies. Thus, it is reasonable to perform monkey 
studies as one of the crucial steps, i. e. target validation, as well as for candidate 
selection to start pre-development. Between target validation and candidate 
selection, it is not necessary to use the monkey model.  
More accessible models to investigate L-DOPA-induced dyskinesia in early stages of 
the drug discovery process involve rodents, the use of which saw a significant upturn 
during the last decade. The unilateral 6-hydroxydopamine (6-OHDA)-lesioned rat 
dyskinesia model is popularly used to investigate either mechanisms underlying the 
induction and expression of dyskinetic behaviour (Buck and Ferger 2008; Buck and 
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Ferger 2009a; Cenci et al. 1998; Lundblad et al. 2002) or to assess potential drug 
targets (Buck and Ferger 2009b; Dekundy et al. 2007). The 6-OHDA rat dyskinesia 
model was first described by Dr. Angela Cenci in 1998 (Cenci et al. 1998), in which 
6-OHDA was unilaterally injected in the medial forebrain bundle (MFB) to destroy 
dopaminergic neurons projecting from the SNc to the striatum. In the meantime, 
some groups modified stereotaxic surgery by infusing 6-OHDA into the striatum 
(Winkler et al. 2002) or SNc in order to achieve a varying degrees of lesion. 
Dopaminergic neurodegeneration, which is achieved following 6-OHDA 
administration in the MFB, is almost complete in the SNc (Winkler et al. 2002) 
ipsilateral to the injection site resulting in an almost complete DA depletion of > 99 % 
(Buck and Ferger 2008). According to this protocol, the lesion is highly reproducible 
with a low postoperative mortality rate. Two to three weeks following the lesion 
surgery, rats are chronically treated with L-DOPA (6 mg/kg) in combination with 
benserazide (12-15 mg/kg).  
A previously published rat model for L-DOPA-induced dyskinesia is not based on 
dopaminergic degeneration but rather on the depletion of DA levels by reserpine and 
subsequent treatment with high doses of L-DOPA (Johnston et al. 2005). This 
treatment schedule led to an induction of vertical and horizontal movements. 
Antidyskinetic drugs were shown to selectively reduce vertical movements, whereas 
a reduction in horizontal activity was associated with worsening of the therapeutic L-
DOPA effect. This model is suggested for use as a simple rodent assay to screen 
potential antidyskinetic compounds.  
Dyskinetic mice can be generated by intracerebral injection of 6-OHDA followed by L-
DOPA treatment (Lundblad et al. 2004; Lundblad et al. 2005), which gives the option 
to investigate transgenic mouse lines in relation to dyskinesia. However, the 6-OHDA 
mouse model is characterised by a high postoperative mortality ranging from 30 – 82 
% depending on the injection site (Lundblad et al. 2004). In addition, there are some 
genetic mouse models of PD which were recently investigated for their ability to 
induce dyskinesia by chronic administration of L-DOPA. For example, regulator of G-
protein signaling 9-2 (RGS9-2) knock-out mice develop abnormal involuntary 
movements after treatment with reserpine or haloperidol to produce supersensitivity 
of striatal DA D2 receptors and subsequent administration of the DA D2 receptor 
agonist quinpirole and the non selective DA D1/D2 receptor agonist apomorphine 
(Kovoor et al. 2005). The more recently reported model of dyskinesia in aphakia mice 
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is due to the selective loss of dopaminergic neurons in the midbrain as a 
consequence of deletions within the Pitx3 gene and chronic L-DOPA treatment (Ding 
et al. 2007). 
 
The drug discovery process for treatment of L-DOPA-induced dyskinesia 
The in vivo drug discovery process first involves proof-of-mechanism studies to 
investigate the target of interest. The ability of tool compounds to modulate the target 
in a non-disease related model is assessed. Alterations of biochemical markers 
including changes of neurotransmitters measured by in vivo microdialysis and/or post 
mortem neurochemistry support the proof-of-mechanism study. At this early stage of 
in vivo drug testing it is advisable to screen obvious deleterious side effects of a 
compound class, e.g. by a personal observation test. Further proof-of-concept (PoC) 
experiments reveal the efficacy of the compounds in a disease-related model. The 
unilateral 6-OHDA dyskinesia model is recommended to test compounds and is 
appropriate to uncover PoC mechanisms, since the model produces a stable and 
reproducible behavioural outcome. As mentioned earlier, the 6-OHDA model can be 
applied to rats or mice. Mice bear the advantage of requiring a lower absolute 
amount of compound to be synthesised by the project chemist. However, the 
behavioural outcome seen in mice is not as clear and easy to assess as observed in 
rats. In PoC studies, tool compounds can also be administered into the ventricles via 
intracerebral cannulae if they cannot cross the blood-brain-barrier. This issue may be 
resolved by local administration of the compound into the ventricles via intracerebral 
cannulae. Finally, most promising drug candidates are screened in an in vivo testing 
procedure including a vehicle group as well as a group treated with the positive 
control amantadine. Drug testing in the dyskinesia model can be carried out using a 
cross-over design in which a sufficient wash-out phase according to the 
pharmacokinetic parameters of the compound is included and in which the animals 
are matched prior to the experiment according to their dyskinesia score to exclude 
compound effects from the last testing day. At this phase of the drug discovery 
process, it is advisable to know the pharmacokinetic parameters of the compound 
including brain or preferably CSF levels at different time points to assess the 
maximum level of the compound resulting in optimisation of the experimental design 
to get the best results. CSF levels seem to be more accurate to predict unbound drug 
concentration in the brain. Thus, CSF exposure is a relevant surrogate marker for the 
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in vivo assessment of CNS druggability (Lin 2008), which is of relevance for the 
assumption that the free drug level is sufficient for interaction with its receptor target.  
During the PoC study, not only behavioural effects of the compound should be 
monitored, but also effects on molecular markers of dyskinesia. L-DOPA-induced 
dyskinesia was found to be associated with molecular changes such as upregulation 
of striatal prodynorphin mRNA, elevated levels of phospho-extracellular signal-
regulated kinase 1/2 as well as induction of FosB-like immunoreactive proteins 
(Cenci et al. 1998; Westin et al. 2001; Westin et al. 2007; Winkler et al. 2002). 
Antidyskinetic compounds have been shown to attenuate these L-DOPA-induced 
molecular correlates (Mela et al. 2007; Rylander et al. 2009; Valastro et al. 2009).  
Furthermore, it is of fundamental importance to control confounding factors when 
drugs are tested on their ability to reduce L-DOPA-induced dyskinesia to enhance 
the predictive validity of the animal model. Recently, Jenner (2008b) emphasized that 
alterations in motor functions due to drugs causing sedation or alterations in 
cardiovascular parameters can restrain dyskinetic movements and lead to false 
positive results in the MPTP-lesioned primate model. Indeed, the same scenario can 
also be applied to the 6-OHDA dyskinesia model. Thus, a prerequisite for a reliable 
outcome of experiments investigating antidyskinetic drugs is the assessment of 
alterations in motor activity due to the drug treatment itself. In addition, an important 
issue to consider is the potential dampening effect of a compound on the beneficial 
effect of L-DOPA. Interaction with L-DOPA should be measured in behavioural tests 
such as the cylinder test, stepping test or rotational test. Results from the latter test 
are regarded to be treated carefully since an automatic rotational system cannot 
distinguish between rotational behaviour, in which the animals turn while having their 
limbs on the ground, and axial dyskinesia, in which the animals show twisting of the 
upper body. A potential interaction with the therapeutic effect of L-DOPA can be also 
detected using in vivo microdialysis measurements, in which alterations of 
extracellular L-DOPA as well as DA levels should be monitored. It is suggested that 
changes of extracellular DA levels in the striatum are analysed under conditions 
which resemble the disease state as close as possible. We have previously shown 
that extracellular DA levels in the 6-OHDA-lesioned striatum significantly increased 
following administration of L-DOPA, whereas DA levels in the intact striatum did not 
change (Buck and Ferger 2008). Thus, interaction with DA levels derived from 
exogenously applied L-DOPA can only be observed in the DA degenerated striatum. 
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Moreover, as one of the last steps before continuing with the monkey study, the 
selected drug candidate should be investigated in a chronic model to exclude effects 
of tachyphylaxy. Eventually, the successful drug candidate is tested on L-DOPA-
induced dyskinesia in the MPTP-lesioned primate model. 
 
Treatment of L-DOPA-induced dyskinesia 
There is an unmet medical need to identify novel targets for the treatment of 
dyskinesia in PD. New treatment strategies aim at non-dopaminergic pathways to 
alleviate motor complications associated with L-DOPA therapy, whilst maintaining the 
anti-parkinsonian effect of L-DOPA. Currently, several approaches have been 
evaluated in clinical trials such as adenosine A2a antagonists, 5-HT1A agonists, 
mGluR5 antagonists, NMDA antagonists, MAO inhibitors and "2 adrenoceptor 
antagonists which aim to treat symptoms of PD and L-DOPA-induced dyskinesia or 
at least try to avoid dyskinesia (please see figure 1 and table 1). 
Currently, the NMDA antagonist amantadine is the only clinically used compound for 
the treatment of L-DOPA-induced dyskinesia. Amantadine has shown antidyskinetic 
efficacy in the MPTP-lesioned primate model (Blanchet et al. 1998; Hill et al. 2004; 
Visanji et al. 2006) as well as in the 6-OHDA-lesioned rat (Buck and Ferger 2009b; 
Dekundy et al. 2007; Lundblad et al. 2002) and mouse (Lundblad et al. 2004) 
dyskinesia model suggesting a high predictive validity of these models in the case of 
amantadine. However, treatment with amantadine is limited due to the development 
of psychiatric side effects. Accordingly, amantadine exacerbated psychosis-like 
behaviour induced by L-DOPA in the MPTP-lesioned primate model (Visanji et al. 
2006). The NMDA antagonist Neu120 (Neurim Pharmaceuticals) is currently in a 
phase II clinical trial, the results of which are not yet disclosed.  
Another approach targeting glutamatergic neurotransmission involves antagonism at 
mGluR5 receptors. At present, the mGluR5 antagonists ADX48621 (Addex) and 
AFQ056 (Novartis AG) are undergoing phase I and phase II clinical trials, 
respectively. Effects of these compounds in preclinical models have not yet been 
published, but tool compounds have demonstrated antidyskinetic efficacy. Indeed, 
the mGluR5 antagonists 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) (Mela 
et al. 2007; Rylander et al. 2009) as well 2-methyl-6-(phenylethynyl)-pyridine (MPEP) 
(Levandis et al. 2008) attenuated L-DOPA-induced dyskinesia in the 6-OHDA rat 
dyskinesia model. The antidyskinetic effect of MTEP and MPEP was paralleled by a  
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Fig. 1. Chemical structures of antidyskinetic compounds, which are/have been investigated in 
clinical trials. Some of the chemical structures are taken from conference reports and commercial 
databases but not verified e. g. by patent literature. 
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Table 1. Compounds for the alleviation of L-DOPA-induced dyskinesia. Comparison between the 
6-OHDA rat dyskinesia model, the MPTP-lesioned primate model and clinical trials. 
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blockade of upregulation of striatal prodynorphin mRNA levels (Mela et al. 2007) and 
a reduction of striatal levels of FosB/Delta FosB immunoreactivity (Levandis et al. 
2008), respectively, both of which are strongly associated with the dyskinesiogenic 
action of L-DOPA. 
The 5-HT1A agonist sarizotan (Merck KGaA) reduced L-DOPA-induced dyskinesia in 
6-OHDA-lesioned rats after local administration into the STN (Marin et al. 2009) as 
well as in MPTP-lesioned primates (Bibbiani et al. 2001; Gregoire et al. 2009). Two 
phase II clinical trials showed an improvement of L-DOPA-induced dyskinesia by 
administration of sarizotan (Bara-Jimenez et al. 2005; Goetz et al. 2007), but two 
large phase III trials (PADDY-1 and PADDY-2) involving more than 1000 PD patients 
failed to meet the primary endpoints. The reason for this discrepancy may be due to 
the low dose applied in the phase III study (1 mg) compared to the effective dose in 
the phase II trials (2 and 5 mg, respectively). Indeed, Iravani et al. (2006) 
demonstrated that the 5-HT1A agonist (R)-(+)-8-OH-DPAT alleviated L-DOPA-
induced chorea but only at the cost of reversal of the motor improvement of L-DOPA. 
Thus, there appears to be a major challenge to keep the balance between an 
excessive DA overflow, which prones dyskinesia, and a pronounced reduction in DA 
levels, which abolishes the beneficial effect of L-DOPA. Additionally, sarizotan also 
exhibits antagonist properties for DA receptors with the highest affinity for the DA D4 
subtype suggesting that sarizotan’s dose has to be well titrated to exclude a 
worsening of L-DOPA’s therapeutic effect via blockade of dopaminergic receptors. A 
5-HT1A agonist without antagonism at dopaminergic receptors is piclozotan (Asubio 
Pharmaceuticals), which offers agonistic properties at DA D3 receptors in addition to 
being a 5-HT1A agonist. Piclozotan is an injectable formulation and is currently under 
investigation in a phase II clinical trial. A short duration phase IIa study successfully 
revealed the PoC by improving both “on” time without dyskinesia as well as “off” time 
(press release).  
The !2 adrenoceptor antagonist idazoxan (Pierre Fabre SA) demonstrated 
antidyskinetic efficacy in the 6-OHDA rat dyskinesia model (Buck and Ferger 2009b) 
as well as in the MPTP-treated monkey (Bezard et al. 1999; Fox et al. 2001; Grondin 
et al. 2000; Henry et al. 1999). Additionally, the “on” time of L-DOPA was extended in 
the latter model. However, there is a controversy concerning the efficacy of idazoxan 
in clinical trials, one phase II clinical trial reported an alleviation of L-DOPA-induced 
dyskinesia in PD patients (Rascol et al. 2001), whereas another did not (Manson et 
Chapter I 
 20 
al. 2000). Additionally, a phase III clinical trial was initiated and terminated early due 
to unknown reasons. Idazoxan is currently in development for the treatment of 
schizophrenia. Another !2 adrenoceptor antagonist, fipamezole (Juvantia Pharma 
Ltd/Santhera Pharmaceuticals AG), reduced L-DOPA-induced dyskinesia in the 
monkey (Savola et al. 2003) as well as in PD patients in a phase IIa clinical trial. Very 
recently, Santhera announced the positive outcome of its phase IIb trial FJORD in a 
press release. This study demonstrated efficacy of fipamezole in alleviation of L-
DOPA-induced dyskinesia compared to placebo without clinically relevant worsening 
of motor disability. However, these results were achieved by analysing the US 
subgroup due to a strong evidence of inhomogeneity between US and Indian study 
populations. The original primary outcome comprising the US and Indian study 
population show a tendency towards reduction in dyskinesia but did not reach 
statistical significance. 
The adenosine A2A antagonist istradefylline (Kyowa Hakko) was shown to be 
effective in symptomatic animal models of PD as well as in clinical studies (reviewed 
in Jenner et al. (2009)). Istradefylline enhanced locomotor activity in MPTP-treated 
and reserpinised mice (Shiozaki et al. 1999), antagonised haloperidol-induced 
catalepsy in rats (Hauber et al. 2001) as well as potentiated L-DOPA- and 
apomorphine-induced rotational behaviour in 6-OHDA-lesioned rats (Koga et al. 
2000) indicating an antiparkinsonian effect of istradefylline. Moreover, administration 
of istradefylline with L-DOPA provoked an additive relief in motor disability in 6-
OHDA-lesioned rats, but dyskinetic behaviour in these rats remained unchanged by 
treatment with istradefylline (Lundblad et al. 2003). Similar results were obtained in 
the MPTP-lesioned primate such as a reversal of motor disability by administration of 
istradefylline (Grondin et al. 1999a; Kanda et al. 1998) and a potentiation of the 
antiparkinsonian effect of L-DOPA following cotreatment of istradefylline and L-DOPA 
(Grondin et al. 1999a; Kanda et al. 2000). However, L-DOPA-induced dyskinesia was 
not affected by administration of istradefylline indicating that this compound is 
effective in reduction of parkinsonian symptoms and potentiation of the therapeutic 
effect of L-DOPA, but has no antidyskinetic effect by itself, even though it does not 
induce dyskinesia by itself or worsen dyskinesia induced by L-DOPA. Some clinical 
trials are available investigating the antiparkinsonian properties of istradefylline. A 
first PoC study including 15 patients showed that istradefylline provided no 
antiparkinsonian benefit as a monotherapy and in combination with optimal-dose 
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infusion of L-DOPA (Bara-Jimenez et al. 2003). However, istradefylline 
coadministered with low-dose infusion of L-DOPA improved cardinal parkinsonian 
symptoms up to the antiparkinsonian response achieved by optimal-dose L-DOPA. 
Notably, 45% less dyskinetic movements were observed at this treatment regime. 
These results are in contrast to the findings from the monkey studies, in which 
istradefylline provided an antiparkinsonian benefit as monotherapy (Grondin et al. 
1999a; Kanda et al. 1998). In agreement with the primate studies is the potentiation 
of L-DOPA efficacy by istradefylline resulting in an additive antiparkinsonian effect. 
Taken together the results from various phase II (Hauser et al. 2008; Lewitt et al. 
2008; Stacy et al. 2008) and a large phase III clinical trial, istradefylline was shown to 
reduce “off” time, whereas no effect on UPDRS scores was observed. Additionally, 
the “on” time with dyskinesia was increased by istradefylline, but most patients 
showed non-troublesome dyskinesia. However, istradefylline has not been 
investigated in conditions that have be proven to be beneficial in primate studies 
such as adjunct therapy to L-DOPA (Jenner et al. 2009). Taken together, 
istradefylline has demonstrated validity in preclinical studies to predict clinical efficacy 
in terms of potentiation of the L-DOPA effect as well as no worsening of dyskinesia. 
The adenosine A2A antagonists V2006/BIIB014 (Biogen Idec), preladenant 
(SCH420814) (Schering-Plough Corp) and SYN115 (Synosia/Roche Holding AG) are 
currently in phase II clinical trials, from which data are not yet disclosed. 
Safinamide (Merck Serono/Newron Pharmaceuticals) is a reversible MAO-B inhibitor 
with additional sodium and calcium channel blocker activities being developed as an 
add-on treatment for patients suffering from PD. Safinamide is currently in a phase III 
clinical trial (SETTLE) for adjunctive use with L-DOPA. Study 016, the first phase III 
trial of safinamide as adjunctive therapy to L-DOPA revealed that safinamide 
significantly improved motor function. Safinamide met its primary endpoint by 
increasing daily “on” time in patients with motor fluctuations, who are in mid- to late-
stage PD, without any increase in “on” time with troublesome dyskinesia. Secondary 
endpoints were also met including decrease in daily “off” time as well as decrease in 
“off” time following first morning L-DOPA dose.  
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Mode of action of antidyskinetic drugs 
The exact mechanism of action of the gold standard amantadine is unclear but it is 
suggested to decrease enhanced glutamatergic transmission within the direct 
striatopallidal pathway of the basal ganglia motor loops resulting in reduction of 
dyskinesia.  
Sarizotan is a representative of the compound class 5-HT1A agonists primarily 
developed for the treatment of L-DOPA-induced dyskinesia. The mechanism of 
action of 5-HT1A agonists seems to be due to the reduction of L-DOPA-derived DA 
overflow in the rat striatum (Kannari et al. 2001), where DA is released as ‘false 
neurotransmitter’ from serotonin (5-HT) terminals. The role of DA released from 
serotonergic neurons as an important presynaptic factor of L-DOPA-induced 
dyskinesia in the rat PD model has been discovered (Carta et al. 2008). In fact, the 
removal of 5-HT afferents by the serotonergic neurotoxin 5,7-dihydroxytryptamine 
resulted in an almost complete reversal of L-DOPA-induced dyskinesia (Carta et al. 
2007). Moreover, serotonergic neurons release less of the original neurotransmitter 
5-HT (5-HT) when releasing DA which causes an upregulation of the activity of 5-HT 
neurons favouring in turn the excessive swings of DA release. In fact, this vicious 
circle can be interrupted by administration of 5-HT1A agonists.  
Several mechanisms of action have been discussed for the antiparkinsonian effects 
of adenosine A2A antagonists (Jenner et al. 2009). Adenosine acting at A2A receptors 
stimulates neurons projecting from the striatum to the globus pallidus (GP) opposing 
the inhibitory effects of DA. In PD, the dopaminergic input is lost and striatopallidal 
neurons become overactive due to the excitatory influence of adenosine. A2A 
antagonists are suggested to dampen the excessive activity of striatopallidal neurons 
by blocking stimulatory A2A receptors and thus reconstitute the imbalance between 
indirect and direct pathway of the basal ganglia network. Another approach involves 
presynaptic A2A receptors in the striatum and GP modulating GABAergic 
neurotransmission resulting in restoration of GP and STN activity. There is increasing 
evidence that A2A receptors form heterodimer complexes with the DA D2 receptor as 
well as mGluR5 receptors. Accordingly, a combination of A2A antagonists and 
mGluR5 antagonists may have an additive antiparkinsonian benefit. The precise 
mechanism of dyskinesia alleviation by mGluR5 antagonists remains unknown. 
However, mGluR5 gene expression was found to be upregulated in the striatum of 
dyskinetic rats (Konradi et al. 2004) and an increase of mGluR5 specific binding was 
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shown in monkeys rendered dyskinetic by MPTP plus L-DOPA treatment (Samadi et 
al. 2008). Additionally, Mela et al. (2007) reported that MTEP attenuated the L-
DOPA-induced increase of extracellular GABA levels in the substantia nigra pars 
reticulata (SNr) of dyskinetic rats measured by in vivo microdialysis. Conversely, the 
GABA overflow in the GP as part of the indirect pathway of the basal ganglia motor 
loops was altered neither by L-DOPA treatment nor by administration of MTEP. 
These findings indicate that the antidyskinetic action of mGluR5 antagonists may be 
due to a decrease of the GABA overflow in the direct pathway of the basal ganglia 
network. 
The reversible MAO-B inhibitor safinamide is reported to have a novel dual 
mechanism of action based on the increase of dopaminergic neurotransmission by 
inhibition of MAO-B and DA uptake and reduction of glutamatergic activity by 
blocking glutamate release. 
 
Conclusion 
There is an unmet medical need for drugs alleviating L-DOPA-induced dyskinesia in 
terms of quality of life for the PD patient as well as socio-economic burden. At 
present, no compounds against L-DOPA-induced dyskinesia are registered. 
Amantadine is the only compound for the treatment of L-DOPA-induced dyskinesia, 
which was originally developed as virustatic agent and is now used off-label for L-
DOPA-induced dyskinesia. In order to predict clinical efficacy of antidyskinetic drugs, 
several preclinical animal models are available, which have proven predictive validity. 
However, one has to critically evaluate findings from preclinical models and consider 
several confounding factors to exclude false positive results. Additionally, the 
mechanisms underlying L-DOPA-induced dyskinesia are complex and still remain 
unknown. Thus, drugs aiming at various targets may be conceivable to be effective 
against L-DOPA-induced dyskinesia. 
 
Objective of the present thesis 
The objective of my thesis is to gain insight into neurochemical and behavioural 
mechanisms underlying the expression of dyskinetic movements and thus 
characterise the rat L-DOPA dyskinesia model in depth. Various pathogenic factors, 
which contribute to the manifestation of dyskinetic movements, will be investigated. 
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Furthermore, I will explore and evaluate novel drug targets for the treatment of L-
DOPA-induced dyskinesia in the rat dyskinesia model. 
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CHAPTER II 
General methodology 
 
Animals 
The present studies were conducted in male Wistar rats (HsdCpb:WU, Harlan 
Winkelmann, Borchen, Germany). The animals were housed in groups of 4 per cage 
under a 12 h light/dark cycle (lights on 06:00 – 18:00) in temperature (23 ± 2°C) and 
humidity (55 ± 5%) controlled rooms with free access to food (GLP Vitamin fortified, 
Provimi Kliba AG, Kaiseraugst, Switzerland) and water throughout the experiment.  
All in vivo studies were approved by the appropriate institutional governmental 
agency (Regierungspräsidium Tuebingen, Germany) and performed in an AAALAC 
(Association for Assessment and Accreditation of Laboratory Animal Care 
International)–accredited facility in accordance with the European Convention for 
Animal Care and Use of Laboratory Animals. 
 
6-OHDA lesion surgery  
Rats were anaesthetised with a mixture of ketamine (70 mg/kg, i.p.) and xylazine (6 
mg/kg, i.p.) and mounted in a stereotaxic frame (David Kopf, Tujunga, CA, USA) on a 
flat-skull position. Anaesthesia was maintained by using 0.4 -2 % isoflurane in 
N2O/O2 (70:30). Animals were treated with a mixture of pargyline hydrochloride (25 
mg/kg; i.p.) and desipramine hydrochloride (6.25 mg/kg; i.p.) 30 minutes prior to the 
infusion of 6-OHDA. 6-OHDA hydrobromide (3 #g/#l of free base) was dissolved in 
0.02% ascorbate solution. Injections were performed at the rate of 0.3 #l/min into the 
left median forebrain bundle at the following coordinates relative to the bregma 
according to the rat brain atlas of Paxinos and Watson (1998): (1) AP: - 4.4 mm, ML: 
+ 1.2 mm, DV: - 7.8 mm (from skull) (2.5 #l); (2) AP: - 4.0 mm, ML: + 0.7 mm, DV: - 
8.0 mm (from skull) (2 #l) (Cenci et al. 1998). 
 
Induction and rating of dyskinesia 
Three weeks after 6-OHDA lesion rats were treated chronically with L-DOPA methyl 
ester, in the following called L-DOPA (6 mg/kg, p.o.), plus benserazide (15 mg/kg, 
p.o.) once daily for 3 x 5 days (Monday - Friday between 9.00 a.m. to 5.00 p.m., 
within three weeks, without treatments at weekends, administration volume 2 ml/kg). 
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This treatment led to an induction of stable dyskinetic movements, which were 
quantified using a previously described rating scale (Cenci et al. 1998) by an 
“experimentally blinded” observer not aware of the experimental group alignment 
every 20 minutes following administration of L-DOPA or vehicle.  
The scoring of abnormal involuntary movement behaviour involves (1) axial subtype: 
axial motor response complications indicated by dystonic posturing or choreiform 
twisting of the neck and upper body, (2) limb subtype: abnormal, purposeless 
movement of the forelimb and digits, (3) orolingual subtype: orolingual dyskinesia 
indicated by empty jaw movements and contralateral tongue protrusion. For each 
observation period (1 min) the subtypes of these abnormal involuntary movements 
were rated individually on a severity scale from 0 to 4 based on their duration and 
severity: 0 = nonexistent; 1 = occasional < 50 % of observation time; 2 = frequent > 
50% of observation time; 3 = continuous but can be interrupted; 4 = continuous, full 
blown and not interruptible. The sum of axial, limb and orolingual dyskinesia rating 
was expressed as a total dyskinesia score and used instead of the individual score if 
the treatments produced similar changes in the different subtype scores. Turning 
behaviour does not provide a specific measure of L-DOPA-induced abnormal 
involuntary movement (Lundblad et al. 2002) and was not included. 
 
In vivo microdialysis surgery 
Under ketamine/xylazine (70/6 mg/kg, i.p.) and isoflurane (0.4 – 2 % in N2O/O2 
(70:30)) anaesthesia one or two intracerebral guide cannulae (striatum: MAB 4.9.IC; 
GP and SNr: MAB 4.15.IC, Microbiotech, Sweden) were implanted aiming at the left 
and right striata at the following coordinates relative to the bregma: striatum: AP: + 
0.7 mm, ML: ± 3.0 mm, DV: - 3.0 mm (from skull); GP: AP: - 1.2 mm, ML: + 3.0 mm, 
DV: - 6.2 mm (from skull); SNr: AP: - 5.5 mm, ML: + 2.2 mm, DV: - 8.2 mm (from 
skull) according to the rat brain atlas of Paxinos and Watson (1998). Two holes were 
drilled for the placement of the guide cannulae, which were fixed to the skull with two 
stainless steel screws and methacrylic cement (Paladur, Heraeus Kulzer GmbH & 
Co. KG, Hanau, Germany) or dental cement (PermaCem, DMG Chemisch-
Pharmazeutische Fabrik GmbH, Hamburg, Germany). Following surgery, rats were 
housed individually in perspex cages and allowed to recover for at least three days 
before performing the in vivo microdialysis procedure. 
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GP and SNr (MAB 4.15.IC, Microbiotech, Stockholm, Sweden) at the following 
coordinates relative to the bregma:  
 
In vivo microdialysis procedure 
The evening before the experiment concentric microdialysis probes (striatum: MAB 
4.9.4.Cu, 4 mm membrane length; GP: MAB 4.15.2.Cu, 2 mm membrane length; 
SNr: MAB 4.15.1.Cu, 1 mm membrane length, Microbiotech, Sweden) were 
introduced and the rats were placed into a microdialysis system with a balanced arm 
for freely moving animals. The probes were connected through a dual channel swivel 
(Instech Laboratories, Inc. USA) to a pump (TSE Technical & Scientific Equipment 
GmbH, Bad Homburg, Germany) via FEP tubing (inner diameter 0.12 mm) and 
perfused with aCSF containing 147 mM NaCl, 2.7 mM KCl, 1.2 mM CaCl2, 0.85 mM 
MgCl2 and 1 mM Na2HPO4, pH 7.0-7.4, at a constant flow rate of 2 #l/min up to the 
end of the experiment. The following morning dialysis samples were collected every 
20 minutes into a vial containing 10 #l of 0.1 M hydrochloric acid. 
Dyskinetic behaviour was individually monitored for each rat every 20 minutes. The 
reported data was not corrected for the in vitro recovery, which was 12-14 % for DA 
and DA metabolites, 13 % for L-DOPA, 27 % for idazoxan and 8 % for PPX (for MAB 
4.9.4.Cu). In vitro recovery for L-DOPA was 4 % for MAB 4.15.1.Cu and 6 % for MAB 
4.15.2.Cu. Using MAB 4.9.2.Cu, the in vitro recovery was 9 % for GABA and 7 % for 
glutamate. To measure the in vitro recovery the probe was placed in a medium with a 
defined concentration of the analyte. After an equilibration period of 60 minutes three 
20 minute samples were collected from the microdialysis probe effluent and analysed 
by high performance liquid chromatography (HPLC). The mean of the three samples 
was compared with a sample taken from the medium and expressed as % relative 
recovery of the medium. After the experiments the correct localisation of the probes 
was verified and only the rats with appropriate probe placement were included in the 
experiment. 
 
Reverse in vivo microdialysis surgery 
Two intracerebral guide cannulae (MAB 4.9.IC, Microbiotech, Sweden) were 
implanted as described above with minor modification of the coordinates for the 
striatum: AP: + 0.7 mm, ML: ± 3.0 mm, DV: - 4.0 mm (from skull). The coordinates for 
the GP and SNr have been used as above described. 
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Reverse in vivo microdialysis procedure 
The reverse in vivo microdialysis procedure was similarly performed to the in vivo 
microdialysis procedure but with minor modifications. On the day of the experiment 
concentric microdialysis probes (striatum: MAB 4.9.2.PES, 2 mm membrane length, 
Microbiotech, Sweden) were introduced and the rats were placed into the 
microdialysis system. The probes were perfused with aCSF at a constant flow rate of 
4 #l/min. Dyskinetic behaviour including axial, limb and orolingual dyskinesia was 
monitored during the whole experiment every 5 minutes. After the experiment the 
correct localisation of the probes was verified and only the rats with appropriate 
probe placement were included in the study. 
 
CSF, brain and plasma sample collection procedure 
The CSF was firstly collected via puncture of the cisterna magna followed by removal 
of the blood via punctuation of the heart. Blood samples were obtained using S-
Monovette™ containing 1.6 mg EDTA/ml blood (Sarstedt AG & Co., Nümbrecht, 
Germany) and gently shaken. Subsequently, the rats were transcardially perfused 
with Ringer’s solution for 3 minutes. Afterwards, the brain was removed, transferred 
into plastic tubes and weighed. Plasma was obtained by centrifugation of the blood 
for 10 minutes (3200 x g) at 4 °C. Plasma, brain and CSF samples were frozen at -20 
°C or -80 °C prior to liquid chromatography/tandem mass spectrometry (LC-MS/MS) 
analysis.  
 
Sample preparation procedure 
Brain tissue was homogenised either using sonication or using Dispomix™ 25 tubes 
(Xiril AG, Hombrechtikon, Switzerland) in LC-MS grade water (1:7). 10 #l aliquots of 
CSF, brain and plasma samples were diluted with 10 #l of acetonitrile/water (80:20) 
and 80 #l of methanol/acetonitrile (50:50) in order to precipitate proteins. The 
samples were mixed and kept at -20 °C for at least 15 minutes to improve the 
precipitation. Subsequently, samples were centrifuged at 3200 x g for 10 minutes at 4 
°C and the supernatants were analysed by LC-MS/MS.  
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HPLC system 
The HPLC system consisted of an ASI-100T autosampler and P680 ISO isocratic 
pump system (Dionex, Idstein, Germany). The detector potential was set at + 650 mV 
using a glassy carbon electrode and an ISAAC Ag/AgCl reference electrode (Antec 
VT-03, Leyden, The Netherlands). Aliquots were injected by an autosampler with a 
cooling module set at 4°C. Data were calculated using an external five-point standard 
calibration by Chromeleon® chromatography data system software (Dionex, Idstein, 
Germany). 
 
LC-MS/MS system 
The HPLC system consisted of a HTS PAL autosampler (CTC Analytics AG, 
Zwingen, Switzerland), Agilent 1200 Binary Pump, Agilent 1200 Micro Vacuum 
Degasser and Agilent 1200 Thermostatted Column Compartment (Agilent 
Technologies, Morges, Switzerland). Eluates were detected using an API 4000™ 
triple quadrupole mass spectrometer (MDS Sciex, Ontario, Canada) in the positive 
ESI mode. The ion spray voltage was set at 4500 V and the source temperature at 
500°C. Data were acquired and analysed using the software Analyst® version 1.4 
(MDS Sciex, Ontario, Canada). 
 
Drugs and chemicals 
All drugs were calculated as free bases. The injection volume was 1 ml/kg unless 
otherwise indicated L-DOPA methyl ester hydrochloride, benserazide hydrochloride, 
DA hydrochloride, DOPAC, HVA, 3-MT, GABA, glutamate, 6-OHDA hydrobromide, 
pargyline hydrochloride, desipramine hydrochloride, amantadine hydrochloride as 
well as HPLC and LC-MS/MS chemicals of the highest available purity were obtained 
from Sigma-Aldrich Chemie GmbH (Steinheim, Germany). Ketamine hydrochloride 
(Ketavet") was purchased from Pfizer Pharma GmbH (Berlin, Germany). Xylazine 
hydrochloride (Rompun") was obtained from Bayer Vital GmbH (Leverkusen, 
Germany). Idazoxan hydrochloride, propranolol hydrochloride, HEAT hydrochloride 
and cirazoline hydrochloride were purchased from Biotrend Chemikalien GmbH 
(Köln, Germany). PPX dihydrochloride as well as [D7]-PPX dihydrochloride was 
synthesised at Boehringer Ingelheim Pharma GmbH & Co. KG. [D6]-GABA, [D5]-
glutamate and [D3]-L-DOPA were purchased from Cambridge Isotope Laboratories, 
Inc. (Andover, MA, USA).  
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Statistical analysis 
The statistical analysis was carried out using SAS version 8.2 (SAS Institute Inc., 
USA), S-PLUS"6.1 (Insightful Corp., USA) and GraphPad Prism version 4.00/5.01 
for Windows (GraphPad software, USA). All values are expressed as mean ± SEM if 
not otherwise stated. P < 0.05 was considered as statistically significant. 
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CHAPTER III 
Intrastriatal inhibition of aromatic amino acid decarboxylase prevents L-
DOPA-induced dyskinesia 
 
ABSTRACT 
L-DOPA-induced dyskinesia consists of involuntary choreiform and dystonic 
movements. Here we report whether intrastriatal L-DOPA itself is able to trigger 
dyskinetic behaviour and which role the neurotransmitter DA and its metabolites play.  
Intrastriatal L-DOPA as well as DA administration at the 6-OHDA-lesioned side led to 
a significant appearance of dyskinetic behaviour, whereas DA metabolites were 
ineffective. Intrastriatal inhibition of the enzyme aromatic amino acid decarboxylase 
(AADC) by benserazide prevented the appearance of L-DOPA-induced dyskinetic 
movements at the lesioned side. Principle component analysis of DA and DA 
metabolite levels with dyskinesia scores after L-DOPA/benserazide (6/15 mg/kg) 
administration indicated a significant correlation only for DA, whereas DA metabolites 
did not show any significant correlation with the occurrence of dyskinetic behaviour.  
We conclude that intrastriatal L-DOPA itself is not able to induce dyskinetic 
movements, whereas the increase of intrastriatal DA levels is instrumental for L-
DOPA- and DA-induced dyskinetic behaviour. 
 
 
INTRODUCTION  
Initially, therapy with the gold standard L-DOPA dramatically alleviates the cardinal 
symptoms of PD namely bradykinesia, rigidity and tremor and improves the quality of 
life of patients suffering from PD (Schapira et al. 2006). However, within a few years, 
the L-DOPA therapy is commonly associated with side effects, most notably motor 
complications including dyskinesia, motor fluctuations and the wearing off 
phenomenon (Brotchie et al. 2005; Muller and Russ 2006). L-DOPA-induced 
dyskinesia involves involuntary movements such as chorea, dystonia and athetosis 
involving head, trunk and limbs (Schapira et al. 2006). L-DOPA-induced dyskinesia 
affects 50% of patients within 5 years and develops in almost 90 % of patients after 9 
years of L-DOPA therapy (Obeso et al. 2000a; Rascol and Fabre 2001; Schapira et 
al. 2006; Ahlskog and Muenter 2001).  
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To date, no animal species develops dyskinesia during its lifetime without undergoing 
pharmacological manipulation. However, different species are used to evoke 
dyskinetic like behaviour, namely primates (Bezard et al. 2003; Jenner 2003) or 
rodents (Lundblad et al. 2002; Lundblad et al. 2005). A prerequisite for the 
development of L-DOPA-induced dyskinesia is a significant nigrostriatal 
neurodegeneration. In rodents unilateral intracerebral injection of 6-OHDA is used to 
generate degeneration of dopaminergic neurons projecting from the SNc to the 
striatum. This lesion is followed by chronic L-DOPA treatment to induce abnormal 
involuntary movements affecting the forelimb contralateral to the lesion, the trunk and 
the orofacial musculature (Lundblad et al. 2002).  
The underlying molecular mechanisms of L-DOPA-induced dyskinesia are not 
resolved. Several factors such as disruption of presynaptic DA homeostasis, plasticity 
changes in the direct and indirect basal ganglia pathway, pathophysiological changes 
of the firing patterns in the basal ganglia output structures, cortical overactivation and 
several receptor mediated changes at dopaminergic, GABAergic and glutamatergic 
neurons contribute to the complex molecular and neuroanatomical dysfunction 
involved in L-DOPA-induced dyskinesia (Cenci 2007). Recently, Carta et al. (2006) 
reported that high levels of L-DOPA in the striatal extracellular fluid are necessary for 
the appearance of dyskinetic motor manifestations and that extracellular striatal L-
DOPA levels paralleled the expression of dyskinetic behaviour. This finding highlights 
the role of the striatum and raises the question of the relevance of downstream 
events which arise after the metabolism of L-DOPA as well as after the metabolism of 
DA.  
The objective of the present study is to investigate (1) whether intrastriatal L-DOPA 
itself triggers dyskinetic behaviour and (2) which role intrastriatal DA and its 
metabolites play in the manifestation of dyskinetic movements. Therefore, we 
administered L-DOPA in combination with benserazide via bilateral in vivo reverse 
microdialysis technique into the striata of dyskinetic rats. Benserazide is a peripheral 
inhibitor of the enzyme AADC, which converts L-DOPA to the neurotransmitter DA. If 
this conversion is blocked within the striatum, the effect of L-DOPA itself can be 
assessed. The method of intrastriatal administration via reverse in vivo microdialysis 
was used to evaluate the effect of DA and its metabolites on the occurrence of 
dyskinetic behaviour. Furthermore, we investigated the effect of systemic 
administration of L-DOPA/benserazide on extracellular levels of DA and its 
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metabolites paralleled by monitoring dyskinesia to underscore which of the 
neurochemical measurements correlates best with the behavioural readout.  
 
 
MATERIALS AND METHODS 
 
Animals, 6-OHDA lesion surgery, Induction and rating of dyskinesia 
Please see chapter II “General methodology” page 22. 
 
In vivo microdialysis surgery in the striatum 
Please see chapter II “General methodology” page 23. 
 
DA and DA metabolite measurement using bilateral in vivo microdialysis in the 
striatum 
Please see chapter II “General methodology” (In vivo microdialysis surgery) page 24. 
Fractions 1 to 4 (0 - 80 min) were used for calculation of the basal levels which were 
regarded as 100 %. At the beginning of fraction 5, saline was administered (p.o.) and 
additional 4 fractions were sampled (80 - 160 min). At fraction 9, L-DOPA (6 mg/kg, 
p.o. (n = 8) or 24 mg/kg, p.o. (n = 7)) in combination with benserazide (15 mg/kg, 
p.o.) was administered and the sampling was continued up to fraction 23 (5 hours 
sampling after L-DOPA injection, 160 - 460 min). The experiment was performed 
using a cross-over design. Half of the rats were treated with L-DOPA 6 mg/kg or L-
DOPA 24 mg/kg on the first day. On the second day of testing the treatment 
allocation was switched. Between the two treatment regimes a washout period of at 
least 2 days was included.  
 
Post mortem tissue preparation 
Dyskinetic rats were sacrificed by decapitation after anaesthesia with isoflurane (n = 
7). Immediately afterwards, the left and right striata were dissected out on an ice-
cooled plate, transferred separately in plastic tubes, weighed, homogenised by 
sonication for 10 s in 1000 #l perchloric acid (0.4 M) and centrifuged at 3200 x g for 
20 minutes at 4°C. The supernatants were passed through a 0.2 #m filter (Minisart 
RC4, Sartorius AG, Goettingen, Germany) and subsequently frozen at - 80 °C until 
HPLC analysis. 
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HPLC analysis of microdialysis and post mortem samples  
Please see chapter II “General methodology” (HPLC system) page 26. The samples 
were analysed for DA and its metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) 
and 4-hydroxy-3-methoxy-phenylacetic acid (HVA) using HPLC combined with 
electrochemical detection (ECD) under isocratic conditions. Chromatographic 
separation was performed using a reversed-phase column (100 x 2.1 mm i.d. with 
pre-column 10 x 2.1 mm i.d., filled with ODS-AQ, 120 Å, 3 #m, YMC Europe GmbH, 
Dinslaken, Germany). The mobile phase consisted of 1.7 mM 1-octanesulfonic acid 
sodium salt, 1.0 mM Na2EDTA x 2 H20, 8.0 mM NaCl, 100.0 mM NaH2PO4 x 2 H2O, 
adjusted to pH 3.80 with H3PO4, filtered through a 0.22 #m filter, mixed up with 9.3 % 
acetonitrile and was delivered at a flow rate of 0.4 ml/min. 
 
Reverse in vivo microdialysis surgery 
Please see chapter II “General methodology” page 24. 
 
Intrastriatal administration of L-DOPA, L-DOPA/benserazide, DA and DA 
metabolites via reverse in vivo microdialysis 
 
Fig. 2. Time flow chart of the intrastriatal administration of three independent experiments: (A) 
L-DOPA/benserazide, (B) L-DOPA and DA, (C) DOPAC, HVA, 3-MT and DA. The compounds were 
administered locally into the ipsilateral 6-OHDA-lesioned or contralateral non lesioned striatum. 
Dyskinetic behaviour, including axial, limb and orolingual movements, was monitored every 5 minutes 
during the whole experiment. 
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Please see chapter II “General methodology” (Reverse in vivo microdialysis 
procedure) page 25. This experiment was independently conducted from the 
measurement of DA and its metabolites. Following insertion of the probes, aCSF was 
perfused for 1 hour. In order to investigate the effect of L-DOPA itself, benserazide 
was administered locally for 30 minutes (0.2 nmol/min; n = 8) subsequently followed 
by L-DOPA/benserazide (0.4/0.2 nmol/min) for 1 additional hour on the contralateral 
side. Afterwards this procedure was repeated on the ipsilateral side (for experimental 
design please see Fig. 2A). L-DOPA (0.4 nmol/min; n = 6) or DA (0.4 nmol/min; n = 
4) were perfused on the contralateral side followed by the ipsilateral side for 60 
minutes each (Fig. 2B). In the second experiment (n = 8), DOPAC (0.4 nmol/min), 
HVA (0.4 nmol/min) and 3-methoxytyramine (3-MT) (0.4 nmol/min) were 
consecutively perfused on the ipsilateral side for 1 hour each. A 30 minutes aCSF 
perfusion was performed as washout between administration of the different 
metabolites. Afterwards a perfusion of DA (0.4 nmol/min) followed for 1 more hour 
(Fig. 2C). Drug concentration was chosen according to Carta et al. (2006), who 
demonstrated the maximum dyskinetic effect at L-DOPA 100mM (= 0.4 nmol/min). 
 
Drugs and chemicals 
Please see chapter II “General methodology” page 26. 
 
Statistical analysis 
Please see chapter II “General methodology” page 27. Rating scores of L-DOPA-
induced dyskinesia were analysed by either one-way analysis of variance (ANOVA) 
with treatment as the independent factor or two-way ANOVA with time as the 
dependent factor and dose as the independent factor followed by the Bonferroni post 
hoc test. For comparison of dyskinesia scores with the theoretical mean which was 
defined as 0.0 (pre dyskinesia score) a one sample t-test was performed.  
Post mortem neurochemical results were analysed with a paired t-test to compare the 
lesioned and the non lesioned striatum. 
The cross-over microdialysis study was analysed by a four-way ANOVA for repeated 
measurements with 4 factors including lesion, treatment, group and test period within 
the cross-over design. Two-way ANOVA with lesion as the dependent factor and 
dose as the independent factor was used to compare basal values between the 
lesioned and non lesioned side. P < 0.05 was considered as statistically significant. 
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A principal component analysis (PCA) was performed to analyse the multivariate 
relations between dyskinetic movement scores and neurochemical parameters. PCA 
transforms the original variables into new variables called principal components. The 
first principal component is taken to be along the direction with the maximum 
variance. Each succeeding component accounts for as much of the remaining 
variability as possible. Hence, PCA and the respective biplot allow a global 
presentation of the high dimensional data within a two-dimensional space of the first 
and second principal component. 
 
 
RESULTS 
 
Effects of systemic L-DOPA administration on dyskinetic behaviour  
 
Fig. 3. L-DOPA-induced 
dyskinesia after 
administration of L-DOPA 
(6 mg/kg (n = 8) or 24 mg/kg 
(n = 7); p.o.) plus 
benserazide (15 mg/kg; 
p.o.). Monitoring of 
dyskinesia was carried out 
every 20 minutes throughout 
the experiment and 
expressed as total 
dyskinesia score. One sample t-test was performed for comparison with a theoretical mean, which was 
defined as 0 (* P < 0.05, ** P < 0.01, *** P < 0.001 for L-DOPA 6 mg/kg; # P < 0.05, ## P < 0.01, ### 
P < 0.001 for L-DOPA 24 mg/kg). Data are presented as mean ± SEM. 
 
Fig. 3 shows the time course of dyskinetic behaviour during the microdialysis 
procedure. Dyskinesia was monitored every 20 minutes for a time period of 5 hours 
following administration (p.o.) of L-DOPA plus benserazide. Administration of vehicle 
did not show any dyskinetic behaviour. Two-way ANOVA for repeated measurements 
yielded a significant interaction of time $ dose of L-DOPA (F(15;195) = 3,81; P < 
0.001). Both doses of L-DOPA (6 mg/kg and 24 mg/kg) led to a significant increase of 
dyskinetic behaviour including axial, limb and orolingual movements (P < 0.001). 
Statistical comparison of maximum values revealed no significant differences 
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between the L-DOPA doses (sum of total dyskinesia score at 40 - 120 min: 6 mg/kg 
and 24 mg/kg 37.4 ± 2.8 and 40 ± 2.40, respectively). In contrast, L-DOPA 24 mg/kg 
induced a significantly longer lasting dyskinetic behaviour indicated by a significant 
increase of the total dyskinesia score (20 - 280 min) whereas dyskinesia returned to 
basal levels after 160 minutes following L-DOPA 6 mg/kg. 
 
 
Effects of systemic L-DOPA administration on striatal DA, DOPAC and HVA 
levels 
 
 
 
Lesioned  
6 mg/kg (n=8) 
 
 
Non lesioned  
6 mg/kg (n=8) 
 
 
Lesioned 
24 mg/kg (n=7) 
 
 
Non lesioned 
24 mg/kg (n=7) 
 
 
DA (nmol/l) 
 
0.40 ± 0.04 
 
2.86 ± 0.28 
 
0.35 ± 0.02 
 
3.70 ± 0.24 
 
DOPAC (nmol/l) 
 
8.75 ± 1.07 
 
621.23 ± 42.36 
 
7.34 ± 1.25 
 
622.5 ± 66.64 
 
HVA (nmol/l) 
 
6.63 ± 0.61 
 
351.86 ± 14.76 
 
5.37 ± 0.50 
 
362.27 ± 29.85 
 
Table 2. Basal values (fraction 1 - 4) of extracellular levels of DA, DOPAC and HVA. Two-way 
ANOVA for repeated measurements revealed a significant difference between lesioned and non 
lesioned side (*** P < 0.001). Data are presented as mean ± SEM. Animals per group are given in 
parenthesis. 
 
Basal levels of DA, DOPAC and HVA of all experimental groups are presented in 
table 2. Statistical analysis revealed a significant difference in basal levels between 
the lesioned and the non lesioned side of DA (F(1;14) = 79.27; P < 0.001), DOPAC 
(F(1;14) = 81.86; P < 0.001) and HVA (F(1;14) = 114.70; P < 0.001). 
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Fig. 4. Effects of systemic L-DOPA 
(6 mg/kg (n = 8) or 24 mg/kg (n = 
7); p.o.) plus benserazide 
administration (15 mg/kg; p.o.) on 
extracellular striatal levels of DA 
(A), DOPAC (B) and HVA (C). A 
four-way ANOVA yielded a significant 
interaction of lesion $ treatment (DA: 
P < 0.01; DOPAC: P < 0.01; HVA: P 
< 0.001). Data are presented as 
mean ± SEM. Please note the 
different scale of the Y-axes. 
 
 
In the cross-over study a 
significant effect of group or 
test period was neither 
observed for DA nor DOPAC or 
HVA, indicating no carry-over 
effects. A four-way ANOVA to 
investigate extracellular DA, 
DOPAC and HVA levels 
yielded a significant interaction 
of lesion $ treatment (DA: 
F(1;16) = 12.33; P < 0.01; 
DOPAC: F(1;16) = 12.54; P < 
0.01; HVA: F(1;16) = 22.82; P 
< 0.001), indicating different treatment effects for the lesioned and the non lesioned 
side. Significant differences on the lesioned side between L-DOPA 6 mg/kg and 24 
mg/kg were obtained in extracellular levels of DA (P < 0.001), DOPAC (P < 0.001) 
and HVA (P < 0.001). L-DOPA revealed a significant dose related increase 
(expressed as mean % values after L-DOPA administration, 180 – 460 min) 
compared to vehicle administration in extracellular levels of DA (6 mg/kg: 324% (P < 
0.01); 24 mg/kg: 680% (P < 0.001)) (Fig. 4A), DOPAC (6 mg/kg: 754% (P < 0.05); 24 
mg/kg: 2380% (P < 0.001)) (Fig. 4B) and HVA (6 mg/kg: 1044% (P < 0.05); 24 
mg/kg: 3770% (P < 0.001)) (Fig. 4C) on the lesioned side. In contrast, the non 
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lesioned side did not show any significant effects in DA and its metabolites after 
treatment with L-DOPA. 
 
Correlation analysis between dyskinetic behaviour and neurochemical 
parameters 
 
Fig. 5. Biplot of PCA for parameters 
DA, DOPAC, HVA and total 
dyskinesia scores. The x- and y-axis 
represent the scores for the first and 
second principal component, 
respectively. 
For DA and total dyskinesia score a 
significant partial correlation was 
obtained (r = 0.73, P < 0.01), whereas 
for DOPAC and HVA no correlation 
was found. DOPAC and HVA are 
highly correlated to each other (r = 
0.92, P < 0.001).The single animals are 
marked by their dose group (different 
L-DOPA doses are indicated by 6 and 
24, respectively). 
 
The PCA is visualized in a biplot (Fig. 5) representing both the original variables and 
the transformed observations regarding to the principal component axes (Gabriel and 
Odoroff 1990). The original variables are represented by arrows from the point of 
origin showing the direction of positive changes of the parameters. The length of the 
arrows represents the standard deviation of the variables. The correlation between 
two parameters is represented by the angle between the corresponding arrows, 
thereby a small angle indicates a strong positive correlation. For each pair of 
variables the Pearson partial correlation coefficient was calculated to measure the 
strength of the relationship between these two variables, while controlling the effect 
of the remaining two variables. For DA and total dyskinesia score a significant partial 
correlation was obtained (r = 0.73, P < 0.01), whereas for DOPAC (r = - 0.22, P = 
0.46) as well as for HVA (r = 0.25, P = 0.41) no correlation was found. As expected, 
DOPAC and HVA are highly correlated to each other (r = 0.92, P < 0.001). 
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Post mortem neurochemistry 
 
Table 3. Post mortem neurochemistry 
results of the lesioned and the non 
lesioned striatum of dyskinetic rats (n 
= 7). Values are expressed as ng/mg wet 
tissue weight. Data are expressed as 
mean ± SEM and analysed by paired t-
test (*** P < 0.001). 
 
To verify the extent of the 6-
OHDA lesion a post mortem analysis of DA, DOPAC and HVA levels of the lesioned 
and the non lesioned striatum was performed. Statistical analysis yielded a significant 
depletion of DA of 99.75 % (P < 0.001), DOPAC of 99.42 % (P < 0.001) and HVA of 
98.80 % (P < 0.001) of the lesioned striatum in comparison to the non lesioned 
striatum (Table 3). 
 
Effects of intrastriatal administration of L-DOPA, L-DOPA/benserazide, DA, 
DOPAC, HVA and 3-MT on dyskinetic behaviour 
 
 Fig. 6. Effects of intrastriatal 
administration of L-DOPA (0.4 nmol/min; 
n = 6), DA (0.4 nmol/min; n = 4) and L-
DOPA/benserazide (0.2/0.4 nmol/min; n = 
8). Part (A) shows the time course of total 
dyskinesia score, which was monitored 
every 5 minutes over 180 minutes. In part 
(B) the sum of total dyskinesia score over a 
period of 180 minutes is displayed. Data are 
mean ± SEM and analysed by one sample t-
test for comparison with the theoretical mean 
(** P < 0.01, *** P < 0.001) and one-way 
ANOVA and Bonferroni post hoc test were 
performed for statistical comparison of the 
treatments (### P < 0.001).  
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Neither the striatal administration of L-DOPA (0.4 nmol/min), DA (0.4 nmol/min) nor 
L-DOPA/benserazide (0.4/0.2 nmol/min) on the contralateral non lesioned side 
produced any dyskinetic behaviour (total dyskinesia score = 0). In contrast, 
intrastriatal DA (P < 0.01) as well as L-DOPA administration on the ipsilateral 6-
OHDA-lesioned side led to a pronounced increase in dyskinesia (P < 0.001) (Fig. 6). 
In addition, L-DOPA- and DA-induced dyskinesia were not significantly different (179 
± 18.7 and 191.3 ± 23.5 total dyskinesia score, respectively). However, the DA-
induced dyskinesia appeared earlier and was of shorter duration than after L-DOPA 
treatment. For comparison of intrastriatal L-DOPA- and DA-induced dyskinetic 
behaviour please see supplementary video clips. 
After intrastriatal administration of L-DOPA a similar pattern of axial, orolingual and 
limb dyskinesia could be observed compared to dyskinetic behaviour following 
systemic administration of L-DOPA/benserazide. However, more fluctuations in 
dyskinetic movements were obtained after intrastriatal administration. Due to the 
suboptimal testing environment in microdialysis cylinders a higher degree of 
rotational behaviour was produced than in rectangular home cages.  
In order to investigate the effect of L-DOPA itself on the appearance of dyskinesia, 
the enzyme AADC was blocked by intrastriatal benserazide administration. 
Intrastriatal L-DOPA in combination with benserazide at the lesioned side did not 
increase dyskinetic behaviour. Notably, a significant difference in total dyskinesia 
scores after striatal administration of L-DOPA in comparison to L-DOPA/benserazide 
treatment was obtained (P < 0.001).  
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Fig. 7. Effects of intrastriatal administration of DOPAC (0.4 nmol/min; n = 8), HVA (0.4 
nmol/min; n = 8), 3-MT (0.4 nmol/min; n = 8) and DA (0.4 nmol/min; n = 8). These compounds 
were perfused consecutively on the ipsilateral side for 1 hour each (30 minutes aCSF between the 
individual compounds). Dyskinetic behaviour was monitored during the whole experiment every 5 
minutes up to 120 minutes after the administration of the last drug. The sum of total dyskinesia score 
over 90 minutes for DOPAC (total dyskinesia score = 0), HVA (total dyskinesia score = 0) and 3-MT 
(total dyskinesia score = 0) and over 180 minutes for DA is presented. Data are expressed as mean ± 
SEM and analysed by one sample t-test for comparison with theoretical mean (*** P < 0.001). 
 
The results of intrastriatal DA and DA metabolite administration are displayed in Fig. 
7. Neither DOPAC (0.4 nmol/min) nor HVA (0.4 nmol/min) nor 3-MT (0.4 nmol/min) 
led to an induction of dyskinesia (total dyskinesia score = 0). 3-MT produced a slight 
enhancement of motor activity, which was mainly attributed to an increase in rearing 
and sniffing behaviour but not to dyskinetic behaviour. In contrast, intrastriatal DA 
administration showed a significant increase in dyskinesia (P < 0.001). 
 
 
DISCUSSION 
The present study demonstrated that striatal L-DOPA administration itself is not able 
to induce dyskinetic behaviour in a rat model of dyskinesia. This result was obtained 
by striatal administration of benserazide blocking the conversion of L-DOPA to DA. 
Accumulating evidence shows that in addition to being a precursor of DA L-DOPA 
may be a neurotransmitter in its own right (Ueda et al. 1995; Misu et al. 2003; Misu et 
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al. 2002; Hornykiewicz 2002). Misu et al. (2003) proposed that L-DOPA itself fulfils 
the criteria for neurotransmitters (synthesis, metabolism, active transport, presence, 
physiological release, competitive antagonism, physiological or pharmacological 
responses).  
The question raised whether L-DOPA could produce dyskinetic behaviour in its own 
right without metabolism to DA, because L-DOPA mimics some of the biological 
effects such as agonism at DA D2 receptors (Hume et al. 1995). 
In the present study we demonstrated that L-DOPA was not able to induce 
dyskinesia suggesting that the expression of dyskinesia is dependent on the 
conversion of L-DOPA to DA or downstream processes. Indeed, after perfusion of DA 
via the microdialysis probe into the lesioned striatum dyskinetic movements were 
observed which were similar in their maximum level to L-DOPA-induced dyskinesia. 
However, the DA-induced dyskinesia appeared earlier and was of shorter duration 
than after L-DOPA treatment, which suggests that L-DOPA has to be converted to 
DA first before it produces dyskinetic behaviour. 
Neither L-DOPA nor DA administered at the non lesioned striatum produced any 
dyskinetic behaviour suggesting that the degeneration of dopaminergic neurons is 
necessary for the manifestation of dyskinetic movements. This result is in agreement 
with a recent study reporting that systemic L-DOPA treatment in sham lesioned 
animals did not display any dyskinetic behaviour (Meissner et al. 2006) and that more 
than 80% of nigrostriatal degeneration is necessary to induce dyskinetic movements 
at therapeutic L-DOPA doses (Winkler et al. 2002). 
Moreover, in MPTP-treated macaques a pronounced nigrostriatal neurodegeneration 
is a necessary but not sufficient condition for the occurrence of L-DOPA-induced 
dyskinesia implicating that neither the extent nor the pattern of the neurotoxin-
induced lesion can predict the manifestation of dyskinetic behaviour (Guigoni et al. 
2005). 
The striatum is the largest dopaminoceptive component of the basal ganglia. The DA 
denervated striatum plays a key role, if not the most important role in L-DOPA-
induced dyskinesia. Dyskinetic behaviour can be prevented or even reversed by 
different strategies targeting the striatum including continuous L-DOPA delivery using 
recombinant adeno-associated viruses (rAAV) vectors applied into the striatum 
(Carlsson et al. 2006) or intrastriatal infusion of fosB antisense (Andersson et al. 
1999).  
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The striatum projects to the output regions of the basal ganglia, GPi as well as to the 
SNr by either the “direct” pathway or the “indirect” pathway involving the globus 
pallidus externus (GPe) and the STN (Alexander and Crutcher 1990). 
Systemic L-DOPA administration eliciting dyskinetic movements led to an increase of  
extracellular gamma aminobutyric acid (GABA) overflow in the SNr but not in the 
GPe indicating that the direct pathway may play a more important role in the 
manifestation of dyskinesia than the indirect pathway (Mela et al. 2007). This notion 
is confirmed by molecular alterations in DA D1 receptor-rich striatal efferent neurons 
of the direct pathway, which are closely associated with L-DOPA-induced dyskinesia 
including an upregulation of transcription factors and plasticity gene in dynorphinergic 
(direct pathway) but not in enkephalinergic (indirect pathway) striatal neurons 
(Andersson et al. 1999; Carta et al. 2005; Mela et al. 2007). 
DBS of the STN which reduces the glutamatergic overactivity in the indirect pathway, 
ameliorates L-DOPA-induced dyskinesia in patients suffering from PD. Currently it is 
debated whether this effect may simply result from a reduction of the daily L-DOPA 
dose (Follett 2004) or if the indirect pathway is involved in L-DOPA induced 
dyskinetic movements. In a case report, Figueiras-Mendez et al. (1999) 
demonstrated that dyskinetic behaviour improved markedly after bilateral STN 
stimulation without reduction of L-DOPA dose. On the other hand, high frequency 
stimulation of the STN did not affect dyskinetic movement in the rat dyskinesia 
model, which led to the conclusion that at least in the rat dykinesia model the indirect 
pathway seems to be of minor importance (Oueslati et al. 2007) 
Severe nigrostriatal neurodegeneration alters the main pharmacokinetic processes of 
L-DOPA such as uptake and metabolism in the striatum (Cenci and Lundblad 2006). 
After a lesion of the nigrostriatal pathway, L-DOPA processing in dopaminergic 
neurons is impaired. In the parkinsonian brain it has been proposed that L-DOPA is 
taken up, decarboxylated and released as DA by non dopaminergic cells containing 
AADC such as serotonergic neurons or astrocytes (Carta et al. 2007; Maeda et al. 
2005). This provides a source of unregulated DA efflux into the extracellular space 
due to the lack of high affinity reuptake by the DA plasmamembrane transporter and 
by missing autoreceptors for regulation of synthesis and release of DA in these cells. 
According to these alterations a degeneration of the nigrostriatal projection neurons 
predisposes to L-DOPA induced dyskinesia because a physiological balance of DA 
transmission could not be achieved leading to high fluctuations of extracellular DA 
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levels. We simulated this high non physiological concentration of DA in the 
extracellular space of the striatum by delivering DA directly into the striatum via the 
microdialysis probe and postulate that intrastriatal administration of DA is a well-
suited model for L-DOPA- and DA-induced dyskinesia.  
Following the DA metabolism pathway we investigated whether the DA metabolites 
DOPAC, HVA and 3-MT contribute to the manifestation of dyskinesia as well.  
In the plasma of dyskinetic patients high levels of 3-O-methyldopa, the 
methylmetabolite of L-DOPA, were detected (Feuerstein et al. 1977). Possibly the 
methylmetabolites of DA as e. g. 3-MT or some other metabolites may also play a 
role in the appearance of dyskinetic movements. In this respect, Charlton and 
Crowell, Jr. (2000) investigated the effect of intraventricular injected 3-MT and 3,4-
dimethoxyphenylethylamine (DIMPEA) on locomotive behaviour of rats as well as 
their effect on DA binding. They showed an increase in locomotor activity and DA 
binding by DIMPEA, whereas administration of 3-MT decreased the activity as well 
as the DA binding. 
In the rat brain DOPAC is the major metabolite of DA. Released DA is metabolized to 
DOPAC after intraneuronal reuptake by the enzyme MAO. Released DA is also 
metabolized by the sequential action of COMT and MAO. Additionally, DA is 
metabolized to 3-MT by COMT to a lesser extent (Cooper et al. 2003). The DA 
metabolites have to be directly administered into the striatum, because they are 
unable to cross the blood-brain-barrier. Neither DOPAC nor HVA or 3-MT were able 
to induce dyskinetic movements, whereas 3-MT caused a slight enhancement of 
activity resembling a dopamimetic effect, which may be due to the conversion to 
DIMPEA, which has been shown to increase locomotor activity (Charlton and 
Crowell, Jr. 2000). 
 Several in vivo microdialysis studies investigating the effect of L-DOPA on 
extracellular DA and DA metabolite levels in 6-OHDA-lesioned rats have been 
reported (Abercrombie et al. 1990; Meissner et al. 2006; Miller and Abercrombie 
1999; Rodriguez et al. 2007; Tanaka et al. 1999; Wachtel and Abercrombie 1994). 
This is the first study to monitor dyskinetic movements and measure the 
neurochemical effects of L-DOPA on extracellular DA and DA metabolite levels 
simultaneously.  
Systemic administration of L-DOPA/benserazide led to an induction of dyskinetic 
behaviour which was dose related. The maximum level of dyskinesia was similar for 
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both doses indicating a ceiling effect. The neurochemical alterations were most 
pronounced in extracellular levels of HVA on the lesioned side (6 mg/kg, 24 mg/kg: 
1044 %, 3770 %, respectively), followed by DOPAC (6 mg/kg, 24 mg/kg 754 %,: 
2380 %, respectively). Extracellular DA levels increased to a lesser extent (6 mg/kg, 
24 mg/kg 324 %, 680 %, respectively).  
Rodriguez et al. (2007) demonstrated in a microdialysis study that the L-DOPA-
induced increase of extracellular DOPAC levels is more pronounced than that of DA. 
Indeed, the increase of DA (600 %) and DOPAC (10,000 %) as well as the dose of L-
DOPA (99 mg/kg) was much higher than in the present study. Recently, Meissner et 
al. (2006) performed a microdialysis study in 6-OHDA lesioned rats primed with L-
DOPA and found an increase of DA (20-fold). DOPAC and HVA levels were 
enhanced 11- and 9-fold, respectively. The peak DA levels were slightly higher in the 
study of Meissner et al. (2006) compared to the present study and the changes in DA 
metabolite were lower, which might be explained by the 4-fold higher dose of L-
DOPA and that the experiment was carried out under anaesthesia. 
As mentioned above, L-DOPA produced a dose-related significant increase in DA on 
the lesioned side, whereas extracellular levels of DA of the non lesioned side were 
not affected. This is in line with the results of many other groups (Abercrombie et al. 
1990; Miller and Abercrombie 1999; Rodriguez et al. 2007; Wachtel and Abercrombie 
1994). The low response of DA on the intact side indicates that under physiological 
conditions dopaminergic neurons are able to handle extracellular DA very efficiently 
thus keeping physiological homeostasis.  
In a principle component analysis the dyskinetic behaviour was correlated to 
extracellular levels of DA but not to DOPAC and HVA. Indeed, the reverse in vivo 
microdialysis experiment showed that the intrastriatal DOPAC and HVA 
administration did not produce any dyskinetic behaviour, whereas intrastriatal DA 
administration significantly induced dyskinesia. 
In conclusion, the present study underpins that intrastriatal L-DOPA has no function 
in its own right in the L-DOPA-induced dyskinesia model of rats. Rather we 
demonstrated that the neurotransmitter DA is able to induce dyskinetic movements 
when administered locally into the lesioned striatum, whereas the metabolites 
DOPAC, HVA and 3-MT did not produce any dyskinetic movements. This data is in 
line with the alterations of DA, DOPAC and HVA after systemic administration of L-
DOPA/benserazide. Alteration in DA levels highly correlates to the occurrence of 
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dyskinesia, whereas DOPAC and HVA do not show any correlation to dyskinetic 
movements. 
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CHAPTER IV 
Comparison of intrastriatal administration of noradrenaline and L-DOPA 
on dyskinetic movements 
 
ABSTRACT 
L-DOPA-induced dyskinesia is known as involuntary debilitating movement, which 
limits quality of life in patients suffering from Parkinson’s disease. The present study 
focuses on the role of the neurotransmitter noradrenaline (NA) on dyskinetic 
movements in comparison to the effect of L-DOPA.  
Rats were unilaterally lesioned with 6-OHDA and treated with L-DOPA/benserazide 
(6/15 mg/kg, p.o.) to induce stable dyskinetic movements. On the day of the 
experiment, NA (0.04 nmol/min, 0.4 nmol/min) as well as L-DOPA (0.04 nmol/min, 
0.4 nmol/min) were perfused into the lesioned and non lesioned striatum of dyskinetic 
rats using the reverse in vivo microdialysis technique. Neither NA nor L-DOPA 
treatment of the non lesioned striatum produced any dyskinetic behaviour. In 
contrast, administration of L-DOPA 0.4 nmol/min into the lesioned striatum led to a 
significant increase in dyskinesia indicated by abnormal axial, limb and orolingual 
movements. Notably, perfusion with NA 0.4 nmol/min into the lesioned striatum 
revealed a highly significant induction of dyskinetic movements, which are similar to 
the dyskinesia subtype profile of L-DOPA. In conclusion, NA is as potent as L-DOPA 
to express dyskinetic movements in L-DOPA primed rats. 
 
 
INTRODUCTION 
In PD the long term use of the gold standard L-DOPA can result in major adverse 
effects to the motor functions, namely dyskinesia, which comprises choreatic and 
dystonic movements. There is pharmacological evidence that noradrenergic 
neurotransmission is involved in the pathogenesis of L-DOPA-induced dyskinesia. 
The "2 adrenoceptor antagonist idazoxan has shown antidyskinetic efficacy in 
monkey studies (Fox et al. 2001; Grondin et al. 2000). Moreover, idazoxan reduced 
L-DOPA-induced dyskinesia without affecting the L-DOPA mediated relief of 
symptoms in clinical trials (Henry et al. 1999; Rascol et al. 2001). The question 
arises, whether an increase in noradrenergic transmission by local administration of 
NA can induce dyskinetic behaviour. Previously, we found that DA as well as L-
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DOPA delivered directly into the lesioned striatum of dyskinetic rats can produce 
dyskinetic movements (Buck and Ferger 2008). In the present study we 
demonstrated that NA is as potent as L-DOPA to provoke dyskinetic movements 
when administered locally into the striatum of L-DOPA primed rats, which previously 
received a unilateral 6-OHDA lesion of the MFB. 
 
 
MATERIALS AND METHODS 
 
Animals, 6-OHDA lesion surgery, Induction and rating of dyskinesia 
Please see chapter II “General methodology” page 22. 
 
Reverse in vivo microdialysis surgery in the striatum 
Please see chapter II “General methodology” page 24. 
 
Reverse in vivo microdialysis procedure in the striatum 
Please see chapter II “General methodology” page 25. Following insertion of the 
probes, aCSF was perfused for 1 hour. L-DOPA (0.04 nmol/min, n = 4; 0.4 nmol/min, 
n = 6) or NA (as bitartrate salt) (0.04 nmol/min, n = 4; 0.4 nmol/min, n = 6) were 
perfused on the contralateral side followed by the ipsilateral side for 60 minutes each. 
 
Drugs and chemicals 
Please see chapter II “General methodology” page 26. 
 
Statistical analysis 
Please see chapter II “General methodology” page 27. A two-factorial ANOVA was 
performed with the factors treatment and dose and the interaction term treatment x 
dose. The ANOVA was followed by pairwise t-tests and a one sample t-test 
(comparison of dyskinesia scores with the theoretical mean which was defined as 
0.0) for each experimental group taking into account the error term of the ANOVA as 
an estimate for the common variation. P < 0.05 was considered as statistically 
significant. 
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RESULTS 
 
Fig. 8. (A) Time course of total dyskinesia score of the intrastriatal ipsilateral administration of 
L-DOPA ((0.04 nmol/min (n = 4), 0.4 nmol/min (n = 6)) and NA (0.04 nmol/min (n = 4), 0.4 
nmol/min (n = 6)) for 60 min. Monitoring of dyskinetic behaviour was continued up for 120 min. (B) 
Sum of axial, limb and orolingual dyskinesia scores after intrastriatal ipsilateral administration over a 
period of 180 min. Data are expressed as mean ± SEM and analysed by one sample t-test within the 
ANOVA model for determination of the increase in dyskinesia (* P < 0.05,*** P < 0.001 for comparison 
with the theoretical mean = 0). 
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L-DOPA as well as NA were administered intrastriatally to assess their effects on 
dyskinetic behaviour of rats. Neither administration of L-DOPA nor NA on the non 
lesioned side produced any behavioural effects (total dyskinesia score = 0). In 
contrast, statistical analysis yielded a significant induction of dyskinesia after 
administration of L-DOPA 0.4 nmol/min on the lesioned side (79.8 ± 32.5 total 
dyskinesia score, P < 0.05) (Fig. 8A and 8B). Ipsilateral administration of NA 0.4 
nmol/min revealed a highly significant increase of dyskinetic movements (179.7 ± 
44.1 total dyskinesia score, P < 0.001). L-DOPA 0.04 nmol/min produced low 
dyskinesia, which was not statistically significant (26.8 ± 3.6 total dyskinesia score). 
NA 0.04 nmol/min showed an increase in dyskinetic behaviour, which was not 
statistically significant but yielded a trend (81.0 ± 40.3 total dyskinesia score, P = 
0.068). Considering the subtype dyskinesia scores, axial dyskinesia was significantly 
evoked after administration of NA 0.04 nmol/min (31.3 ± 12.6, P < 0.05) as well as 
NA 0.4 nmol/min (61.5 ± 11.4, P < 0.001). Orolingual dyskinesia was significantly 
produced after treatment with L-DOPA 0.4 nmol/min (29.7 ± 10.8, P < 0.05) and NA 
0.4 nmol/min (60.3 ± 17.2, P < 0.001). Limb dyskinesia increased significantly after 
administration of L-DOPA 0.4 nmol/min (29.7 ± 10.7, P < 0.05) and NA 0.4 nmol/min 
(57.8 ± 17.8, P < 0.001). The ANOVA revealed a significant difference in treatment 
for axial dyskinesia scores (F(1,16) = 7.62, P < 0.05), followed by a pair wise t-test 
which showed a significant difference in axial dyskinesia scores between L-DOPA 0.4 
nmol/min (20.5 ± 11.6) and NA 0.4 nmol/min (61.5 ± 11.4) administration (P < 0.05). 
Furthermore, the NA-induced dyskinesia appeared earlier than the dyskinesia 
evoked by intrastriatal administration of L-DOPA.  
 
 
DISCUSSION 
This is the first study which demonstrates that local administration of NA into the 
lesioned striatum can induce dyskinetic movements in rats in a similar manner to 
intrastriatal L-DOPA treatment. 
Most of the studies investigating dyskinetic behaviour were performed after systemic 
administration of L-DOPA (Dekundy et al. 2007; Lundblad et al. 2002). Recently, it 
was demonstrated that L-DOPA induced dyskinetic movements in rats after local 
administration into the 6-OHDA-lesioned striatum, suggesting that the striatum plays 
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a key role in L-DOPA-induced dyskinesia (Buck and Ferger 2008; Carta et al. 2006). 
In a subsequent experiment, the effect of striatal administration was abolished by 
blocking the conversion of L-DOPA to DA (Buck and Ferger 2008), which highlights 
the importance of DA in the striatum of dyskinetic rats.  
However, it has become increasingly apparent that PD and L-DOPA-induced 
dyskinesia are multisystemic disorders in which neurotransmitter systems other than 
DA are involved. There is evidence that NA in fact plays a major role in PD pathology 
and symptomatology as well as in motor complications (Brotchie 2005; Colosimo and 
Craus 2003; Fornai et al. 2007; Linazasoro et al. 2008; Nagatsu and Sawada 2007; 
Rommelfanger and Weinshenker 2007; Schapira 2005).  
Previous experimental studies have demonstrated that "2 adrenoceptor antagonists 
such as yohimbine reduce L-DOPA-induced dyskinesia in rodent (Dekundy et al. 
2007; Lundblad et al. 2002) as well as primate models (Gomez-Mancilla and Bedard 
1993). Moreover, some "2 adrenoceptor antagonists like idazoxan and fipamezole 
have shown antidyskinetic efficacy without compromising the anti-parkinsonian action 
of L-DOPA in monkey studies (Fox et al. 2001; Grondin et al. 2000; Savola et al. 
2003) and clinical trials. However, the mechanism of the alleviation of L-DOPA-
induced dyskinesia by these anti-adrenergic drugs remains elusive. The 
blockade of the action of NA synthesised from L-DOPA is thought to be involved (Fox 
et al. 2001), because dyskinesia evoked by L-DOPA, but not by DA agonists like 
apomorphine, can be reduced by an !2 adrenoceptor antagonist.  
In situ hybridisation studies revealed a poor distribution of !1B, !1D, !2A, !2B, #1 and 
#2 adrenoceptor mRNA in the rat striatum, whilst the !2C adrenoceptor mRNA was 
found to be highly expressed in this brain area (McCune et al. 1993; Nicholas et al. 
1996). More precisely, the !2C adrenoceptor is located on GABAergic medium spiny 
projection neurons of the striatum (Holmberg et al. 1999) and modulates GABA 
outflow from the striatum to GP and the SN (Zhang and Ordway 2003). Mela et al. 
(2007) demonstrated an increase in extracellular GABA release after administration 
of L-DOPA in dyskinetic rats in the SNr. Conversely, the GABA overflow was not 
altered in the GPe. This finding indicates that the direct pathway seems to be more 
important for the manifestation of dyskinetic movements in the L-DOPA rat 
dyskinesia model. This result may also be relevant for the NA-induced dyskinesia, 
because stimulation of !2C adrenoceptors by NA in the striatum is a key modulator of 
GABA release within the SNr (Alachkar et al. 2006). 
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Another explanation could be that NA mediates its dyskinesiogenic effect by acting 
on dopaminergic receptors. NA was found to act as a D1 dopaminergic agonist in the 
embryonic avian retina (Kubrusly et al. 2007) and mimics the effect of DA on the DA 
D2 receptor indicated by the inhibition of adenylate cyclase activity in the rat striatum 
(Onali et al. 1985). Furthermore, it was demonstrated that NA binds to the human DA 
D4 receptor with high affinity (Lanau et al. 1997; Newman-Tancredi et al. 1997) and 
10% of total D2-like receptors are of the DA D4 receptor located in the caudate 
putamen (Tarazi et al. 1997). Hence, NA may act also on dopaminergic receptors in 
the striatum to induce dyskinetic movements. Pharmacological studies to test this 
hypothesis are necessary. 
Additionally to a direct DA receptor mediated effect, NA indirectly may enhance 
striatal DA levels by a presynaptic mechanism. However, the loss of terminals and 
the level of DA depletion in the striatum are almost complete in dyskinetic rats under 
the conditions used in the present study (Buck and Ferger, 2008) and it is unlikely 
that NA releases DA from striatal terminals. 
In conclusion, this experiment provides the first evidence that NA produces dyskinetic 
movements resembling those induced by local or systemic L-DOPA administration, 
which underscores the relevance to investigate anti-adrenergic mechanisms for the 
treatment of dyskinetic movements in PD. 
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CHAPTER V 
The selective !1 adrenoceptor antagonist HEAT reduces L-DOPA-
induced dyskinesia in a rat model of Parkinson’s disease 
 
ABSTRACT 
In PD, the long term use of L-DOPA results in major adverse effects including 
dyskinesia or abnormal involuntary movements. The present study focuses on the 
effect of the selective "1 adrenoceptor antagonist HEAT (2-[[#-(-4-
hydroxyphenyl)ethyl]aminomethyl]-1-tetralone) in the 6-OHDA rat model of L-DOPA-
induced dyskinesia. We demonstrate that the selective "1 adrenoceptor antagonist 
HEAT (1 and 2mg/kg), the "2 adrenoceptor antagonist idazoxan (9mg/kg) and the 
non-selective %1/%2 adrenoceptor antagonist propranolol (20mg/kg) alleviate 
dyskinetic movements induced by L-DOPA. Furthermore, the adrenoceptor 
antagonists at the doses used did not influence exploratory behaviour in the open 
field system indicating that the antidyskinetic effect is not due to a reduction in 
general motor activity. Intrastriatal administration of the selective "1 adrenoceptor 
agonist cirazoline via reverse in vivo microdialysis did not induce dyskinesia. 
Additionally, we measured plasma, brain and cerebrospinal fluid (CSF) levels of 
HEAT. HEAT is a CNS active compound with a brain/plasma and CSF/plasma ratio 
of 4.29 and 0.15, respectively, which is appropriate for the investigation of "1–
mediated mechanisms in CNS disorders. In conclusion, these results demonstrate for 
the first time that a "1 adrenoceptor antagonist reduced L-DOPA-induced dyskinesia 
in a rat model. Further studies assessing the risk benefit in comparison to existing 
therapies are needed before considering "1 adrenoceptor antagonists as a target for 
the development of new antidyskinetic compounds. 
 
 
INTRODUCTION 
L-DOPA-induced dyskinesia eventually develops as serious treatment-limiting motor 
complication in the majority of patients suffering from PD (Jenner 2008a). Dyskinesia 
comprises abnormal involuntary movements such as chorea and dystonia and 
develops in up to 40% of PD patients within 4-6 years of L-DOPA therapy (Ahlskog 
and Muenter 2001).  
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The underlying pathophysiological mechanisms of L-DOPA-induced dyskinesia are 
not well understood. Several factors such as the dysregulation of DA release and 
clearance resulting in a large DA surge, upregulation of striatal transcription factors 
and plasticity genes, abnormal corticostriatal plasticity and altered firing patterns in 
basal ganglia output neurons are thought to play a role (Cenci 2007; Jenner 2008a). 
The main risk factors for the generation of dyskinetic movements are the degree of 
dopaminergic neurodegeneration within the basal ganglia (Obeso et al. 2000b), the 
onset and dose of L-DOPA therapy (Rascol 2000) as well as the young onset of the 
disease (Kumar et al. 2005). 
Alternative pharmacological approaches to L-DOPA to alleviate the cardinal 
symptoms of PD involve the treatment with synthetic DA agonists as well as 
compounds influencing the enzymatic metabolism of DA such as MAO-B or COMT 
inhibitors. However, none of these drugs has surpassed the clinical benefit derived 
from L-DOPA. Additionally, monotherapy with DA agonists in PD patients can induce 
dyskinetic movements, albeit with a reduced incidence of motor complications 
(Rascol et al. 2000).  
To date the weak non-competitive N-methyl-D-aspartate (NMDA) antagonist 
amantadine is the only drug which is clinically used to alleviate L-DOPA-induced 
dyskinesia. However, amantadine is not tolerated well because of cognitive side 
effects. There is a controversy in the literature regarding the duration of amantadine’s 
antidyskinetic effect. Stocchi et al. (2008) reported that the effect of amantadine is 
often transient and lost within 1 year, whereas Verhagen Metman et al. (1999) 
showed that amantadine’s effect on motor response complications is maintained for 
at least 1 year after treatment initiation. Nevertheless, there is an unmet medical 
need to identify novel mechanisms for the treatment of dyskinesia in PD. New 
treatment strategies would therefore target non-dopaminergic pathways to alleviate 
motor complications associated with L-DOPA therapy, whilst maintaining the anti-
parkinsonian effect of L-DOPA. Currently, several approaches are evaluated in 
clinical trials such as adenosine A2a antagonists, 5-HT1A agonists, mGluR5 
antagonists, NMDA antagonists, MAO inhibitors and "2 adrenoceptor antagonists 
which are aiming to treat symptoms of PD and L-DOPA-induced dyskinesia or at 
least try to avoid dyskinesia. 
Indeed, there is evidence that drugs influencing noradrenergic neurotransmission can 
be used as an adjunct therapy to L-DOPA in order to reduce motor complications. 
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Alleviation of established dyskinesia was achieved by treatment with "2 adrenoceptor 
antagonists in rodents (Dekundy et al. 2007; Lundblad et al. 2002) and MPTP-treated 
monkeys (Fox et al. 2001; Gomez-Mancilla and Bedard 1993; Grondin et al. 2000; 
Henry et al. 1999; Savola et al. 2003) as well as in parkinsonian patients (Rascol et 
al. 2001). Additionally, the non-selective %1/%2 adrenoceptor antagonist propranolol 
was found to show antidyskinetic properties in the rat dyskinesia model (Dekundy et 
al. 2007), in monkeys (Gomez-Mancilla and Bedard 1993) and PD patients 
(Carpentier et al. 1996). Recently, the "1 adrenoceptor antagonist prazosin 
demonstrated a reduction of L-DOPA-induced hyperactivity in MPTP-treated 
macaques. However, dyskinesia provoked by L-DOPA was not affected (Visanji et al. 
2009). 
The aim of the present study was to investigate the antidyskinetic properties of the 
selective "1 adrenoceptor antagonist 2-[[#-(-4-hydroxyphenyl)ethyl]aminomethyl]-1-
tetralone (HEAT) in hemiparkinsonian rats. Additionally, the selective !1 
adrenoceptor agonist cirazoline was administered locally into the lesioned striatum to 
study if !1 adrenoceptor activation is able to provoke dyskinesia.  
 
 
MATERIALS AND METHODS 
 
Animals, 6-OHDA lesion surgery, Induction and rating of dyskinesia 
Please see chapter II “General methodology” page 22. 
 
Pharmacological antagonism of L-DOPA-induced dyskinesia 
The "1 adrenoceptor antagonist HEAT, the "2 adrenoceptor antagonist idazoxan and 
the non-selective %1/%2 adrenoceptor antagonist propranolol were investigated for 
their effects on L-DOPA-induced dyskinesia. The compounds were tested in a blind, 
randomised, repeated measurement design. Between the different days of testing, a 
washout period of four days was included. The rats were treated with L-
DOPA/benserazide (6/15 mg/kg, p.o.) once daily to maintain stable dyskinetic 
behaviour. Before each testing day, the rats were matched according to their total 
dyskinesia score to exclude compound effects from the last testing day. Each group 
of rats exhibits approximately the same mean of the total dyskinesia score as well as 
the same SEM to make sure that the initial conditions were the same. All compounds 
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were dissolved in saline and administered 30 minutes (i.p.) prior to L-
DOPA/benserazide (6/15 mg/kg, p.o.). Amantadine (40 mg/kg, i.p.) served as a 
positive control (n = 8). HEAT was given at doses of 0.5 mg/kg (n = 8), 1 mg/kg (n = 
8) and 2 mg/kg (n = 8). Idazoxan was administered at doses of 6 mg/kg (n = 8) and 9 
mg/kg (n = 8). Propranolol was injected at doses of 10 mg/kg (n = 8) and 20 mg/kg (n 
= 8). Dyskinesia including axial, limb and orolingual subtype was monitored every 20 
minutes for 240 minutes following administration of L-DOPA/benserazide by an 
“experimentally blinded” observer not aware of the experimental group alignment. 
 
Assessment of motor side effects of adrenoceptor antagonists and amantadine 
The measurement of the exploratory behaviour in rats was used to determine 
potential motor side effects of the different adrenoceptor antagonists. Exploratory 
behaviour was detected in the open field system Actimot™ (TSE Systems GmbH, 
Bad Homburg, Germany) in the dark with a hole board inserted in order to increase 
exploratory activity. Rats were placed individually in the centre of the activity box 
(46.5 cm x 46.5 cm) and horizontal motor activity (s) was determined at 1 minute 
intervals by infrared sensor pairs (interspace 1.4 cm) with a sampling rate of 100 Hz. 
A total number of 96 naive rats was used in this experiment. The following 
compounds and doses were used: amantadine at 20 mg/kg (n = 6) and 40 mg/kg (n 
= 6); HEAT at 0.5 mg/kg (n = 6), 1 mg/kg (n = 6) and 2 mg/kg (n = 6); idazoxan at 6 
mg/kg (n = 6) and 9 mg/kg (n = 6); propranolol at 10 mg/kg (n = 6) and 20 mg/kg (n = 
6). The drugs were administered (i.p.) 30 minutes prior to the rats being placed 
individually in the open field system. Horizontal activity (s) was measured 
immediately afterwards for 20 minutes. 
 
Reverse in vivo microdialysis surgery in the striatum 
Please see chapter II “General methodology” page 24. 
 
Intrastriatal administration of the !1 adrenoceptor agonist cirazoline via 
reverse in vivo microdialysis in the striatum 
Please see chapter II “General methodology” (Reverse in vivo microdialysis 
procedure) page 25. Following insertion of the probes and an equilibration period, the 
selective !1 adrenoceptor agonist cirazoline hydrochloride (0.4 nmol/min, n = 4) was 
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perfused in the lesioned striatum for 60 minutes followed by an aCSF perfusion for 2 
hours. 
 
Sample collection procedure 
Please see chapter II “General methodology” (CSF, plasma and brain sample 
collection procedure) page 25. The "1 adrenoceptor antagonist HEAT (2 mg/kg, i.p.) 
was administered to naive rats. At time points 0.5 h (n = 6), 1 h (n = 6), 2 h (n = 6), 4 
h (n = 6) and 8 h (n = 6), samples of CSF, blood and brain tissue were taken.  
 
Sample preparation procedure 
Brain tissue was homogenised using Dispomix™ 25 tubes and processed as 
described in chapter II “General methodology” page 25. 
 
LC-MS/MS analysis of plasma, brain and CSF samples 
Please see chapter II “General methodology” (LC-MS/MS system) page 26. Samples 
were analysed for HEAT using LC-MS/MS. Mobile phase “A” and “B” consisted of 0.1 
% formic acid in LC-MS grade water and acetonitrile, respectively. The gradient was 
chosen as follows: 0.00 min: 95 % A, 0.10 min 95 % A, 1.00 min 0 % A, 1.40 min 0 % 
A, 1.50 min 95 % A, 2.00 min 95 % A and delivered at 0.5 ml/min onto a reversed-
phase column (YMC-Pack ProC18, 50 x 2.1 mm i. d., 5 #m particles, YMC Europe 
GmbH, Dinslaken, Germany) at 20 °C. The column switching valve was set at 0.00 
min to the waste, at 0.80 min to the mass spectrometer and at 1.40 min to the waste 
again. 
Three transitions were chosen: 296-150 (declustering potential (DP) 61 V, collision 
energy (CE) 21 V, cell exit potential (CXP) 10 V), 296-121 (DP 61 V, CE 35 V, CXP 8 
V), 296-77 (DP 61 V, CE 89 V, CXP 6 V) and transition 296-150 was used for the 
quantification of HEAT. 
 
Drugs and chemicals 
Please see chapter II “General methodology” page 26. 
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Statistical analysis 
Please see chapter II “General methodology” page 27. To compare rating scores of 
L-DOPA-induced dyskinesia, a Kruskal-Wallis test was carried out followed by a 
Mann Whitney test.  
In order to show not only a comparison between the dyskinesia scores of different 
treatment groups, but also the existence or absence of dyskinesia, a theoretical 
mean was assumed. The theoretical mean was defined as 0.0, which is equivalent to 
the pre dyskinesia score. A one-sample t-test was performed to compare dyskinesia 
scores with the theoretical mean. 
The measurement of exploratory behaviour was analysed by two-way ANOVA with 
time as a dependent factor and dose as an independent factor followed by a 
Bonferroni post hoc test.  
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RESULTS 
 
Effects of adrenoceptor antagonists on L-DOPA-induced dyskinesia 
 
 
Fig. 9. Effects of adrenoceptor antagonists on L-DOPA-induced dyskinesia. The compounds 
were tested in a blind, randomised, cross-over design. Vehicle (n = 15), amantadine (40 mg/kg (n = 
8)), HEAT (0.5 mg/kg (n = 8), 1 mg/kg (n = 8), 2 mg/kg (n = 8)), idazoxan (6 mg/kg (n = 8), 9 mg/kg (n 
= 8)) and propranolol (10 mg/kg (n = 8), 20 mg/kg (n = 8)) were administered 30 minutes (i.p.) prior to 
L-DOPA/benserazide (6/15 mg/kg, p.o.). Data are expressed as mean ± SEM and were analysed by a 
Kruskal-Wallis test followed by a Mann Whitney test .for statistical comparison of the treatments (***P 
< 0.001, **P < 0.01, *P < 0.05). 
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Fig. 10. Time course of total dyskinesia 
score following administration of HEAT 
(0.5 mg/kg (n = 8), 1 mg/kg (n = 8), 2 mg/kg 
(n = 8)) and vehicle (n = 15) 30 minutes (i.p.) 
prior to L-DOPA/benserazide (6/15 mg/kg, 
p.o.). Data are expressed as mean ± SEM. 
 
 
 
 
 
Different adrenoceptor antagonists were investigated for their effects on L-DOPA-
induced dyskinesia (Fig. 9 and 10). Statistical analysis displayed a significant effect 
of treatment on the axial (P < 0.01), limb (P < 0.01) and orolingual (P < 0.01) as well 
as on the total dyskinesia score (P < 0.01). Rats injected with vehicle plus L-
DOPA/benserazide (6/15 mg/kg; p.o.) showed a significant induction (P < 0.001) of 
axial (15.1 ± 1.4), limb (13.5 ± 1.1) and orolingual (13.7 ± 1.0) dyskinesia, expressed 
as total dyskinesia score (42.3 ± 3.4). Amantadine 40 mg/kg revealed a significant 
reduction in the single dyskinesia scores indicated by axial (3.1 ± 1.5, P < 0.001), 
limb (2.8 ± 1.4, P < 0.001) and orolingual (3.4 ± 1.5, P < 0.001) dyskinesia as well as 
in the total dyskinesia score (9.3 ± 4.3, P < 0.001) in comparison to vehicle. 
Furthermore, the "1 adrenoceptor antagonist HEAT at a dose of 1 mg/kg and 2 
mg/kg reduced axial (1 mg/kg: 8.3 ± 2.4, P < 0.05; 2 mg/kg: 6.6 ± 3.3, P < 0.05), limb 
(1 mg/kg: 8.1 ± 2.0, P < 0.05; 2 mg/kg: 6.3 ± 2.6, P < 0.05) and orolingual (1 mg/kg: 
8.3 ± 2.0, P < 0.05; 2 mg/kg: 6.3 ± 2.6, P < 0.05) dyskinetic movements significantly 
as well as the total dyskinesia score (1 mg/kg: 24.6 ± 6.3, P < 0.05; 2 mg/kg: 19.1 ± 
8.4, P < 0.05). Additionally, treatment with the "2 adrenoceptor antagonist idazoxan 
at a dose of 9 mg/kg alleviated axial (5.9 ± 2.9, P < 0.05), limb (5.9 ± 2.7, P < 0.05) 
and orolingual (5.9 ± 2.7, P < 0.05) dyskinesia significantly as well as the total 
dyskinesia score (17.6 ± 8.4, P < 0.05). Administration of the non selective %1/ %2 
adrenoceptor antagonist propranolol at a dose of 20 mg/kg showed a significant 
reduction in the single dyskinesia subtype scores indicated by axial (6.3 ± 2.8, P < 
0.05), limb (6.3 ± 2.2, P < 0.05) and orolingual (6.3 ± 2.2, P < 0.05) dyskinesia as well 
as in total dyskinesia score (18.8 ± 7.1, P < 0.05) compared to the vehicle group. The 
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lowest dose of HEAT (0.5 mg/kg), idazoxan (6 mg/kg) and propranolol (10 mg/kg) did 
not show a significant alleviation in dyskinesia. 
 
Effects of adrenoceptor antagonists on motor activity 
 
 
Fig. 11. Effects of the NMDA antagonist amantadine (A), the !1 adrenoceptor antagonist HEAT 
(B), the !2 adrenoceptor antagonist idazoxan (C) and the nonselective "1/"2 adrenoceptor 
antagonist propranolol (D) on exploratory behaviour in naive rats. Rats were injected with 
amantadine (vehicle (n = 6), 20 mg/kg (n = 6), 40 mg/kg (n = 6)), HEAT (vehicle (n = 6), 0.5 mg/kg (n = 
6), 1 mg/kg (n = 6) and 2 mg/kg (n = 6)), idazoxan (vehicle (n = 6), 6 mg/kg (n = 6), 9 mg/kg (n = 6)) 
and propranolol (vehicle (n = 6), 10 mg/kg (n = 6), 20 mg/kg (n = 6)) 30 minutes (i.p.) prior to being 
placed into the open field system. The sum of activity over 20 minutes is displayed in a bar graph as 
an insert to each time course figure. Data are expressed as mean ± SEM and were analysed by two-
way ANOVA and the Bonferroni post hoc test. No significant differences between the treatment groups 
were observed.  
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Adrenoceptor antagonists were investigated for their effects on exploratory behaviour 
in naive rats (Fig. 11). None of the adrenoceptor antagonists HEAT, idazoxan or 
propranolol showed any significant differences in exploratory behaviour compared to 
the vehicle group (P > 0.05) indicating that the compounds do not influence the motor 
activity of the rats. However, propranolol 20 mg/kg displayed a trend towards 
decreased exploratory activity, which did not reach statistical significance. 
 
Effects of intrastriatal administration of cirazoline on dyskinetic behaviour 
The selective !1 adrenoceptor agonist cirazoline was perfused into the lesioned 
striatum of dyskinetic rats via reverse in vivo microdialysis. Intrastriatal treatment with 
cirazoline did not produce dyskinetic movements (data not shown). However, 
hypersalivation a !1-related effect was observed. 
 
Exposure to HEAT in plasma, brain and CSF 
 
time Plasma 
ng/ml 
(nmol/l) 
Brain 
ng/g 
(nmol/kg) 
CSF 
ng/ml 
(nmol/l) 
 
0.5h 
 
71.10 ± 39.79 
(240.70 ± 134.71) 
 
 
304.89 ± 101.49 
(1032.20 ± 343.59) 
 
10.94 ± 3.34 
(37.03 ± 11.30) 
1h 56.16 ± 74.59 
(190.13 ± 252.51) 
 
229.57 ± 216.79 
(777.20 ± 733.93) 
 
6.44 ± 5.96 
(21.79 ± 20.18) 
 
2h 6.99 ± 6.65 
(23.68 ± 22.52) 
 
31.35 ± 25.16 
(106.12 ± 85.18) 
 
0.73 ± 0.65 
(2.48 ± 2.20) 
 
4h 2.86 ± 1.79 
(9.67 ± 6.06) 
 
17.36 ± 11.94 
(58.76 ± 40.41) 
 
0.27 ± 0.49 
(0.90 ± 1.67) 
 
8h 1.02 ± 0.41 
(3.47 ± 1.37) 
 
6.54 ± 2.49 
(22.14 ± 8.43) 
 
0.10 ± 0.24 
(0.33 ± 0.80) 
 
 
Table 4. Plasma, brain and CSF levels of HEAT (2 mg/kg) at 0.5 h (n = 6), 1 h (n = 6), 2 h (n = 6), 4 
h (n = 6) and 8 h (n = 6) following administration (i.p.) in naive rats. Data are expressed as mean ± SD. 
 
The selective "1 adrenoceptor antagonist HEAT was injected into naive rats. The 
concentration of HEAT was determined in plasma, brain and CSF at 0.5 h, 1 h, 2 h, 4 
Chapter V 
 64 
h and 8 h post administration (Table 4). Plasma, brain as well as CSF tmax values 
were observed at the 0.5 h time point. Cmax values for plasma, brain and CSF were 
71.10 ± 39.79 ng/ml, 304.89 ± 101.49 ng/g and 10.94 ± 3.34 ng/ml, respectively. The 
brain/plasma and CSF/plasma ratio at tmax was found to be 4.29 and 0.15, 
respectively.  
 
 
DISCUSSION 
The present study suggests that "1 adrenoceptor antagonists play a role in L-DOPA-
induced dyskinesia. We demonstrated that the selective "1 adrenoceptor antagonist 
HEAT alleviated dyskinetic movements as well as the "2 adrenoceptor antagonist 
idazoxan and the non-selective %1/%2 antagonist propranolol, whilst showing no 
confounding motor depressant effects. 
During the preparation of this manuscript, Visanji et al. (2009) investigated the "1 
adrenoceptor antagonist prazosin in MPTP-lesioned macaques on motor behaviour. 
Assessment of L-DOPA-induced hyperactivity resulted in a 1.5-fold increase in L-
DOPA-treated MPTP monkeys in comparison to normal, non MPTP-lesioned 
animals. Dyskinesia was scored by a well established rating scale (Hill et al. 2004). L-
DOPA led to only a mild to moderate level of dyskinesia comprising predominantly of 
dystonia, but was in the absence of the choreic form of dyskinesia. Prazosin reduced 
L-DOPA-induced hyperactivity, whilst not significantly affecting dyskinetic 
movements. However, the authors discussed that due to the limited group size of the 
monkey study and the diversity of the phenomenology, an effect on one form of 
dyskinesia cannot be excluded (Visanji et al., 2009). Our results are in contrast to the 
conclusion of Visanji et al. (2009) that "1 adrenoceptors plays no major role in 
dyskinetic effects of L-DOPA per se. 
Recently, Paquette et al. (2009) observed no effect of prazosin (0.1 mg/kg) on L-
DOPA-induced dyskinesia in the 6-OHDA rat model. However, using a single dose of 
prazosin an effect on dyskinesia cannot be entirely excluded since a higher dose 
may show antidyskinetic efficacy. HEAT (0.5 mg/kg) was found not to be effective 
whereas HEAT (1 and 2 mg/kg) significantly reduced dyskinesia scores. Additionally, 
Hill and Brotchie (1999) demonstrated that prazosin at higher doses (1, 3 mg/kg) 
potentiated the antiparkinsonian effect of a non-dopaminergic drug. 
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Prazosin and HEAT are both potent inhibitors of the "1 adrenoceptor, showing a Ki 
value of 0.1 nM with equal affinity for the "1A, "1B and "1D subtype and their radio 
ligands are widely used in "1 binding studies (Alexander et al. 2005). At high doses, 
prazosin may also act on other receptors such as the "2B and "2C adrenoceptor 
(Bylund et al. 1994) as well as the melatonin MT3 receptor (Paul et al. 1999).  
Most of the research concerning "1 adrenoceptor antagonists has been performed in 
peripheral organs, particularly in the cardiovascular system. Here we identified that 
HEAT is appropriate for the investigation of central "1-dependent mechanisms. We 
clearly demonstrated that HEAT crosses the blood brain barrier as indicated by a 
brain/plasma ratio of 4.29. Notably, HEAT achieves a high CSF exposure. CSF levels 
appear to be reasonably accurate to predict unbound drug concentration in the brain, 
which has been proven by preclinical and clinical studies. Hence, CSF exposure is a 
relevant surrogate for the in vivo assessment of CNS druggability (Lin 2008). This is 
of relevance for the assumption that the free drug level is sufficient for interaction with 
its receptor target.  
In the present study, we demonstrated that HEAT reduced dyskinetic movements 
provoked by treatment with L-DOPA in 6-OHDA-lesioned rats. HEAT (1 and 2 mg/kg) 
significantly decreased axial, limb as well as orolingual dyskinetic movements, 
whereas no reduction in exploratory behaviour was observed indicating that the 
antidyskinetic action of HEAT is not due to a general motor depressant effect. We 
used exploratory behaviour to detect potential motor depressant effects and found 
that the automated open field system equipped with hole boards make the system 
more sensitive for monitoring alterations within the first 20 minutes. To reduce 
variability, we carried out this test in the dark. In order to increase the predictive 
validity of the dyskinesia model, it is necessary to control confounding factors. One 
relevant confounding factor may be alterations in motor activity. Recently, Jenner 
(2008b) pointed out that drugs causing sedation or altering cardiovascular 
parameters or altering muscle tone along with many others can worsen the effects of 
motor activity and alter the expression of dyskinesia in the MPTP-treated primate 
model. Indeed, the same factors are also relevant in the rat dyskinesia model. HEAT 
was free of motor depressant effects at the doses used as indicated by measurement 
of exploratory activity. In a preliminary study HEAT (2mg/kg, i.p.) administered 30 
minutes prior to L-DOPA/benserazide (6/15 mg/kg, p.o.) reduced the total dyskinesia 
score in rats which received for the first time L-DOPA/benserazide. This effect was 
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accompanied by a reduction of automated motor activity measured by light beam 
interruptions reflecting both hyperactivity and dyskinetic movements. Although HEAT 
did not reduce exploratory behaviour in non lesioned rats (Fig. 11) we cannot rule out 
that in 6-OHDA-lesioned rats part of the antidyskinetic affect might be mediated by a 
reduction of L-DOPA-induced hyperactivity which is more prominent in lesioned than 
in intact rats. Additionally, "1 adrenoceptor antagonists are clinically used for 
treatment of arterial hypertension suggesting that a higher dose of HEAT may 
provoke side effects such as sedation and hypotension. Further studies are needed 
to clarify the evaluation of "1 adrenoceptor antagonists in animal models of 
cardiovascular dysfunction including measurement of blood pressure and heart rates 
and to investigate a potential interaction of "1 adrenoceptor antagonists with the 
beneficial effects of L-DOPA. 
Recently, local administration of NA in the DA-denervated striatum has been found to 
produce dyskinetic movements in rats (Buck and Ferger 2009a). In dyskinesia, the 
neurotransmitter NA may derive from exogenously applied L-DOPA and binds to !1 
adrenoceptors. Thus, the !1 adrenoceptor antagonist HEAT may act via competitive 
antagonism of the neurotransmitter NA. To investigate if a direct "1-mediated 
mechanism is underlying the appearance of dyskinesia, the effect of the selective "1 
adrenoceptor agonist cirazoline on dyskinetic movements was assessed by local 
perfusion into the lesioned striatum of rats. The model of administration of potentially 
dyskinesiogenic compounds into the 6-OHDA-lesioned striatum via reverse in vivo 
microdialysis has been validated using several compounds. It has been 
demonstrated that L-DOPA, DA as well as NA induces dyskinetic behaviour after 
perfusion into the lesioned striatum (Buck and Ferger 2008; Buck and Ferger 2009a; 
Carta et al. 2006). Administration of the selective "1 adrenoceptor agonist cirazoline 
into the lesioned striatum did not produce any dyskinetic movements suggesting that 
activation of "1 adrenoceptors itself does not play a role in the appearance of 
dyskinesia. Recently, the role of noradrenergic !1 and !2 receptors on subthalamic 
neuron firing rate in intact and 6-OHDA-lesioned rats has been elaborated. Belujon et 
al. (2007) demonstrated that at least in part motor activity is affected by presynaptic 
!2 and postsynaptic !1 adrenoceptor receptors in the STN. Thus, we cannot exclude 
that cirazoline may provoke its dyskinesiogenic effect via !1 adrenoceptors brain 
structures in other than the striatum. Theoretically, HEAT may exert its antidyskinetic 
effect via modulation of noradrenergic activity in the STN. 
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It was previously shown that the !1 adrenoceptor antagonist prazosin attenuated DA 
release after striatal administration, whereas systemic prazosin did not result in a 
decrease of striatal DA release (Sommermeyer et al. 1995). Conversely, evoked DA 
release after stimulation with NA (Pan et al. 2004), MK-801 (Mathe et al. 1996) and 
morphine (Auclair et al. 2004) was reduced by prazosin as measured by in vivo 
microdialysis. We hypothesize that HEAT attenuates the stimulated DA overflow 
derived from exogenously applied L-DOPA in the striatum. This mechanism may 
contribute to the alleviation of dyskinesia by decreasing pulsatile DA receptor 
stimulation which is regarded as an important factor in dyskinesia.  
Previous experimental studies have demonstrated that "2 adrenoceptor antagonists 
such as the traditional drug yohimbine reduced L-DOPA-induced dyskinesia in rodent 
(Dekundy et al. 2007; Lundblad et al. 2002) as well as primate models (Gomez-
Mancilla and Bedard 1993). The present study showed that the more selective "2 
adrenoceptor antagonist idazoxan alleviated dyskinetic movements in 6-OHDA-
lesioned rats in a similar manner to HEAT, without reducing exploratory activity. 
Idazoxan has not been previously tested in the 6-OHDA-lesioned rat model of L-
DOPA-induced dyskinesia. However, the drug was investigated in a simple rodent 
assay for the in vivo identification of agents with potential to reduce L-DOPA-induced 
dyskinesia (Johnston et al. 2005). Idazoxan was found to selectively reduce L-DOPA-
induced vertical activity in reserpinised rats, which was indicated to be a surrogate 
marker for putative antidyskinetic compounds. Idazoxan was effective at a dose of 3 
mg/kg, which is 3-fold lower than the antidyskinetic dose in the present study. This 
discrepancy may be due to the different model and/or rat strain differences. 
Additionally, idazoxan alleviated dyskinetic movements in the MPTP-lesioned primate 
model without compromising the anti-parkinsonian response to L-DOPA (Fox et al. 
2001; Grondin et al. 2000; Henry et al. 1999). However, the dyskinetic behaviour 
induced by treatment with the DA agonist apomorphine was not affected by idazoxan 
suggesting that the apomorphine-induced dyskinesia does not involve "2 
adrenoceptors (Fox et al. 2001). This discrepancy may be explained by the fact that 
L-DOPA, in contrast to apomorphine, can be metabolised to NA. Thus, it can be 
hypothesized that NA derived from exogenous L-DOPA may contribute to L-DOPA-
induced dyskinesia. Concordantly, it was recently shown, that intrastriatal NA can 
induce dyskinetic movements by itself in a similar manner to L-DOPA in primed 6-
OHDA-lesioned rats (Buck and Ferger 2009a). Moreover, the clinical effects of 
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idazoxan were investigated in patients with advanced PD and it was shown that 
dyskinesia severity improved without compromising the beneficial response to L-
DOPA. However, the treatment with idazoxan resulted in adverse side effects 
including hypertension, tachycardia, flushing and headache (Rascol et al. 2001). 
In the present study, the non selective %1/%2 adrenoceptor antagonist propranolol was 
found to be antidyskinetic at the dose of 20 mg/kg. Our results are in agreement with 
a previous study of Dekundy et al. (2007), which reported that propranolol reduced 
dyskinetic movements in the 6-OHDA rat model. Dekundy et al. (2007) additionally 
showed a trend towards a reduction in the motor performance of rats in the rotarod 
test at the highest dose of propranolol (20 mg/kg), which is again in agreement with 
results in the exploratory behaviour test of our study. Furthermore, propranolol was 
found to be effective against L-DOPA-induced dyskinesia in PD patients (Carpentier 
et al., 1996) and in MPTP-treated monkeys (Gomez-Mancilla and Bedard, 1993). 
Amantadine, which was included as a positive control, reduced dyskinesia scores in 
a similar manner as previously shown by other groups (Dekundy et al. 2007; 
Lundblad et al. 2002).  
In conclusion, the present study provides the first evidence that "1 adrenoceptor 
antagonists play a role in L-DOPA-induced dyskinesia, which is in contrast to Visanji 
et al. (2009), who did not show an effect of the "1 adrenoceptor antagonist prazosin 
on dyskinesia. The selective "1 adrenoceptor antagonist HEAT reduced axial, limb 
and orolingual dyskinesia in 6-OHDA-lesioned rats, whilst showing no confounding 
motor depressant effects. HEAT is qualified for the investigation of "1–mediated 
mechanisms in CNS disorders as demonstrated by measurement of plasma, brain 
and CSF HEAT levels. 
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CHAPTER VI 
The !2 adrenoceptor antagonist idazoxan alleviates L-DOPA-induced 
dyskinesia by reduction of striatal dopamine levels 
 
ABSTRACT 
L-DOPA-induced dyskinesia is characterised by involuntary debilitating movement, 
which limits quality of life in patients suffering from Parkinson’s disease. Here we 
investigate effects of the !2 adrenoceptor antagonist idazoxan on L-DOPA-induced 
dyskinesia as well as on alterations of extracellular L-DOPA and DA levels in the 
striatum in dyskinetic rats.  
Male Wistar rats were unilaterally lesioned with 6-OHDA and subsequently treated 
with L-DOPA/benserazide to induce stable dyskinetic movements. Administration of 
idazoxan (9mg/kg, i.p.) significantly alleviated L-DOPA-induced dyskinesia, whereas 
idazoxan (3mg/kg, i.p.) did not affect dyskinetic behaviour. Bilateral in vivo 
microdialysis revealed that idazoxan 9mg/kg reduces extracellular peak L-DOPA 
levels in the lesioned and intact striatum as well as DA levels in the lesioned striatum. 
In parallel, the exposure to idazoxan in the striatum was monitored. Furthermore, no 
idazoxan and L-DOPA drug-drug interaction was found in plasma, brain tissue and 
CSF.  
In conclusion, the decrease of L-DOPA-derived extracellular DA levels in the lesioned 
striatum significantly contributes to the antidyskinetic effect of idazoxan. 
 
 
INTRODUCTION 
Motor impairments associated with PD are the result of a massive depletion of striatal 
DA due to a progressive loss of dopaminergic neurons within the SNc (Ehringer and 
Hornykiewicz 1960; Riederer and Wuketich 1976). Consequently, the primary 
therapeutic treatment strategy involves the restoration of dopaminergic 
neurotransmission in the basal ganglia. Many dopaminergic drugs are currently 
available but none have surpassed the clinical efficacy derived from the DA precursor 
L-DOPA, which remains the most effective anti-parkinsonian compound since its 
introduction in the late 1960s (Cotzias et al. 1969). However, long term use of L-
DOPA can eventually result in serious treatment-limiting motor complications, namely 
dyskinesia which comprises mainly of choreic and dystonic movements. Dyskinesia 
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develops progressively over time and up to 40% of PD patients suffer from 
dyskinesia within 4-6 years of L-DOPA therapy (Ahlskog and Muenter 2001).  
At present the non-competitive NMDA glutamatergic antagonist amantadine is the 
only compound which is clinically used to alleviate L-DOPA-induced dyskinesia but 
its success has been limited (Stocchi et al. 2008). Thus, there is an unmet medical 
need to identify novel mechanisms for the treatment of dyskinesia in PD. Additionally, 
the predictive validity of preclinical animal models of L-DOPA-induced dyskinesia has 
to be further improved to promote drug discovery. During the progression of PD, the 
buffering capacity of DA, released from exogenously applied L-DOPA, disappears. 
As a consequence peak DA levels, which are suspected to cause peak dyskinesia, 
evolve. However, reduction of peak DA levels by simply reducing the L-DOPA dose is 
not the ultimate solution since a sufficient DA receptor stimulation has to be 
maintained. Indeed, achieving the balance between high extracellular DA levels 
which prone dyskinesia and low DA levels which cause the cardinal symptoms of PD 
is a major challenge in late stage PD. 
There is pharmacological evidence that noradrenergic neurotransmission is involved 
in the pathogenesis of L-DOPA-induced dyskinesia and antiadrenergic compounds 
may positively affect PD symptomatology. The "2 adrenoceptor antagonist idazoxan 
has shown antidyskinetic efficacy in monkey studies (Fox et al. 2001; Grondin et al. 
2000). Moreover, in clinical trials idazoxan reduced L-DOPA-induced dyskinesia 
without affecting the L-DOPA mediated relief of symptoms (Henry et al. 1999; Rascol 
et al. 2001). Furthermore, fipamezole, another "2 adrenoceptor antagonist targeting 
"2A, "2B and "2C receptors, has been investigated in a phase II study in PD patients 
suffering from L-DOPA-induced dyskinesia. Fipamezole, as idazoxan, was able to 
reduce dyskinesia scores without compromising the anti-parkinsonian action of L-
DOPA.  
The mechanism of alleviation of L-DOPA-induced dyskinesia by these anti-
adrenergic drugs remains elusive. The reduction of NA synthesised from L-DOPA is 
thought to be involved (Fox et al. 2001). This hypothesis is due to the fact that 
dyskinesia evoked by DA agonists like apomorphine cannot be reduced by a !2 
adrenoceptor antagonist as DA agonists cannot be metabolised to NA. Moreover, the 
anti-parkinsonian action of L-DOPA was prolonged by idazoxan whilst the 
combination of idazoxan and apomorphine did not result in an extension of the anti-
parkinsonian effect (Fox et al. 2001). Recently, we studied the role of the !1 
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adrenoceptor antagonist HEAT in the rat dyskinesia model and found an 
antidyskinetic effect in the range of other antiadrenergic drugs (Buck and Ferger 
2009). 
The present study was performed to investigate the effect of the !2 adrenoceptor 
antagonist idazoxan on dyskinetic behaviour and neurochemical alterations of L-
DOPA and DA levels following administration of L-DOPA/benserazide in the rat L-
DOPA dyskinesia model. Extracellular levels of L-DOPA and DA were assessed 
using bilateral in vivo microdialysis technique in the lesioned as well the intact 
striatum using HPLC-ECD. In parallel, levels of idazoxan were monitored using LC-
MS/MS. Additionally, the exposure to idazoxan plus L-DOPA was investigated in 
plasma, brain tissue and CSF to exclude a drug-drug interaction which might give 
false positive receptor mediated effects. 
 
 
MATERIALS AND METHODS 
 
Animals, 6-OHDA lesion surgery, Induction and rating of dyskinesia 
Please see chapter II “General methodology” page 22. 
 
In vivo microdialysis surgery in the striatum 
Please see chapter II “General methodology” page 23. 
 
In vivo microdialysis procedure in the striatum 
Please see chapter II “General methodology” page 24. Fractions 1 to 4 (0 - 80 min) 
were used for calculation of the basal levels which were regarded as 100 %. At 90 
minutes, idazoxan hydrochloride (9 mg/kg, i.p. (n = 8) and 3 mg/kg, i.p. (n = 8)) and 
vehicle (saline, i.p. (n = 8)) was administered, respectively. Thirty minutes later (120 
min), L-DOPA (6 mg/kg, p.o.) in combination with benserazide (15 mg/kg, p.o.) was 
administered and the sampling was continued for 5 hours (up to 420 min).  
 
Assessment of pharmacokinetics of L-DOPA and idazoxan 
Please see chapter II “General methodology” (CSF, plasma and brain sample 
collection procedure) page 25. Idazoxan hydrochloride (9 mg/kg, i.p. (n = 4)) and 
vehicle (i.p. (n = 4)) were administered 30 minutes prior to the treatment with L-
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DOPA/benserazide (6/15 mg/kg, p.o.) to naive rats. Forty minutes following L-DOPA 
administration samples of CSF, blood and brain tissue were taken. 
One hemisphere of the brain was homogenised by sonication and processed as 
previously described in chapter II “General methodology” (Sample preparation 
procedure) page 25. 
 
HPLC analysis of microdialysis samples (L-DOPA and DA) 
Please see chapter II “General methodology” (HPLC system) page 26. Samples were 
splitted for HPLC (45 #l) and LC-MS/MS (5 #l) analysis. Microdialysis samples were 
analysed for L-DOPA as well as DA using HPLC combined with ECD under isocratic 
conditions. Chromatographic separation was performed using a reversed-phase 
column (Grom-Sil 120 ODS-4 HE, 250 x 4.0 mm i.d., 5 #m, Grace Davison Discovery 
Sciences™, Lokeren, Belgium). The mobile phase consisted of 1.85 mM 1-
octanesulfonic acid sodium salt, 0.13 mM Na2EDTA $ 2 H2O, 8.00 mM NaCl, 57.51 
mM NaH2PO4, 10 % acetonitrile, adjusted to pH 2.50 with H3PO4, filtered through a 
0.22 #m filter, and was delivered at a flow rate of 1 ml/min. 
 
LC-MS/MS analysis of microdialysis and plasma, brain and CSF samples 
(idazoxan) 
Please see chapter II “General methodology” (LC-MS/MS system) page 26. 
Microdialysis as well as plasma, brain and CSF samples were analysed for idazoxan 
using LC-MS/MS.). Mobile phase “A” and “B” consisted of 0.1 % formic acid in water 
and acetonitrile (LC-MS grade), respectively. The gradient elution profile was chosen 
as follows: 0 min: 15 % A (1000 #l/min), 0.10 min: 15 % A (200 #l/min), 1.00 min: 80 
% A (200 #l/min), 1.50 min: 80 % A (200 #l/min), 1.60 min: 15 % A (200 #l/min), 2.40 
min: 15 % A (200 #l/min), 2.50 min: 15% A (1000 #l/min), 3.00 min: 15 % A (1000 
#l/min). Chromatographic retention was obtained using a hydrophilic interaction liquid 
chromatography (HILIC) column (ZIC®-HILIC, 20 x 2.1 mm i.d., 3.5 #m, SeQuant AB, 
Umeå, Sweden) with a pre-microfilter (0.5 #m, Upchurch Scientific, Oak Harbor, WA, 
USA) at 20°C. The column switching valve was set at 2.50 minutes to the waste. 
Two transitions were chosen: 205-97 (DP 71 V, CE 33 V, CXP 6 V) and 205-54 (DP 
71 V, CE 71 V, CXP 10 V). Transition 205-97 was used for the quantification of 
idazoxan. 
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LC-MS/MS analysis of plasma, brain and CSF samples (L-DOPA) 
Please see chapter II “General methodology” (LC-MS/MS system) page 26. Plasma, 
brain and CSF samples were analysed for L-DOPA using LC-MS/MS. Mobile phase 
“A” and “B” consisted of 0.1 % formic acid in water (LC-MS grade) and methanol (LC-
MS grade), respectively, and was delivered at 300 #l/min. The gradient elution profile 
was chosen as follows: 0 min: 95 % A, 0.50 min: 95 % A, 2.00 min: 5 % A, 2.40 min: 
5 % A, 2.60 min: 95 % A, 9.00 min: 95 % A. Chromatographic retention was obtained 
using a reversed-phase column (Zorbax Eclipse XDB-C18, 150 x 4.6 mm i.d., 5 #m, 
Agilent Technologies, Morges, Switzerland) with a pre-microfilter (0.5 #m, Upchurch 
Scientific, Oak Harbor, WA, USA) at 20°C.  
Three transitions were chosen: 198-181 (DP 51 V,  CE 15 V, CXP 12 V), 198-107 
(DP 51 V, CE 37 V, CXP 8 V) and 198-135 (DP 51 V, CE 27 V, CXP 8 V). Transition 
198-181 was used for the quantification of L-DOPA. [D3]-L-DOPA was used as 
internal standard and analysed using the transition 201-154 (DP 56 V, CE 19 V, CXP 
12 V).  
 
Drug and chemicals 
Please see chapter II “General methodology” page 26. 
 
Statistical analysis 
Please see chapter II “General methodology” page 27. The time course of total 
dyskinesia was analysed by a two-way ANOVA for repeated measurements with time 
as dependent factor and dose as independent factor followed by a Bonferroni post 
hoc test. A one-way ANOVA with treatment as an independent factor was carried out 
to compare the sum of total dyskinesia scores followed by a two-tailed t-test. 
In general, behavioural scores are regarded to be analysed using non-parametric 
statistics due the ordinal scaling associated with the scores. However, dyskinesia 
scores reflect a proportion of time in which a specific kind of behaviour is observed. 
Therefore, he dyskinesia scores can be treated as almost proportional scoring data, 
in which the score 4 can be assumed to be twice as large as the score 2. Thus, we 
analysed dyskinesia score using parametric statistics (Cenci and Lundblad 2007). 
Additionally, this the advantage that lower animal numbers are needed for parametric 
statistics which is in agreement with animal welfare and for the purpose of the ethical 
guidelines of AAALAC. 
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A two-way ANOVA with lesion as the dependent factor and treatment as the 
independent factor was used to compare basal values between the lesioned and the 
intact striatum. Statistical analysis of the in vivo microdialysis data was carried out by 
calculating the area under the curve (AUC) and logarithmising the AUC. A one-way 
ANOVA with treatment as the independent factor was used to analyse the 
logarithmised AUCs followed by a two-tailed t-test. For the idazoxan data, the limit of 
quantitation (LOQ) (10-12 M) was used in case of idazoxan levels which were not 
detectable. The correlation analysis between extracellular idazoxan and L-DOPA 
levels measured with in vivo microdialysis was performed with the nonparametric 
Spearman test using the logarithmised AUCs of idazoxan as well as L-DOPA. 
The comparison of L-DOPA and idazoxan levels in plasma, brain and CSF was 
carried out using an unpaired t-test. 
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RESULTS 
 
Effects of idazoxan on L-DOPA-induced dyskinesia 
Fig. 12. Effects of idazoxan on total dyskinesia score (a), axial dyskinesia (b), orolingual 
dyskinesia (c) and limb dyskinesia (d). Idazoxan (9 mg/kg, i.p. (n = 8) and 3 mg/kg, i.p. (n = 8)) and 
vehicle (saline, i.p. (n = 8)) was administered 30 minutes prior to L-DOPA/benserazide (6/15 mg/kg, 
p.o.). Dyskinesia was monitored every 20 minutes. Data are expressed as mean ± SEM and were 
analysed by a two-way repeated measurement ANOVA followed by a Bonferroni post hoc test for 
statistical comparison of the treatments (***P < 0.001, **P < 0.01, *P < 0.05). 
 
The dyskinesia scores following administration of vehicle and idazoxan 3 and 9 
mg/kg in combination with L-DOPA are displayed in Fig. 12. Dyskinetic movements 
were monitored during the microdialysis experiment every 20 minutes up to 5 hours 
following treatment with L-DOPA. Statistical analysis of the total dyskinesia time 
course yielded a significant interaction of time x treatment (F(42,441) = 4.303, P < 
0.001) as well as a significant effect on time (F(21,441) = 30.30, P < 0.001) and 
treatment (F(2,441) = 9.840, p = 0.001) (Fig. 12a). Time interval 140 – 220 minutes 
showed a significant decrease in total dyskinesia score comparing idazoxan 9 mg/kg 
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and vehicle (140 – 200 minutes: P < 0.001, 220 minutes: P < 0.01) indicating an 
antidyskinetic effect of the "2 adrenoceptor antagonist idazoxan at dose 9 mg/kg. 
Statistical comparison of idazoxan 3 mg/kg and vehicle showed a significant effect in 
total dyskinesia score at time points 140 minutes (P < 0.001) and at 260 minutes (P < 
0.001).  
Statistical analysis of the axial dyskinesia time course revealed a significant 
interaction of time x treatment (F(42,441) = 3.791, P < 0.001) as well as a significant 
effect on time (F(21,441) = 24.78, P < 0.001) and treatment (F(2,441) = 6.449, P < 0.01) 
(Fig. 12b). The orolingual dyskinesia time course showed a significant interaction of 
time x treatment (F(42,441) = 3.798, P < 0.001) as well as a significant effect on time 
(F(21,441) = 29.86, P < 0.001) and treatment (F(2,441) = 9.988, P < 0.001) (Fig. 12c). The 
limb dyskinesia time course demonstrated a significant interaction of time x treatment 
(F(42,441) = 4.462, P < 0.001) as well as a significant effect on time (F(21,441) = 29.18, P 
< 0.001) and treatment (F(2,441) = 11.77, P < 0.001) (Fig. 12d). Axial dyskinesia score 
following administration of idazoxan 9 mg/kg was reduced during the time interval 
140 – 200 minutes and orolingual as well as limb dyskinesia scores were alleviated 
during the time interval 140 – 220 minutes using idazoxan 9 mg/kg. A significant 
effect in axial, orolingual and limb dyskinesia subtypes was observed at time point 
140 minutes as well as 260 minutes using idazoxan 3 mg/kg. 
In conclusion, idazoxan 9 mg/kg demonstrated a significant alleviation of dyskinesia 
in contrast to idazoxan 3 mg/kg.  
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Effects of administration of idazoxan plus L-DOPA on extracellular L-DOPA and 
DA levels in the striatum 
 
Fig. 13. In vivo microdialysis. Effects of idazoxan (9 mg/kg, i.p. (n = 8) and 3 mg/kg, i.p. (n = 8)) 
and vehicle (saline, i.p. (n = 8)) on extracellular levels of DA (a, b) and L-DOPA (c, d) in the 
lesioned (a, c) and intact striatum (b, d) of dyskinetic rats. The AUC of the time interval 140 – 220 
minutes is displayed in a bar graph as an insert to each time course figure. Data are expressed as 
mean ± SEM. Please note the different scales of the y-axes. 
 
In vivo microdialysis samples were analysed for extracellular DA and L-DOPA levels 
using HPLC-ECD (Fig. 13). In the lesioned striatum, basal levels of DA were 0.24 ± 
0.07 nM in the vehicle group, 0.15 ± 0.02 nM in the idazoxan 3 mg/kg group and 0.20 
± 0.04 nM in the idazoxan 9 mg/kg group. In the intact striatum, basal levels of DA 
were 2.07 ± 0.27 nM in the vehicle group, 2.09 ± 0.16 nM in the idazoxan 3 mg/kg 
group and 2.48 ± 0.27 nM in the idazoxan 9 mg/kg group. Basal levels on the 
lesioned as well as on the intact side did not differ significantly between the treatment 
groups (F(2,21) = 0.9132, p = 0.4166). Statistical comparison demonstrated a 
significant difference in basal levels of DA between the lesioned and the intact 
striatum in all groups (F(1,21) = 224.26, P < 0.001). 
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According to the behavioural data, statistical analysis of the AUC was carried out at 
the time interval 140 - 220 minutes. Statistical analysis of DA levels in the lesioned 
striatum yielded a significant treatment effect (F(2,16) = 4.762, P < 0.05) (Fig. 13a). 
The AUC of DA levels was significantly decreased in the idazoxan 9 mg/kg group 
compared to the vehicle group (P < 0.05), whereas idazoxan 3 mg/kg showed no 
significant difference in DA levels in comparison to vehicle (p = 0.6712). Statistical 
analysis of DA levels on the intact side yielded no significant effect (F(2,21) = 1.382, p 
= 0.2730) (Fig. 13b) as well as comparison between idazoxan 9 mg/kg and vehicle (p 
= 0.3768) and idazoxan 3 mg/kg and vehicle (p = 0.4529). Post hoc tests showed a 
significant decrease of L-DOPA levels between idazoxan 9 mg/kg and vehicle (P < 
0.05) on the lesioned side (Fig. 13c), whilst no effect between idazoxan 3 mg/kg and 
vehicle was observed (p = 0.2722). A significant treatment effect of L-DOPA levels 
was observed in the intact striatum (F(2,21) = 4.954, P < 0.05) (Fig. 13d). Comparison 
between idazoxan 9 mg/kg and vehicle demonstrated a significant decrease of L-
DOPA levels in the idazoxan group (P < 0.05), whilst idazoxan 3 mg/kg did not show 
an effect on L-DOPA levels (p = 0.0661). 
In conclusion, idazoxan 9 mg/kg revealed a significant decrease of extracellular L-
DOPA levels in the lesioned and intact striatum as well as a significant reduction of 
extracellular DA levels in the lesioned striatum. 
 
Measurement of extracellular idazoxan levels 
In vivo microdialysis samples were measured on extracellular idazoxan levels using 
LC-MS/MS (Fig. 14). Statistical analysis of the AUCs from time point 0 to 420 
minutes showed a significant treatment effect on the lesioned side (F(2,21) = 45.77, P 
< 0.001) as well as on the intact side (F(2,21) = 34.26, P < 0.001). Idazoxan levels in 
both the idazoxan 3mg/kg group (P < 0.001) and the idazoxan 9mg/kg group (P < 
0.001) were significantly increased in comparison to the vehicle group in the lesioned 
as well as in the intact striatum.  
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Fig. 14. In vivo microdialysis. 
Measurement of extracellular idazoxan 
levels in the lesioned (a) and intact (b) 
striatum following administration of 
idazoxan (9 mg/kg, i.p. (n = 8) and 3 
mg/kg, i.p. (n = 8)) and vehicle (saline, 
i.p. (n = 8)). The AUC is displayed in a bar 
graph as an insert to each time course 
figure. Data are expressed as mean  
SEM. 
 
A significant negative correlation 
was observed between idazoxan 
and L-DOPA levels for the time 
interval 140 – 220 minutes 
confirming that treatment with 
idazoxan reduces L-DOPA levels 
(data not shown). On the lesioned 
side, the correlation coefficient was 
found to be -0.4652 (P < 0.05), on 
the intact side -0.6057 (P < 0.01). 
 
Pharmacokinetic drug-drug interaction of L-DOPA and idazoxan 
Plasma, brain and CSF levels in rats treated with vehicle + L-DOPA and idazoxan 9 
mg/kg + L-DOPA were measured to assess a drug-drug interaction between L-DOPA 
and idazoxan (Table 5). L-DOPA levels in plasma (p = 0.9865), brain (p = 0.6318) as 
well as CSF (p = 0.9935) did not differ significantly between rats receiving only L-
DOPA and rats treated with idazoxan + L-DOPA indicating that the reduction of 
extracellular L-DOPA levels by idazoxan is not due to a general drug-drug 
interaction. 
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Table 5. Plasma, brain and CSF levels of L-DOPA and idazoxan. Idazoxan (9 mg/kg, i.p. (n = 4)) 
and vehicle (i.p. (n = 4)) were administered 30 minutes prior to the treatment with L-
DOPA/benserazide (6/15 mg/kg, p.o.) to naive rats. Forty minutes following L-DOPA administration 
samples of CSF, blood and brain tissue were taken and analysed using LC-MS/MS. Data are 
expressed as mean ± SEM. 
 
DISCUSSION 
The present study demonstrated that the "2 adrenoceptor antagonist idazoxan 
attenuates extracellular peak L-DOPA levels in the lesioned and intact striatum as 
well as extracellular DA levels in the lesioned striatum which contribute to the 
antidyskinetic action of idazoxan. 
The antidyskinetic effect of idazoxan is in agreement with studies using other "2 
adrenoceptor antagonists as well as idazoxan itself. Previous experimental studies 
have demonstrated that "2 adrenoceptor antagonists such as the traditional drug 
yohimbine reduced L-DOPA-induced dyskinesia in rodent (Dekundy et al. 2007; 
Lundblad et al. 2002) as well as in primate models (Gomez-Mancilla and Bedard 
1993). Yohimbine offers a broad pharmacological profile: it mainly acts as a "2 
adrenoceptor antagonist, but it also binds to DA D2 receptors and serotonergic 5-
HT1A, 5-HT1D and 5-HT2B receptors, thus, it cannot be ruled out that the antidyskinetic 
 Vehicle + L-DOPA  
 
Idazoxan + L-DOPA  
 
 
L-DOPA plasma levels [nmol/L] 
 
4160.0 ± 540.7 
 
4147.5 ± 461.4 
 
L-DOPA brain levels [nmol/kg] 
 
514.8 ± 220.3 
 
366.6 ± 153.5 
 
L-DOPA CSF levels [nmol/L] 
 
260.5 ± 47.8 
 
261.0 ± 34.7 
 
Idazoxan plasma levels [nmol/L] 
 
0 ± 0 
 
373.3 ± 71.2 
 
Idazoxan brain levels [nmol/kg] 
 
0 ± 0 
 
2212.5 ± 425.5 
 
Idazoxan CSF levels [nmol/L] 
 
1.1 ± 0.4 
 
232.0 ± 56.0 
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effect of yohimbine is due to the unspecific action at receptors other than the "2 
adrenoceptor. Compared to yohimbine, the "2 adrenoceptor antagonist idazoxan 
shows improved selectivity but the compound was also found to interact with I2 
imidazoline binding sites (Miralles et al. 1993) as well as with moderate affinity to 5-
HT1A receptors (Fozard et al. 1987). Idazoxan has no selectivity for "2 adrenoceptor 
subtypes and binds to the "2A, "2B and "2C adrenoceptor with Ki values of 10 nM, 37 
nM and 20 nM, respectively. The distribution of "2 adrenoceptor subtypes varies 
between different brain regions. The "2A adrenoceptor is widely distributed within the 
cerebral cortex, locus coeruleus, hippocampus and cerebellum (MacDonald and 
Scheinin 1995; McCune et al. 1993; Nicholas et al. 1993). The "2B adrenoceptor is 
not highly expressed in the CNS but a relatively low signal was detected in the 
thalamus (MacDonald and Scheinin 1995; Nicholas et al. 1993). "2C adrenoceptors 
are present in many brain regions, but the highest expression was shown in the basal 
ganglia (MacDonald and Scheinin 1995; Nicholas et al. 1993) suggesting that the "2C 
adrenoceptor is the most likely subtype at which idazoxan mediates its antidyskinetic 
action. 
L-DOPA-induced dyskinesia was not reduced by treatment with idazoxan 3 mg/kg, 
whereas idazoxan 9 mg/kg significantly alleviated dyskinetic movements. Bilateral in 
vivo microdialysis revealed that L-DOPA injection led to a pronounced increase in 
extracellular L-DOPA levels, which did not differ in the lesioned and in the intact 
striatum. As previously demonstrated, administration of L-DOPA induced a significant 
increase of extracellular DA levels in the lesioned striatum. In contrast, DA levels on 
the contralateral side did not increase indicating that DA can be handled very 
efficiently under physiological conditions (Buck and Ferger 2008). Treatment with 
idazoxan 3 mg/kg showed a trend towards a reduction of peak L-DOPA levels on 
both sides but this did not reach statistical significance. DA levels were not affected 
by treatment with idazoxan 3 mg/kg at all, correlating with its lack of antidyskinetic 
effect. The higher dose of idazoxan 9 mg/kg significantly attenuated extracellular 
peak L-DOPA levels in the lesioned as well as intact striatum. In addition, 
extracellular peak DA levels in the lesioned striatum were significantly reduced which 
we consider to be the reason for the antidyskinetic action of idazoxan. Extracellular 
DA levels in the intact striatum were not affected either by L-DOPA treatment as 
demonstrated previously (Buck and Ferger 2008) or by idazoxan. Furthermore, a 
significant correlation between idazoxan and L-DOPA levels was obtained confirming 
Chapter VI 
 82 
that idazoxan affects extracellular L-DOPA levels. Thus, the higher the concentration 
of idazoxan in the striatum, the lower L-DOPA levels were observed in individual rats. 
In order to clarify if a drug-drug interaction of idazoxan and L-DOPA is responsible for 
this effect, the combination of L-DOPA and idazoxan was investigated on L-DOPA 
levels in plasma, CSF and brain. Idazoxan did not alter plasma, brain and CSF L-
DOPA levels indicating that idazoxan acts via modulation of extracellular L-DOPA 
levels rather than by binding to L-DOPA. The antidyskinetic effect of idazoxan and 
the correlation with the reduction of L-DOPA peak levels in striatal microdialysates is 
a key finding. Notably, only the high dose led to a decrease in L-DOPA as well as DA 
microdialysate levels and importantly this correlates well with the behavioural data. 
Idazoxan improved parkinsonian symptoms in different PD rat models such as in the 
haloperidol-induced catalepsy test (Invernizzi et al. 2003; Kleven et al. 2005), in the 
reserpine-induced L-DOPA hyperactivity model (Johnston et al. 2005), in the 6-
OHDA-induced bar and grid test (Srinivasan and Schmidt 2004) as well as in the 
methylphenidate- and apomorphine-induced rotational test (Chopin et al. 1999). 
Idazoxan (0.3 and 2.5 mg/kg) reversed haloperidol-induced catalepsy significantly 
but did not modify the DA overflow in the striatum and had no effect on haloperidol-
induced increase of DA measured by in vivo microdialysis (Invernizzi et al. 2003). In 
line with these results, the present study revealed no effect of idazoxan 3 mg/kg on 
extracellular DA levels derived from exogenously applied L-DOPA in the striatum.  
Idazoxan exhibits moderate 5-HT1A agonist properties (Kleven et al. 2005) which 
might contribute to the effect on dyskinesia as well as on extracellular DA levels. 
Recently, the role of DA released from serotonergic neurons as an important 
presynaptic factor of L-DOPA-induced dyskinesia in the rat PD model has been 
demonstrated (Carta et al. 2008). Indeed, the removal of 5-HT afferents by the 
serotonergic neurotoxin 5,7-dihydroxytryptamine, or by reducing 5-HT neuron activity 
by 5-HT1A and 5-HT1B drugs, resulted in an almost complete reversal of L-DOPA-
induced dyskinesia (Carta et al. 2007). The concept of DA as a ‘false transmitter’ 
released from 5-HT terminals has also been proposed by Kannari et al. (2001), who 
showed that 5-HT1A agonists reduced the L-DOPA-induced DA overflow in the rat 
striatum. Thus, the effect of idazoxan might also be mediated by agonism at 5-HT1A 
receptors taking into account that idazoxan reduced dyskinesia at a relatively high 
dose of 9 mg/kg. Moreover, idazoxan decreased DOPA synthesis in the striatum 
measured by post mortem neurochemistry in rats (Sastre-Coll et al. 1999). It was 
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found that the idazoxan-induced reduction of DOPA was abolished by pre-treatment 
with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline, an alkylating compound used 
to irreversibly inactivate !2 adrenoceptors. This suggests that the effect of idazoxan 
in the striatum is mediated by !2 adrenoceptors. In addition to the effect on 
extracellular L-DOPA levels, idazoxan reduced spontaneous activity of STN neurons 
resulting in enhanced motor activity of rats which was postulated to account for the 
behavioural effects in animal models and PD patients (Belujon et al. 2007). 
A widely used predictive animal model of L-DOPA-induced dyskinesia is the MPTP-
lesioned monkey treated with L-DOPA. This model not only provides data on the 
antidyskinetic efficacy of a compound but also gives insight into “on-time” regulation 
by L-DOPA. Idazoxan alleviated dyskinetic movements provoked by L-DOPA in 
MPTP-lesioned primates. Additionally, idazoxan did not compromise the anti-
parkinsonian response to L-DOPA, rather the combination of idazoxan and L-DOPA 
extended the “on-time” of L-DOPA (Fox et al. 2001; Grondin et al. 2000; Henry et al. 
1999). These effects are largely in line with dampening L-DOPA/DA peak levels. 
Furthermore, the dyskinetic behaviour induced by treatment with the DA agonist 
apomorphine was not affected by idazoxan in the monkey dyskinesia model (Fox et 
al. 2001). This observation argues for the fact that idazoxan alleviates dyskinesia due 
to reduction of extracellular L-DOPA and DA levels. The effect of apomorphine is 
mediated by postsynaptic DA D2 receptor stimulation and not by an increase of 
extracellular DA levels explaining that idazoxan does not relieve apomorphine-
induced dyskinesia. 
The intention of this study was to investigate a potential mechanism of idazoxan’s 
mode of action rather to promote idazoxan for the treatment of PD patients suffering 
from disabling dyskinesia. Eventually, idazoxan failed to be an acceptable treatment 
in clinical trials. Indeed, the clinical effects of idazoxan were investigated in patients 
with advanced PD and it was shown that dyskinesia severity improved without 
compromising the beneficial response to L-DOPA. However, treatment with idazoxan 
caused adverse side events such as hypertension, tachycardia, flushing and 
headache (Rascol et al. 2001) and precludes its clinical use. 
In conclusion, the present study showed for the first time that idazoxan reduces 
extracellular L-DOPA levels in the striatum. In addition, extracellular DA levels in the 
lesioned striatum are attenuated which contribute to the alleviation of L-DOPA-
induced dyskinesia by idazoxan. We postulate that it is important when evaluating 
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prospective targets aiming at the alleviation of L-DOPA-induced dyskinesia to 
investigate extracellular levels of L-DOPA and DA under conditions which closely 
resemble the disease state. 
 
This study was conducted with the help of Patrizia Voehringer, who measured L-DOPA and 
idazoxan levels. 
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CHAPTER VII 
Striatal L-DOPA but not GABA and glutamate is the crucial trigger to 
evoke dyskinetic movements in 6-OHDA-lesioned rats 
 
ABSTRACT 
Dyskinesia eventually develops in the majority of PD patients treated with L-DOPA. 
Here, we investigate the role of the striatum, GP and SNr associated with GABA, 
glutamate and L-DOPA to provoke dyskinetic movements. 
We demonstrated that GABA and glutamate did not trigger the manifestation of 
dyskinesia in the striatum, the GP nor the SNr using the model of reverse in vivo 
microdialysis. As expected, L-DOPA administration into the lesioned striatum was a 
highly effective trigger to switch on dyskinesia. Notably, local L-DOPA perfusion in 
the ipsilateral GP and SNr did not provoke dyskinetic behaviour. 
We conclude that an acute and local increase of neither GABA nor glutamate 
provokes dyskinesia. Since L-DOPA in the striatum but not in the GP or SNr switched 
on dyskinetic behaviour, we postulate a site specific action of L-DOPA at least for the 
evocation of already established dyskinesia. 
 
 
INTRODUCTION 
The DA precursor L-DOPA was the first antiparkinsonian drug to be introduced and 
still remains the cornerstone of symptomatic pharmacotherapy for patients suffering 
from PD. However, there are major limitations to L-DOPA therapy including the 
development of motor fluctuations and dyskinesia. Dyskinesia consists of debilitating 
abnormal involuntary movements such as chorea and dystonia. Eventually up to 40% 
of PD patients develop dyskinesia within 4-6 years of L-DOPA therapy (Ahlskog and 
Muenter 2001), which are perceived as disabling and non disabling dyskinesia. The 
prevalence of dyskinesia escalates with duration and severity of the disease (Obeso 
et al. 2000b) as well as with duration and dosage of L-DOPA treatment (Rascol 
2000). 
The induction and manifestation of dyskinetic movements involves multiple factors 
including disruption of presynaptic DA homeostasis, pathophysiological changes of 
firing patterns within the basal ganglia nuclei, cortical overactivation, several receptor 
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mediated changes at dopaminergic, GABAergic and glutamatergic neurons affecting 
neurotransmission within the direct and indirect pathway of the basal ganglia motor 
loops (Cenci 2007). The classical view for the onset of dyskinesia involves 
neurotransmitter changes within the basal ganglia opposite from that assumed for the 
parkinsonian state following DA depletion. However, there is much discussion 
regarding the contribution of the direct versus the indirect pathway of the basal 
ganglia loops to the mechanisms of L-DOPA-induced dyskinesia. The weaknesses of 
some of the proposed basal ganglia models arise questions to elucidate the 
complexity of dyskinesia (Jenner 2008b). Moreover, the interpretation of data 
obtained from animal models mimicking L-DOPA-induced dyskinesia becomes 
increasingly complex when considering that alterations during the expression of 
dyskinesia may be either a consequence of drug treatment or simply the abnormal 
involuntary movements themselves (Jenner 2008a).  
Several animal models mimicking L-DOPA-induced dyskinesia are available including 
non-human primates and rodents. For practical reasons the 6-OHDA rat dyskinesia 
model (Cenci et al. 1998) is preferred to study mechanisms whenever using invasive 
techniques such as in vivo microdialysis and when higher animal numbers are 
required. Dyskinesia can be induced systemically by treatment with L-DOPA, 
originally described by Cenci et al. (1998), or locally by administration of L-DOPA into 
the 6-OHDA-lesioned striatum via reverse in vivo microdialysis (Buck and Ferger 
2008; Buck and Ferger 2009a; Carta et al. 2006). The model of reverse in vivo 
microdialysis offers three main advantages for mechanistic studies: 1) target specific 
delivery of compounds, 2) compounds which do not cross the blood brain barrier, 
such as most neurotransmitters, can be investigated on alterations of dyskinetic 
movements, 3) differentiation between a trigger for the expression of dyskinesia or a 
consequence of the abnormal involuntary movement and drug treatment, 
respectively.  
The present study focuses on the role of GABA, glutamate as well as L-DOPA in the 
striatum, GP and SNr for evocation of L-DOPA-induced dyskinesia in 6-OHDA-
lesioned rats with already established dyskinesia by chronic L-DOPA priming 
procedure. 
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MATERIALS AND METHODS 
 
Animals and 6-OHDA lesion surgery 
Please see chapter II “General methodology” page 22. 
 
Induction and rating of dyskinesia 
Please see chapter II “General methodology” page 22. The sum of axial, limb and 
orolingual dyskinesia ratings was expressed as a total dyskinesia score and used 
instead of the individual score because the dyskinesia scores did not differ from each 
other. For the subsequent experiments rats were divided into two groups, dyskinetic 
and non dyskinetic rats, according to their total dyskinesia score at the day of the 
experiment. The history of both groups (6-OHDA lesion, L-DOPA treatment) was 
identical. 
 
In vivo microdialysis surgery in the striatum, GP and SNr 
Please see chapter II “General methodology” page 23. The study was divided in two 
experiments: one series of rats was implanted with one probe in the GP and one 
probe in the SNr; another series of rats was implanted with one probe in the striatum. 
In the first experiment, two intracerebral guide cannulae were implanted aiming at the 
GP and SNr. In the second experiment, one intracerebral guide cannula was 
implanted aiming at the striatum. 
 
Reverse in vivo microdialysis procedure in the striatum, GP and SNr 
Please see chapter II “General methodology” page 25. Following insertion of the 
probes, aCSF was perfused for 1 hour. GABA (0.4 nmol/min), glutamate (0.4 
nmol/min) and L-DOPA (0.4 nmol/min) were consecutively perfused on the ipsilateral 
side (GP: n = 3; SNr: n = 4; striatum: n = 7) for 1 hour each, except L-DOPA in the 
striatum, which was perfused for 90 minutes, since slight dyskinesia appeared 30 
minutes after beginning of L-DOPA treatment and increased very slowly. A 30 
minutes aCSF perfusion was performed as washout between perfusion of the 
different compounds. Dyskinetic behaviour was monitored during the whole 
experiment every 5 minutes up to 150 minutes after the end of the L-DOPA 
treatment. In the GP and SNr monitoring of dyskinesia was stopped 30 minutes after 
the end of L-DOPA treatment since the rats did not show any dyskinetic movements.  
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In vivo microdialysis procedure in the striatum, GP and SNr 
Please see chapter II “General methodology” page 24. For the measurement of L-
DOPA in SNr and GP experiment, dyskinetic (n = 9) and non dyskinetic (n = 9) rats 
were used. For the determination of L-DOPA in the striatum, which was performed in 
a parallel study, dyskinetic (n = 7) and non dyskinetic (n = 5) rats were included.  
Fractions 1 to 4 (0 – 80 min) were used for calculation of the basal levels which were 
regarded as 100 %. At time point 80 minutes, L-DOPA/benserazide (6/15 mg/kg, 
p.o.) was administered and the sampling was continued up for 5 hours (80 – 380 
min). After the experiments the correct localisation of the probes was verified and 
only the rats with appropriate probe placement were included in the experiment 
(please see Fig. 15). 
 
 
Fig. 15. Probe localisation in the GP (A) and the SNr (B). Placement of the probes was verified 
using Indian Ink. The arrows indicate the origin and the end of the membrane of the probe. 
 
Sample preparation procedure 
Ten #l of the microdialysis sample were diluted with 10 #l of internal standard 
solution ([D3]-L-DOPA in acetonitrile). Ten #l of this solution were injected into the 
LC-MS/MS. 
 
Striatal L-DOPA but not GABA and glutamate is the crucial trigger to evoke dyskinesia 
 89 
LC-MS/MS analysis of microdialysis samples 
Please see chapter II “General methodology” (LC-MS/MS system) page 26. Samples 
from the GP, SNr and striatum were analysed for L-DOPA using LC-MS/MS. Mobile 
phase “A” and “B” consisted of 0.1 % formic acid in water and acetonitrile (LC-MS 
grade), respectively. The gradient elution profile was chosen as follows: 0 min: 15 % 
A (1000 #l/min), 0.10 min: 15 % A (200 #l/min), 1.00 min: 80 % A (200 #l/min), 1.50 
min: 80 % A (200 #l/min), 1.60 min: 15 % A (200 #l/min), 2.40 min: 15 % A (200 
#l/min), 2.50 min: 15% A (1000 #l/min), 3.00 min: 15 % A (1000 #l/min). 
Chromatographic retention was obtained using a HILIC column (ZIC®-HILIC, 20 x 
2.1 mm i.d., 3.5 #m, SeQuant AB, Umeå, Sweden) with a pre-microfilter (0.5 #m, 
Upchurch Scientific, Oak Harbor, WA, USA) at 20°C. The column switching valve 
was set at 0.00 minutes to the waste, at 0.70 minutes to the mass spectrometer and 
at 2.00 minutes to the waste again. 
Three transitions were chosen for L-DOPA: 198-181 (DP 51 V, CE 15 V, CXP 12 V), 
198-107 (DP 51 V, CE 37 V, CXP 8 V) and 198-135 (DP 51 V, CE 27 V, CXP 8 V). 
Transition 198-181 was used for the quantification of L-DOPA. [D3]-L-DOPA was 
used as internal standard and analysed using the transition 201-154 (DP 56 V, CE 19 
V, CXP 12 V).  
 
Drugs and chemicals 
Please see chapter II “General methodology” page 26. 
 
Statistical analysis 
Please see chapter II “General methodology” page 27. L-DOPA levels in the 
microdialysis experiment are expressed as mean ± SEM and analysed by parametric 
statistics. Scores of dyskinesia are expressed as median ± interquartile range and 
analysed by non parametric statistics. P < 0.05 was considered as statistically 
significant. 
For comparison of dyskinesia scores with the theoretical median which was defined 
as 0.0 (pre dyskinesia score), a Wilcoxon signed rank test was performed. Statistical 
comparison between dyskinetic and non dyskinetic animals was carried out using a 
Mann Whitney U test.  
Statistical analysis of the in vivo microdialysis data (L-DOPA measurement) was 
performed by calculating the AUC and transformed by logarithmising the AUC to 
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obtain Gaussian data distribution. A two-tailed t-test was used to compare the 
logarithmised AUCs of the 2 groups. 
 
 
RESULTS 
 
Effects of local administration of GABA, glutamate and L-DOPA in the GP, SNr 
and striatum on dyskinesia 
 
Fig. 16. Reverse in vivo microdialysis. Effects of administration of GABA (0.4 nmol/min), 
glutamate (0.4 nmol/min) and L-DOPA (0.4 nmol/min) into the ipsilateral striatum (A), GP (B) 
and SNr (C). Panel A-C show the time course of total dyskinesia score monitored every 5 minutes. In 
panel D, the sum of total dyskinesia score/session is displayed. Data are presented as median ± 
interquartile range. Cumulative scores were analysed by a Wilcoxon signed rank test for comparison 
to the theoretical median, which was defined as 0.0 (*P < 0.05). 
 
GABA, glutamate and L-DOPA were administered into GP, SNr and striatum on the 
side ipsilateral to the lesion using reverse in vivo microdialysis (Fig. 16). Dyskinesia 
was monitored every 5 minutes during the experiment. Administration of GABA as 
well as glutamate into the GP, SNr and striatum did not induce dyskinetic behaviour 
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(sum of total dyskinesia score = 0). Treatment with L-DOPA in the GP led to 
sporadic, very slight and not significant dyskinetic movements (sum of total 
dyskinesia score = 3), whilst L-DOPA administration in the SNr did not evoke 
dyskinesia (sum of total dyskinesia score = 0). In contrast, perfusion of L-DOPA in 
the lesioned striatum led to a significant increase in dyskinetic movements (sum of 
total dyskinesia score = 204 ± 19, P < 0.05).  
Thirty minutes after onset of L-DOPA administration dyskinesia developed. Fifty-five 
minutes after starting the L-DOPA perfusion dyskinetic movements significantly 
increased (P < 0.05) to a plateau and persisted over the whole observation period 
until 240 minutes following onset of L-DOPA administration (except time point 65 
minutes). 
 
Effects of systemic L-DOPA administration on dyskinetic behaviour 
 
Fig. 17. In vivo microdialysis. Effects of systemic administration of L-DOPA/benserazide (6/15 
mg/kg; p.o.) on extracellular L-DOPA levels in the striatum (A), GP (B) and SNr (C). Statistical 
analysis revealed no differences between dyskinetic and non dyskinetic rats. Data are presented as 
mean ± SEM. 
 
The time course of total dyskinesia during the in vivo microdialysis experiment is 
displayed in Fig. 17. Dyskinesia was monitored every 20 minutes during the 
experiment. Rats of the dyskinesia group significantly developed dyskinetic 
movements 20 minutes following L-DOPA which lasted for 140 minutes. Rats of the 
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non dyskinetic groups did not show dyskinetic behaviour during the whole 
observation period. Comparison of the sum of total dyskinesia score between 
dyskinetic (sum of total dyskinesia score = 43.6 ± 2.6) and non dyskinetic rats (sum 
of total dyskinesia score = 1.4 ± 0.7) revealed a significant difference (P < 0.001).  
 
Measurement of extracellular L-DOPA levels  
Fig. 18. Time course of L-DOPA-induced 
dyskinesia in dyskinetic and non dyskinetic 
rats. Monitoring of dyskinesia was carried out 
every 20 minutes throughout the experiment and 
expressed as a total dyskinesia score. Data are 
presented as median ± interquartile range and 
analysed by a Mann Whitney U test for statistical 
comparison of the groups (***P < 0.001, **P < 
0.01, *P < 0.05). 
 
In order to investigate differences 
regarding the exposure to L-DOPA 
between dyskinetic and non dyskinetic 
rats, extracellular L-DOPA levels in the 
GP, SNr as well as striatum were 
analysed using in vivo microdialysis (Fig. 
18). Basal levels of L-DOPA were not 
detectable. Time course of extracellular 
L-DOPA levels paralleled in all 3 brain 
areas. Maximum levels were achieved 
40 minutes following per oral 
administration of L-DOPA/benserazide 
(6/15 mg/kg) and declined within 3 
hours. Statistical comparison of the AUC 
of L-DOPA levels after L-DOPA injection 
in the striatum did not show a significant 
difference between dyskinetic and non dyskinetic rats (P = 0.7990). Maximum L-
DOPA levels were 106 nM and 101 nM in dyskinetic and non dyskinetic animals, 
respectively. In the GP, analysis of the AUC of L-DOPA levels following injection of L-
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DOPA did not reveal a significant difference between dyskinetic and non dyskinetic 
rats (P = 0.5319). Maximum L-DOPA levels in the GP were found to be 74 and 75 nM 
in the dyskinetic and non dyskinetic rats, respectively. Considering the SNr, statistical 
analysis of the AUC of L-DOPA levels did not yield a significant difference between 
the dyskinetic and non dyskinetic group as well (P = 0.8136). In the SNr, maximum 
levels of L-DOPA achieved 64 and 50 nM in dyskinetic and non dyskinetic cases, 
respectively. Comparison of the maximum level of L-DOPA between the dyskinetic 
and non dyskinetic cases did not reveal a significant difference either in the GP (P = 
0.5086), the SNr (P = 0.6453) or the striatum (P = 0.6431). 
 
 
DISCUSSION 
The present study demonstrated that an acute and local increase of neither GABA 
nor glutamate in the striatum, GP and SNr did evoke dyskinetic movements in rats 
with already established dyskinesia. In contrast, local L-DOPA administration into the 
DA denervated striatum was a highly effective trigger to switch on dyskinetic 
movements. Notably, local L-DOPA in the GP and SNr on the side ipsilateral to the 
lesion did not provoke dyskinetic movements indicating that the action of L-DOPA is 
site specific and that the striatum is the crucial brain area for the manifestation of 
dyskinesia. 
To the best of our knowledge, no studies have been undertaken which investigate 
the ability of different compounds to evoke dyskinesia after local administration into 
different brain areas of rats with already established L-DOPA-induced dyskinesia. 
Local administration of drugs was used to antagonise L-DOPA-induced dyskinesia as 
shown by intrastriatal administration of the 5-HT1A agonist (±)-8-OH-DPAT (Dupre et 
al. 2008) or local administration of the 5-HT1A agonist sarizotan into the STN (Marin 
et al. 2009). As a matter of course, the rat dyskinesia model is an appropriate and 
acknowledged model to investigate various drugs on their ability to alleviate 
dyskinetic movements following systemic administration (Dekundy et al. 2007; 
Lundblad et al. 2002; Monville et al. 2005). However, the effect of dyskinesia 
evocation by local administration of different compounds has been more rarely 
investigated (Buck and Ferger 2008; Buck and Ferger 2009a; Carta et al. 2006). This 
model provides an excellent technique to study trigger factors for the expression of 
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dyskinesia as well as the involvement of certain brain areas within the manifestation 
of dyskinetic behaviour.  
The reverse in vivo microdialysis technique to deliver potentially dyskinesiogenic 
compounds into the DA denervated striatum has been validated. Indeed, L-DOPA, 
DA as well as NA evoked dyskinesia in rats when given locally into the 6-OHDA-
lesioned striatum (Buck and Ferger 2008; Buck and Ferger 2009a; Carta et al. 2006). 
In contrast, intrastriatal administration of DA metabolites, namely DOPAC, HVA and 
3-MT did not produce dyskinetic movements (Buck and Ferger 2008). Thus, the 
present model of striatal reverse in vivo microdialysis is sensitive to differentiate 
between dyskinesiogenic and non dyskinesiogenic compounds. In comparison to 
other studies, we focused on the evocation of dyskinesia in rats with already 
established dyskinetic history rather than the development of dyskinesia. In fact, the 
model of reverse in vivo microdialysis to provoke dyskinetic movements can be 
clearly distinguished from mechanisms underlying the induction of dyskinesia (Nadjar 
et al. 2009). In the present study, we found that the amino acid neurotransmitters 
GABA and glutamate did not evoke dyskinetic movements following intrastriatal 
perfusion, whereas intrastriatal L-DOPA triggered the expression of dyskinesia.  
Systemic injection of L-DOPA was found to increase extracellular glutamate levels in 
the DA denervated and intact striatum (Jonkers et al. 2002). Another study showed 
that chronic L-DOPA treatment increased basal glutamate levels in the lesioned 
striatum, but L-DOPA injection did not result in an additional alteration of extracellular 
glutamate levels (Robelet et al. 2004). In contrast, it was recently demonstrated that 
chronic L-DOPA induced an increased basal glutamate output in the striatum, but 
following L-DOPA injection a decline in extracellular glutamate levels in the 6-OHDA-
lesioned striatum was observed (Morgese et al. 2009). Thus, there are ambivalent 
results whether L-DOPA increases, decreases or does not alter the extracellular 
striatal glutamate overflow. In the present study we observed that a local and acute 
increase of glutamate in the striatum is not a trigger for evocation of dyskinesia. This 
finding is not in contrast to the established role of glutamatergic receptors in the 
pathophysiology of L-DOPA-induced dyskinesia. For example, Samadi et al. (2008) 
demonstrated a markedly different pattern of mGluR5 receptor binding and mGluR5 
negative allosteric modulators such as MTEP are effective to treat the development 
and manifestation of L-DOPA-induced abnormal involuntary movements (Dekundy et 
al. 2006; Mela et al. 2007). 
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Consistent with previous findings, local administration of L-DOPA into the 6-OHDA-
lesioned striatum produced a significant increase in total dyskinesia scores 
suggesting that DA derived from exogenously applied L-DOPA is instrumental for the 
manifestation of dyskinesia. Recently, we demonstrated that local administration of 
DA into the lesioned striatum provokes dyskinetic behaviour in a similar manner as 
local L-DOPA (Buck and Ferger 2008). However, perfusion of L-DOPA plus 
benserazide locally in the lesioned striatum did not lead to dyskinetic movements 
indicating that L-DOPA itself is not able to evoke dyskinesia and that L-DOPA has to 
be converted to DA which is the dyskinesiogenic trigger. In contrast to the intrastriatal 
L-DOPA treatment, local perfusion of L-DOPA into the GP and SNr on the side 
ipsilateral to the lesion did not provoke dyskinetic behaviour. These results underpin 
the hypothesis that the striatum is the crucial brain area in L-DOPA-induced 
dyskinesia. In fact, it has been shown that dyskinesia can be prevented by various 
strategies targeting the striatum including continuous L-DOPA delivery using rAAV 
vectors applied into the striatum (Carlsson et al. 2006) or reversed by intrastriatal 
infusion of fosB antisense (Andersson et al. 1999). We postulate a site specific action 
of L-DOPA in the striatum since L-DOPA delivered locally into the striatum but not 
into the GP and SNr on the side ipsilateral to the lesion provoked dyskinetic 
movements. 
The central pharmacokinetics of L-DOPA seems to play a major role in dyskinetic 
movements. Accordingly, we measured extracellular levels of L-DOPA in the 
striatum, GP and SNr of dyskinetic and non dyskinetic rats using in vivo 
microdialysis. The time course paralleled in all three brain areas reaching a maximum 
level 40 minutes following administration and declining within 3 hours. The maximum 
level and AUC of extracellular L-DOPA levels were almost identical in dyskinetic and 
non dyskinetic cases either in the striatum, GP or in the SNr. These results are in 
contrast to a study from Carta et al. (2006), who showed that the central 
pharmacokinetics following treatment with L-DOPA differs in the striatum of 
dyskinetic and non dyskinetic rats. In the latter study, extracellular levels of L-DOPA 
in the striatum reached peak levels within 40 minutes and were 5-fold elevated in 
dyskinetic (250 nM) compared to non dyskinetic rats (50 nM). In the present study we 
determined maximum L-DOPA levels in the striatum of 106 nM and 101 nM in 
dyskinetic and non dyskinetic animals, respectively. The underlying reasons for this 
discrepancy may involve some methodological differences including route of 
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administration, rat strain used as well as different time schedules for L-DOPA 
treatment. A study from Meissner et al. (2006) investigating extracellular L-DOPA 
levels in the striatum of primed and non-primed sham-operated rats and primed and 
non-primed 6-OHDA-lesioned rats showed that the maximum levels of L-DOPA are 
higher in 6-OHDA-lesioned animals compared to sham-operated rats. In this study, 
the maximum level of L-DOPA injection was reported to be 140 nM 50 minutes 
following L-DOPA which is in the same range as in the present study. For the first 
time extracellular L-DOPA levels in the GP and SNr following treatment with L-DOPA 
in dyskinetic rats were monitored. In agreement to the results of the striatum, 
extracellular L-DOPA levels in the GP as well as SNr increased to the same extent in 
both dyskinetic and non dyskinetic rats. 
In conclusion, the present study provides evidence that enhancement of GABA and 
glutamate in different brain areas within the basal ganglia is not a trigger for the 
manifestation of dyskinesia. In fact, a high concentration of exogenously applied L-
DOPA provokes dyskinesia in the striatum, but not in the GP and SNr. This data 
indicates a site specific effect of L-DOPA and encircles a potential drug targeting for 
antidyskinetic compounds in PD. 
 
This study was performed with the help of Patrizia Voehringer, who measured L-DOPA 
levels.  
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CHAPTER VIII 
Continuous dopaminergic stimulation by pramipexole is effective to treat 
early morning akinesia in animal models of Parkinson’s disease: 
a pharmacokinetic-pharmacodynamic study 
 
ABSTRACT 
Short-acting DA agonists are usually administered several times a day resulting in 
fluctuating plasma and brain levels. DA agonists providing continuous dopaminergic 
stimulation (CDS) may achieve higher therapeutic benefit for example by alleviating 
nocturnal disturbances as well as early morning akinesia. In the present study, 
continuous release (CR) of pramipexole (PPX) was maintained by subcutaneous 
implantation of Alzet" minipumps, whereas subcutaneous PPX injections were used 
to mimic PPX immediate release (IR). 
In the catalepsy bar test, PPX-CR (1 mg/kg/day) reversed the haloperidol-induced 
motor impairment in the morning and over the whole observation period of 12h. In 
contrast, PPX-IR (tid 1 mg/kg, pre-treatment the day before) was not effective in the 
morning but catalepsy was reduced for 6h after PPX-IR (1 mg/kg) injection. In the 
reserpine model, early morning akinesia indicated by the first motor activity 
measurement in the morning was significantly reversed by PPX-CR (2 mg/kg/day). 
Again, PPX-IR (tid 0.3 mg/kg, pre-treatment the day before) was not able to 
antagonise early morning akinesia. These results are in agreement with in vivo 
microdialysis measurements showing a continuous decrease of extracellular DA 
levels and a continuous PPX exposure in the PPX-CR (1 mg/kg/day) group. In 
contrast, PPX-IR (0.3 mg/kg) produced a transient decrease of extracellular DA 
levels over 6h and showed maximum PPX levels 2h after dosing which decreased 
over the following 6-8h. 
The present study demonstrates that PPX-CR may offer a higher therapeutic benefit 
than PPX-IR on early morning akinesia and confirms earlier reports that PPX-IR 
reverses motor impairment for several hours. 
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INTRODUCTION 
After discovery of L-DOPA and various DA receptor agonists, a new area of research 
started for the pharmacotherapy of PD. Indeed, not only the affinity, potency and 
selectivity for the distinct DA receptors of anti-parkinsonian drugs were regarded as 
important to improve the pharmacotherapy, but also the knowledge about the impact 
of pulsatile or CDS received more and more attention. DA agonists or L-DOPA 
formulations resulting in long plasma half-lives are aiming to achieve CDS which 
eventually should prevent unwanted effects related to fluctuations in brain and 
plasma drug levels.  
The concept of CDS (Bezard et al. 2001; Jenner 2008b; Nutt et al. 2000; Olanow et 
al. 2006) postulates that it is desirable to avoid the non-physiological pulsatile DA 
receptor stimulation. This concept could translate into prolonged therapeutic efficacy 
and on top would result in lower propensity to develop motor fluctuations, dyskinesia 
and less nocturnal disturbances as well as early morning akinesia. PPX may be a 
candidate for CDS because of its good tolerability and favourable pharmacokinetic 
properties (high oral bioavailability, no significant interaction with hepatic cytochrome 
P450 enzymes, long half-life) in humans (Kvernmo et al. 2006). PPX is a non-
ergoline full DA receptor agonist with selectivity for the DA D3 receptor (Mierau and 
Schingnitz 1992; Mierau et al. 1995; Piercey et al. 1996; Piercey 1998) and has been 
approved by the FDA and other regulatory authorities in 1997 for the treatment of 
early and advanced stages of PD. Since this time, PPX has become one of the most 
widely used DA receptor agonists and is in use in monotherapy as well as in 
combination with other anti-parkinsonian medication such as L-DOPA for the 
treatment of PD. More recently, PPX is also registered for treatment of patients 
suffering from restless legs syndrome. 
Preclinical data on CDS by PPX in animal models of PD are sparse. To date only one 
study using CDS by PPX has been published which aimed to investigate the 
neuroprotective effects of CDS against lipopolysaccharide (LPS)-induced 
dopaminergic cell death in vivo. Iravani et al. (2008) demonstrated in this study that 
continuous subcutaneous infusion of PPX over 4 weeks preserved tyrosine 
hydroxylase positive neurons in the nigrostriatal pathway against dopaminergic cell 
death induced by the supranigrally administered LPS in rats. This effect was absent 
in rats acutely injected with PPX arguing for the beneficial effects on neuroprotection 
of CDS over acute treatment. 
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The present study focuses on CDS by PPX targeting symptomatic effects in two 
animal models of PD. In addition, for the first time brain PPX pharmacokinetics was 
simultaneously investigated with levels of the biomarker DA after PPX immediate 
(PPX-IR) and continuous release (PPX-CR). 
 
 
MATERIALS AND METHODS 
 
Animals 
Please see chapter II “General methodology” page 22. 
 
Haloperidol-induced catalepsy 
Haloperidol-induced catalepsy is used as an animal model of extrapyramidal side-
effects and for screening anti-parkinsonian drugs. Cataleptic immobility is regarded 
as an animal equivalent of akinesia and is demonstrated by an animal allowing its 
body to be placed in and maintain abnormal or unusual postures (Sanberg et al. 
1988; Schmidt et al. 1992). Catalepsy was induced by treatment of rats with 
haloperidol (0.5 mg/kg, i.p.) and maintained for 12 hours by administration of 
haloperidol (0.1 mg/kg, i.p.) every 4 hours. The rats were placed with their forelimbs 
on a horizontal bar elevated 6 cm from the floor. The time (s) during which the rats 
maintain in this unusual position was recorded up to 60 seconds (cut-off period 60 
seconds). Catalepsy considered fulfilled when the rat moved its forelimbs and 
stepped down the bar or climbed upon the bar. Three treatment groups were chosen. 
In the PPX-CR group (n = 9), ALZET" osmotic minipumps (model 2004 or 1007D, 
DURECT Corporation, Cupertino, CA, USA) filled with PPX solution were implanted 
subcutaneously under isoflurane anaesthesia the day before the catalepsy 
experiment. PPX was delivered continuously at the dose of 1 mg/kg/day. The PPX-IR 
group (n = 9) was treated with PPX (1 mg/kg, s.c.) 3 times (morning, midday, 
evening) on the day before the catalepsy experiment. On the day of the experiment, 
the first measurement of catalepsy was performed 2 hours after the bolus injection of 
haloperidol. Subsequently, the PPX-IR and vehicle group (n = 9) were treated with 
PPX (1 mg/kg, s.c.) and vehicle, respectively. Catalepsy was measured 2, 4, 6, 8, 10 
and 12 hours later. 
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Reserpine-induced akinesia 
Reserpine-induced akinesia was measured in the open field system Actimot™ (TSE 
Systems GmbH, Bad Homburg, Germany) for 1 hour in the morning. Rats were 
placed individually in the centre of the activity box (46.5 cm x 46.5 cm) and horizontal 
motor activity (m) was determined in 10 minutes intervals by infrared sensor pairs 
(interspace 1.4 cm) with a sampling rate of 100 Hz. 
Three treatment groups were chosen. In the PPX-CR group (n = 7), ALZET" osmotic 
minipumps (model 1007D, DURECT Corporation, Cupertino, CA, USA) filled with 
PPX solution were implanted subcutaneously under isoflurane anaesthesia 3 days 
before the measurement of akinesia. PPX was delivered continuously at the dose of 
2 mg/kg/day. The PPX-IR (n = 6) group was treated with PPX (0.3 mg/kg, s.c.) 3 
times (morning, midday, evening) on the day before the akinesia measurement. All 
rats were treated with reserpine (1 mg/kg, s.c.) in the afternoon the day before the 
experiment. Reserpine was first dissolved in 100% acetic acid and in a subsequent 
step diluted with water to a final concentration of 1% acetic acid. Seventeen hours 
later, motor activity was measured in the open field system for 60 minutes (early 
morning akinesia). 
 
In vivo microdialysis surgery 
Please see chapter II “General methodology” page 23. Subsequently, the ALZET" 
osmotic minipump (model 1007D, DURECT Corporation, Cupertino, CA, USA) filled 
with PPX solution was implanted subcutaneously in rats of the PPX-CR group. PPX 
was delivered continuously at a dose of 1 mg/kg/day. Following surgery, rats were 
allowed to recover for 2 days before performing the in vivo microdialysis procedure. 
 
In vivo microdialysis procedure 
Please see chapter II “General methodology” page 24. The in vivo microdialysis 
procedure was performed with minor modifications in this study. After an equilibration 
period of 2 hours, dialysis samples were collected every 30 minutes into a vial 
containing 10 #l of hydrochloric acid (0.1 M). During the night, the sampling interval 
was prolonged to 60 minutes (20 #l of hydrochloric acid). Fractions 1 to 4 (0 - 2 h) 
were used for calculation of the basal levels. After 2 hours, the PPX-IR and PPX-CR 
group were treated with PPX (0.3 mg/kg, s.c. (n = 4)) and vehicle (saline, s.c. (n = 
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4)), respectively. The sampling was then continued for 17.5 hours up to the next 
morning. 
 
HPLC analysis of microdialysis samples 
Please see chapter II “General methodology” (HPLC system) page 26. Microdialysis 
samples were splitted for HPLC-ECD (60 #l) and LC-MS/MS (10 #l) analysis. 
Samples were analysed for DA using HPLC-ECD under isocratic conditions. 
Chromatographic separation was achieved using a reversed-phase column (Grom-Sil 
120 ODS-4 HE, 250 x 4.0 mm i.d., 5 #m particles, Grace Davison Discovery 
Sciences, Deerfield, IL, USA) at 35°C. The mobile phase consisted of 1.85 mM 1-
octanesulfonic acid sodium salt, 0.13 mM Na2EDTA $ 2 H2O, 8.00 mM NaCl, 57.51 
mM NaH2PO4, adjusted to pH 2.50 with H3PO4, filtered through a 0.22 #m filter, 
mixed up with 5 % acetonitrile and was delivered at a flow rate of 1 ml/min.  
 
LC-MS/MS analysis of microdialysis samples 
Please see chapter II “General methodology” (LC-MS/MS system) page 26. 
Microdialysis samples were analysed for PPX using LC-MS/MS. Mobile phase “A” 
and “B” consisted of 0.1 % formic acid in LC-MS grade water and acetonitrile, 
respectively. The gradient was chosen as follows: 0.00 min: 100% A, 1.40 min 100% 
A, 1.41 min 0% A, 2.00 min 0% A, 2.10 min 100% A, 2.50 min 100 % A and delivered 
at 0.5 ml/min onto a reversed-phase column (Synergi Polar-RP 80 A, 150 x 2.0 mm i. 
d., 5 #m particles, Phenomenex, Inc., Aschaffenburg, Germany) at 20 °C. The 
column switching valve was set at 0.00 min to the waste, at 0.75 min to the mass 
spectrometer and at 2.00 min to the waste again. 
Three transitions were chosen: 212-153 (DP 56 V, CE 21 V, CXP 10 V), 212-111 (DP 
56 V, CE 37 V, CXP 8 V), 212-126 (DP 56 V, CE 39 V, CXP 8 V) and transition 212-
153 was used for the quantification of PPX. As internal standard [D7]-PPX was 
analysed using transition 219-153 (DP 86 V, CE 21 V, CXP 10 V). 
 
Drugs and chemicals 
Please see chapter II “General methodology” page 26. 
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Statistical analysis 
Please see chapter II “General methodology” page 27. The time course of 
haloperidol-induced catalepsy test as well as reserpine-induced akinesia was 
analysed by a two-way ANOVA with treatment as independent and time as 
dependent factor followed by a Bonferroni post hoc test. Statistical analysis of the 
cumulative data of the haloperidol-induced catalepsy and the reserpine-induced 
akinesia test was carried out using one-way ANOVA with treatment as independent 
factor followed by a Bonferroni post hoc test. For comparison of basal DA and PPX 
levels an unpaired t-test was performed. 
 
 
RESULTS 
 
Haloperidol-induced catalepsy 
Fig. 19 shows the effect of PPX on haloperidol-induced catalepsy. Statistical analysis 
yielded a significant interaction of time x treatment (F(12;144) = 6.388; P < 0.001) as 
well as significant effects on time (F(6;144) = 4.786; P < 0.001) and treatment 
(F(2;144) = 15.33; P < 0.001) (Fig. 19A). Time spent on the bar of the PPX-CR group 
was significantly decreased in comparison to the vehicle group during the whole 
experiment (0h, 2h, 8h, 10h: P < 0.001; 4h: P < 0.05; 6h, 12h: P < 0.01). The PPX-IR 
and vehicle group did not display a significant difference 2 h after haloperidol 
injection (time point 0; pre-test before PPX/vehicle injection) indicating that pre-
treatment with PPX the day before did not show an effect on haloperidol-induced 
catalepsy the next morning. treatment with PPX the day before did not show an effect 
on haloperidol-induced catalepsy the next morning. Following injection with PPX, the 
time spent on the bar decreased significantly in the PPX-IR group at time points 2h 
and 4h (P < 0.001) as well as 6h (P < 0.05). Regarding the cumulative data (Fig. 
19B), PPX-CR (P < 0.001) as well as PPX-IR (P < 0.05) showed an improvement of 
haloperidol-induced catalepsy, whilst PPX-CR revealed a significant higher effect in 
comparison to PPX-IR (P < 0.05). 
 
Continuous dopaminergic stimulation by PPX is effective to treat early morning akinesia 
 103 
Fig. 19. Effects of PPX-IR (1 mg/kg, 
s.c., n = 9), PPX-CR (1 mg/kg/day, 
s.c., n = 9) and vehicle (n = 9, s.c.) on 
the time course (Fig. 19A) and 
cumulative data (Fig. 19B) of 
haloperidol-induced catalepsy. The 
PPX-IR group was treated with PPX 3 
times on the day before the catalepsy 
experiment. Haloperidol (0.5 mg/kg, 
i.p.) was injected 2 hours prior to the 
first catalepsy measurement. Catalepsy 
was maintained for 12 hours by 
administration of haloperidol (0.1 
mg/kg, i.p.). Data are expressed as 
mean ± SEM. The time course was 
analysed by a two-way ANOVA 
followed by a Bonferroni post hoc test 
(***P < 0.001, **P < 0.01, *P < 0.05 vs. 
vehicle). Cumulative data was analysed 
using one-way ANOVA followed by a 
Bonferroni post hoc test (***P < 0.001, 
*P < 0.05 vs. vehicle, #P < 0.05 PPX-IR 
vs. PPX-CR). 
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Reserpine-induced akinesia 
Fig. 20. Effects of PPX-IR (2 mg/kg, s.c., 
n = 7), PPX-CR (2 mg/kg/day, s.c., n = 6) 
and vehicle (n = 6, s.c.) on the time 
course (Fig. 20A) and cumulative data 
(Fig. 20B) of reserpine-induced 
akinesia. The PPX-IR group was treated 
with PPX 3 times on the day before the 
akinesia measurement. Reserpine (1 
mg/kg, s.c.) was injected 17 hours prior to 
the experiment. Data are expressed as 
mean ± SEM. The time course was 
analysed by a two-way ANOVA followed 
by a Bonferroni post hoc test (***P < 
0.001, *P < 0.05 vs. vehicle). The 
cumulative data was analysed using one-
way ANOVA followed by a Bonferroni post 
hoc test (**P < 0.01 vs. vehicle, #P < 0.05 
PPX-IR vs. PPX-CR). 
 
The effects of PPX on reserpine-
induced early morning akinesia are 
shown in Fig. 20. Statistical 
analysis revealed a significant 
treatment effect (F(2;18) = 7.266; P < 0.01). No significant differences were observed 
between the vehicle and the PPX-IR group indicating that pre-treatment with PPX the 
day before does not alter early morning akinesia. In contrast, akinesia was improved 
by treatment with PPX-CR at 10 min (P < 0.001) and 30 min (P < 0.05) (Fig. 20A) as 
well as considering the whole experiment over 60 min (P < 0.01) (Fig. 20B). 
 
Measurement of extracellular DA levels 
Effects of PPX on extracellular DA levels in the striatum are displayed in Fig. 21A. 
Pre-dose basal levels of DA in the PPX-IR were found to be 1.86 nM. In the PPX-CR 
group no pre-dose values could be measured because the microdialysis surgery and 
the implantation of the pump were carried out at the same time. At the time of DA 
measurement in the PPX-CR stable levels of approximately 0.07 nM were obtained 
which did not vary over time implicating steady state conditions. Statistical analysis 
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revealed significantly lower DA levels in the PPX-CR group (96.2 %) in comparison to 
the pre-dose values of the PPX-IR group (P < 0.01). The maximum effect in the PPX-
IR group was observed 90 minutes after PPX treatment (44.4 % in comparison to 
basal DA levels). 
 
Fig. 21. In vivo microdialysis. 
Effects of PPX-IR (0.3 mg/kg, 
s.c., n = 4) and PPX-CR (1 
mg/kg/day, s.c., n = 4) on 
extracellular levels of DA (Fig. 
21A) and PPX (Fig. 21B) in the 
striatum. Data are expressed as 
mean  SEM. 
 
Measurement of micro-
dialysate PPX levels 
Extracellular PPX levels in 
the striatum are displayed 
in Fig. 21B. Pre-dose levels 
of PPX in the PPX-IR were 
found to be 0.25 nM. As 
mentioned before, no pre-
dose levels in the PPX-CR 
were obtained and basal 
PPX levels of the PPX-CR 
were found to be 1.86 nM. 
Injection of PPX in the PPX-
IR group led to an increase in PPX levels, which was maximum 90 min following PPX 
injection (3.48 nM). 
 
 
DISCUSSION 
The present neuropharmacological study demonstrated the effects of acute and 
continuous exposure of the DA D3/D2 agonist PPX in two symptomatic animal models 
of PD including in vivo microdialysis measurements of PPX and DA. 
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We found in both animal models of PD that the effects of PPX are dependent on the 
PPX exposure in the brain. In particular, the day following acute PPX pre-treatment 
the symptomatic effects of PPX were no longer present which resulted in early 
morning akinesia. In contrast, continuous PPX exposure using subcutaneously 
implanted Alzet" minipumps prevented early morning akinesia. Additionally, 
continuous PPX exposure produced significantly lower extracellular DA levels than 
the peak decrease obtained after acute PPX administration, although the PPX 
exposure was lower in the PPX-CR group. 
Haloperidol is able to induce parkinsonian-like symptoms such as muscle rigidity 
(Lorenc-Koci et al. 1996) and catalepsy (De Ryck and Teitelbaum 1983; Fischer et al. 
2002). Haloperidol-induced catalepsy is considered as an animal model of 
parkinsonian akinesia which reflects the exaggerated reflex reaction necessary to 
maintain postural stability, the obstruction to actively challenge stable static 
equilibrium and to initiate phasic locomotor movements (De Ryck et al. 1980). 
Haloperidol-induced akinesia is a result of the blockade of DA D2 receptors in the 
corpus striatum (Ellenbroek et al. 1985). We found a pronounced effect of PPX-IR 
which was reversible, declined after 6 hours and was absent at 8 hours. Because the 
effect of a single haloperidol injection led only to significant catalepsy within 6 hours, 
we adapted the catalepsy model to maintain catalepsy over a longer period of time 
by multiple haloperidol injections using low haloperidol doses. This allowed us to 
study the effects of PPX-IR and PPX-CR over a long observation period of 12 hours. 
Only PPX-CR antagonised the haloperidol-induced catalepsy over the whole 
observation period which is in agreement with PPX exposure measurements (please 
see above). In terms of maximum efficacy the PPX-IR and PPX-CR groups did not 
differ. The duration of the anti-cataleptic effect was longer in the PPX-CR group. The 
anti-cataleptic effects are in line with a previous study on haloperidol-induced 
catalepsy in which a single subcutaneous injection of PPX (1 and 3 mg/kg) led to a 
2.5-3 h lasting relieve of catalepsy (Maj et al. 1997). In contrast, higher doses of PPX 
(3 and 5 mg/kg) were necessary to antagonise the haloperidol-induced muscle 
rigidity (Lorenc-Koci and Wolfarth 1999). 
In the second symptomatic animal model of PD, reserpine was used to investigate 
the effects of PPX-IR and PPX-CR on the motor behaviour symptom akinesia. In 
comparison to haloperidol which has a high affinity for DA D2-like receptors (D2, D3, 
D4: Ki value 1.2, 7, 2.3 nM, respectively) (Seeman and Van Tol 1994) reserpine acts 
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presynaptically by blocking the uptake of monoamines by the vesicular monoamine 
transporter 2. This inhibition unselectively affects the storage of monoamine 
neurotransmitters such as adrenaline, noradrenaline, DA, histamine and 5-HT in the 
CNS and also in the periphery. Although not specific to a single neurotransmitter 
pathway and without involvement of neurodegenerative events the reserpine model 
is still a valuable tool to investigate symptomatic effects of DA receptor agonists in 
PD (Maj et al. 1997) as well as to study non-dopaminergic mechanisms in PD 
(Kreitzer and Malenka 2007; Niswender et al. 2008). We optimised the typical 
reserpine model by reducing the dose of reserpine to 1 mg/kg.  
As seen in the haloperidol-induced catalepsy model, PPX-CR antagonised the motor 
impairment. PPX-CR was effective over the whole observation period including the 
first measurement on early morning akinesia. Using a higher dose of reserpine (5 
mg/kg) in combination with !-methyl-p-tyrosine (250 mg/kg, i.p.) to additionally block 
DA biosynthesis, Maj et al. (1997) showed that a single subcutaneous injection of 
PPX (0.3 and 1 mg/kg) increased locomotor activity. The effect of PPX was even 
higher than obtained in the vehicle+reserpine/!-MT group as well as in the 
vehicle+vehicle control group. Under our conditions we did not observe any 
hyperactivity neither in the PPX-IR nor in the PPX-CR group. 
Unbound PPX brain tissue levels, CSF or microdialysate levels have not been 
published so far. Most of the pharmacokinetic data on PPX exposure relied on 
studies measuring PPX plasma levels. For example in healthy volunteers the plasma 
concentrations of PPX were proportional to dose under steady-state conditions 
(elimination half-life t1/2 8-12 hours, tmax 1-3 hours, cmax 0.375-4.5 ng/ml) (Kvernmo et 
al. 2006; Wright et al. 1997). Recently, we reported that PPX accumulated in the 
brain indicated by a brain plasma ratio of 6.7 obtained in mice after oral 
administration (Danzeisen et al. 2006), which is in accordance with the proposed 
active transport of PPX through the blood-brain barrier by an organic cation-sensitive 
transporter (Okura et al. 2007). In vivo microdialysis is the method of choice to 
analyse both the drug as well as the biomarker at the target side (i.e. the striatum in 
PD) in the same sample. We took advantage of the DA measurement using HPLC-
ECD which is very sensitive and additionally established a method to analyse PPX in 
microdialysates using LC-MS/MS. The PPX exposure in the rat striatum was 
maximum at 90 minutes (3.48 nM) following injection in the PPX-IR group and 
declined over a period of 3 hours. Animals continuously treated with PPX showed 
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lower maximum PPX levels and revealed an almost constant striatal PPX exposure 
of 2.46 nM over the whole experiment. 
In the present study PPX-IR and PPX-CR affected extracellular DA levels. The 
reduction of extracellular DA levels can be explained by stimulation of presynaptic 
DA receptors in dopaminergic nerve terminals. This effect is characteristic for DA 
receptor agonists including PPX and reflects both the involvement on regulation of 
DA synthesis and on Ca2+ dependent exocytotic DA release by the DA autoreceptor 
mediated feedback inhibition (Wolf and Roth 1987). PPX binds preferentially to DA 
D3 receptors followed by DA D2 receptors (Mierau et al. 1995; Piercey et al. 1996), 
which fits to the role of presynaptic DA D3 receptors on DA release (Gainetdinov et 
al. 1996) and DA synthesis (Wolf and Roth 1990). Additionally, it was demonstrated 
that DA D3 preferring compounds modulate the DA uptake in vitro and in vivo 
suggesting that the DA D3 receptor activation increases DA uptake by modulating the 
DA transporter activity (Zapata and Shippenberg 2002). 
Indeed, systemic PPX administration caused a long-lasting reduction of extracellular 
DA and DA metabolite levels in rat striatum (Carter and Muller 1991; Robertson et al. 
1993). This effect was reversed by the D2 DA receptor antagonist sulpiride but not by 
the D1 DA receptor antagonist SCH 23390 (Carter and Muller 1991). Local PPX 
administration reduced the 6-OHDA-induced increase of extracellular DA in rat 
striatum (Ferger et al. 2000) and reduced the L-type Ca2+ channel activator (BAY K 
8644)-induced rise in extracellular DA levels (Maruya et al. 2003). Cumulative 
evidence underlines that extracellular DA levels measured by in vivo microdialysis is 
a suitable biomarker to indicate DA D2/D3 receptor stimulation and therefore can be 
used to compare the effects of PPX-IR and PPX-CR. Although slightly higher peak 
PPX levels were obtained after PPX-IR, the extracellular DA levels were consistently 
lower in the PPX-CR group which speaks against desensitization and a tolerance 
effect on regulation of extracellular DA levels after CDS by PPX. (Chernoloz et al. 
2009) performed an electrophysiological experiment in anesthetised rats which were 
subcutaneously implanted with osmotic minipumps delivering PPX at a dose of 1 
mg/kg per day for 2 or 14 days. They demonstrated a decrease in the spontaneous 
firing of dopaminergic neurons by 40 % after 2 days of treatment, whereas after 14 
days of PPX treatment the firing rate of DA neurons had recovered and implicated a 
desensitization of D2/D3 cell body autoreceptors after long-lasting continuous PPX 
treatment. 
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Continuous DA receptor stimulation using DA agonists delivered by miniosmotic 
pumps or by external infusion systems are useful in preclinical animal experiments 
but are impractical in most patients suffering from PD. In patients the most 
convenient route of administration is the oral one. Subcutaneous administration of 
DA receptor agonists as used in the present study can be alternatively used when a 
rapid onset of action is needed. A continuous subcutaneous infusion is suitable to 
stabilise motor functions (Nyholm 2006). A drawback of long-term subcutaneous 
infusion, however, could be adverse events such as skin reactions and nodules 
accompanied by variable drug absorption (Deleu et al. 2004). These disadvantages 
prompted the development to oral sustained or extended release formulations in 
several drug development programmes. In case of low bioavailability of a compound, 
transdermal delivery of dopaminergic drugs can be a practical method to achieve 
CDS and may be useful in patients with swallowing difficulties (Steiger 2008). 
Particularly at night and in the early morning hours constant plasma levels of short 
acting DA agonists cannot be maintained because of drug clearance. In fact, the 
therapeutic efficacy of the symptomatic effects of DA agonists including PPX is 
closely related to sufficient drug exposure levels. As a matter of fact cardinal PD 
symptoms appear if dopaminergic receptor stimulation cannot be maintained. 
Another issue beyond the prolongation of the symptomatic effects of CDS by DA 
agonists is the reduced risk to develop motor complications such as dyskinesia as 
demonstrated in parkinsonian cynomolgus monkeys (Bibbiani et al. 2005). 
Furthermore, the reversal of motor deficits without dyskinesia induction in MPTP-
treated common marmosets argues for the concept of CDS (Stockwell et al. 2008). 
In conclusion, this study highlights the potential benefit of CDS using PPX-CR and 
the advantage over PPX-IR in two symptomatic PD models. Currently, a once-daily 
PPX extended release formulation (tablet) undergoes regulatory review. The 
outcome of clinical studies will show if the beneficial effects of CDS provided by PPX-
CR translates into daily life of individuals affected with PD 
 
This study was performed in collaboration with colleagues. My contribution was the 
measurement of DA levels using HPLC-ECD as well as preparation of the manuscript by 
preparing figures and writing the “materials and methods” as well as “results” part. 
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CHAPTER IX 
Effects of L-DOPA on striatal monoamines in mice with L-DOPA-induced 
hyperactivity 
 
ABSTRACT 
L-DOPA remains the "gold standard" pharmacological treatment for PD, but has a 
tendency to produce disabling hyperactive movements called dyskinesias in a 
substantial number of these patients. As a precursor molecule, exogenous L-DOPA 
is converted to DA in the striatum of PD patients, but its utilization in other 
monoamine pathways, as related to its hyperactive side effects, is still not well 
understood. Using HPLC and a C57 mouse model of L-DOPA-induced dyskinesia 
that was developed in our laboratory, the present study examined the effects of 
exogenous L-DOPA with carbidopa (CD) on monoamines and their metabolites in the 
striatum versus the olfactory bulb as a control. Thus, mice previously exposed to 
MPTP and later made hyperactive with high dose exogenous L-DOPA (n = 10) were 
compared to normal acting mice who received L-DOPA without previous MPTP (n = 
4) or no treatment at all (n = 4). In the olfactory bulb, exogenous L-DOPA uniformly 
caused increased DA levels and increased DA-, 5-HT- and NA turnover rates, but 
decreased 5-HT and NA levels, regardless of animal activity. These trends were also 
seen in the striatum, but, DA and 5-HT levels were less and DA- and 5-HT-turnover 
rates were higher, in dyskinetic animals. In addition, the expected increased NA-
turnover rate was not seen in the striatum of dyskinetic animals. The results of the 
present study demonstrates that striatal monoamines in dyskinetic animals have a 
unique profile that must be considered when trying to explain the effects of 
antidyskinetic drugs that utilize monoamine receptors.  
 
 
INTRODUCTION 
As a precursor molecule, exogenous L-DOPA can theoretically be converted to DA 
by any cell containing the enzyme AADC. This enzyme is found not only in all 
neurons that produce catecholamines, including DA, and NA, but also in those that 
produce indolamines such as 5-HT (5-HT). In normal adult C57 mice given large 
amounts exogenous L-DOPA, brain DA levels increased while brain 5-HT levels 
decreased in a dose dependent manner (Everett and Borcherding 1970). These 
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experiments and others (Arai et al. 1994; Arai et al. 1995; Carta et al. 2007; Ng et al. 
1970) suggested that AADC in 5-HT neurons, if overwhelmed by large amounts of 
exogenous L-DOPA, can produce DA and that this would be done at the expense of 
5-HT production. In NA producing cells, on the other hand, it was suspected that 
exogenous L-DOPA would be converted to DA, but then this would be further 
converted by the enzyme dopamine beta hydroxylase (DBH) to increase NA 
production. Indeed, when large doses of exogenous L-DOPA were given to normal 
rats, levels of brain NA increased, but only transiently (Chalmers et al. 1971; Romero 
et al. 1972). In PD, it is well known that catecholamine neurons, such as those in the 
dopaminergic nigrostriatal pathway, and noradrenergic neurons of the locus 
coeruleus are severely degenerated (Alvord 1968; Forno 1966). Prior to the use of L-
DOPA, striatal DA and NA in PD patients were found to be decreased by 
approximately 90% and 80%, respectively (Hornykiewicz 1975). As a result, it has 
long been suspected that the efficacy of L-DOPA as one of the best pharmacological 
treatments for PD, depends upon surviving striatal 5-HT pathways containing AADC 
to convert a significant amount of the exogenous L-DOPA into DA; however, prior to 
the use of L-DOPA, striatal 5-HT levels were also found to be decreased by about 
56% (Hornykiewicz 1975). Due to the fact that striatal DA, NA and 5-HT levels seem 
to be affected both by the pathophysiological processes of PD and by exposure to 
exogenous L-DOPA, it has also been theorized that the side effect of debilitating, 
hyperactive involuntary movements referred to as L-DOPA-induced dyskinesia that 
have been reported in approximately 50% of PD patients taking L-DOPA therapy 
over 5 years (Ahlskog and Muenter 2001), are related to a combination of these 
monoamine changes (Brotchie 2005). However, the influence of exogenous L-DOPA 
on all striatal monoamines as it relates to the emergence of this hyperactive side 
effect of PD treatment has not yet been fully examined. In a C57 mouse model of PD, 
it has been shown that the neurotoxin MPTP depletes striatal DA by approximately 
84% (Nishi et al. 1991; Sundstrom et al. 1987) and NA by 46% (Nishi et al. 1991), 
while leaving striatal 5-HT virtually intact (Heikkila et al. 1984; Sundstrom et al. 1987). 
Using this model, the present study examines the influence of high dose L-DOPA 
given with the peripheral AADC inhibitor CD, on monoamine production and 
metabolism in the striatum of hyperactive mice previously exposed to MPTP, 
compared to normal acting mice that either received high dose L-DOPA/CD without 
previous MPTP exposure or no treatment at all. Olfactory bulbs from these animals 
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served as controls, since they represent an easily accessible, non-motor brain area 
containing the same monoamines as those present in the striatum and were shown 
in C57 mice to result in similar MPTP-induced depletions of DA (Sundstrom et al. 
1987). The results should determine if exogenous L-DOPA influences monoamine 
levels and metabolism of different brain areas in different ways and if there is a 
unique monoamine profile in the striatum of dyskinetic animals in particular.  
 
 
MATERIALS AND METHODS 
Methods for preparing the mouse model of L-DOPA-induced dyskinesia were 
performed in accordance with NIH guidelines and described previously (Nicholas 
2007). Briefly, 10-12 month old male C57 BL/6 mice (Charles River) were divided into 
three groups (Fig 26), including 1) untreated normoactive controls (n = 4), 2) 
hyperactive animals previously exposed to MPTP (30 mg/kg in 5% ethanol) for 10 
consecutive days and later given high dose L-DOPA after an additional 10-14 days of 
rest (n = 10), and 3) normoactive mice that also received high dose L-DOPA but were 
not previously exposed to MPTP (n = 4). Stable motor responses of surviving MPTP-
treated and non-treated animals were measured using an external cage rack 
Photobeam Activity System (San Diego Instruments, San Diego, California). 
Behavioural responses of the animals used in this study have been previously 
reported (Nicholas 2007). Animals that received L-DOPA (Sigma, 200 mg/kg) were 
given intraperitoneal injections mixed with CD (DuPont, 25 mg/kg) in normal saline, 
twice daily and were sacrificed by decapitation 60 minutes after the fifth L-DOPA 
dose at the peak of hyperactivity in dyskinetic mice and at the same time as control 
animals receiving L-DOPA that were not hyperactive. The striatum and olfactory 
bulbs of these mice were quickly removed, frozen on dry ice and stored at –80ºC. 
Prior to HPLC analysis, all tissue samples were transferred separately to 15ml plastic 
tubes and weighed. Ice-cooled perchloric acid (0.4 M) was added to the striatum (500 
µl), and olfactory bulbs (300 µl) and the tissue was homogenised for 10 s using an 
ultrasonicator and centrifuged for at least 20 min at 3200 x g at 4 °C. The 
supernatant was passed through a 0.2 µm filter (Minisart RC4, Sartorius AG, 
Germany) and frozen again at -80 °C. Using HPLC-ECD, the samples were analysed 
for DA and its metabolite DOPAC, 5-HT and its metabolite 5-hydroxyindoleacetic acid 
(5-HIAA) and NA and its metabolite 3-methoxy-4- hydroxyphenylglycol (MHPG), 
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under isocratic conditions. Chromatographic separation was performed using a 
reversed-phase column (Discovery C18, 150 x 4.6 mm i.d., 5 µm particles, with pre-
column, Supelco, USA). The mobile phase included 1-octanesulfonic acid sodium 
salt (0.32 mM), Na2EDTA x 2 H20 (0.27 mM), NaCl (8.0 mM) and KH2PO4 (50.0 mM) 
After the pH was adjusted to 4.00 with H3PO4, the mobile phase was then passed 
through a 0.22-µm filter, mixed with acetonitrile (95:5, v/v) and delivered at a flow rate 
of 1.0 ml/min. Quantification of brain monoamine levels were calculated as mean ± 
standard deviation and compared among experimental groups using ANOVA and 
two-tailed t-tests. 
 
RESULTS AND DISCUSSION 
The results showed that, compared to untreated animals and regardless of animal 
activity and previous MPTP exposure, exogenous L-DOPA tended to significantly 
increase DA and deplete 5-HT and NA in the olfactory bulb (Fig. 22A) and striatum 
with a few important caveats (Fig. 22B). For example, the highest DA levels were 
found in normal acting animals that received L-DOPA but not MPTP, proving that 
high striatal DA alone was not responsible for hyperactivity. In dyskinetic mice, 
striatal DA was increased and 5-HT and NA decreased as compared to untreated 
controls, but only DA and 5-HT were statistically significantly decreased as compared 
to normal acting mice that received L-DOPA but not MPTP. These results suggest 
that exogenous L-DOPA tends to increase DA at the expense of 5-HT and NA, but 
these are even more pronounced in the striatum where MPTP has an additional 
detrimental effect. It also seems that in the striatum, the ability to decrease NA is 
more due to MPTP than to L-DOPA exposure.  
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Fig. 22. Monoamines in the olfactory bulb 
(A) and striatum (B) of untreated normal 
acting control mice (Control), animals with 
L-DOPA-induced dyskinesia (L-DOPA-
HYPER) and L-DOPA-treated normal acting 
control mice (L-DOPA-Normal). P values of L-
DOPA-treated groups vs untreated group: **** < 
0.0001, *** < 0.001, ** < 0.01, * < 0.05; P 
values between L-DOPA-treated groups: #### 
< 0.0001, # < 0.05. 
 
Turnover rates were determined after 
examining monoamines and their 
metabolites (Table 6) and L-DOPA 
treatment was shown to universally 
increase DA-, 5-HT- and NA-turnover 
rates (Fig. 23), with a few important 
exceptions. In the olfactory bulb, 
monoamine turnover rates were not statistically significantly different between 
hyperactive mice and normoactive mice receiving L-DOPA (Fig. 23A). In contrast, 
DA- and 5-HT-turnover rates in the striatum of dyskinetic mice were highest, while 
striatal NA-turnover was not significantly different from normal acing control animals, 
whether they received L-DOPA or not (Fig. 23B). As a result, the expected increase 
in striatal NA-turnover was not seen in mice with L-DOPA-induced dyskinesia.  
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Normoactive (n=4) no 
treatment 
Hyperactive (n=10) 
MPTP/carbidopa/ 
L-DOPA 
Normoactive (n=4) 
carbidopa/ 
L-DOPA 
 
Olfactory bulb monoamine metabolites: mean ng/mg wet tissue weight ± SEM 
 DOPAC 0.1455 ± 0.0072 11.5616 ± 0.5087*** 12.8095 ± 0.8265*** 
 HVA 0.2604 ± 0.0188 3.5230 ± 0.1604*** 3.1426 ± 0.2245*** 
 5-HIAA 0.3677 ± 0.0099 0.1946 ± 0.0068*** 0.1711 ± 0.0171*** 
 MHPG 0.5595 ± 0.0407 0.5275 ± 0.0492 0.3833 ± 0.0755 
 
Striatal monoamine metabolites: mean ng/mg wet tissue weight ± SEM 
 DOPAC 0.9818 ± 0.1150 20.6017 ± 1.1671*** 19.8405 ± 0.8227*** 
 HVA 0.6805 ± 0.0878 6.5243 ± 0.2871***,# 5.5688 ± 0.2680*** 
 5-HIAA 0.6856 ± 0.0716 0.6230 ± 0.0336***,## 0.4943 ± 0.0193*** 
 MHPG 0.2393 ± 0.0137 0.5862 ± 0.2937 0.2141 ± 0.0177 
 
Table 6. Monoamine metabolites in olfactory bulb and striatum in LID vs. control mice. ***P < 
0.0001 vs. non-treated controls; ##P < 0.001, #P < 0.01 hyperactive vs. normoactive carbidopa/L-
DOPA treated groups. 
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Fig. 23. Monoamine turnover rates 
in the olfactory bulb (A) and 
striatum (B) of untreated normal 
acting control mice (Control), 
animals with L-DOPA-induced 
dyskinesia (L-DOPA-HYPER) and 
L-DOPA-treated normal acting 
control mice (L-DOPA-Normal). DA 
turnover (DOPAC/DA); 5-HT 
turnover (5HIAA/5-HT); NA turnover 
(MHPG/NA); P values for L-DOPA-
treated groups vs untreated group: 
**** < 0.0001, ** < 0.01, * < 0.05; P 
values between L-DOPA-treated 
groups: ## < 0.007.  
 
These findings are consistent 
with the hypothesis that when 
the nigrostriatal system is 
damaged, as in the PD or one 
of its animal models, a 
relatively better intact 5-HT terminal networks converts much of the exogenous L-
DOPA into DA and this is done at the expense of 5-HT production. However, these 
results also show that previous damage of DA pathways is not a prerequisite to 
causing decreases in 5-HT, as conversion of exogenous L-DOPA to DA at the 
expense of 5-HT takes place even in animals not exposed to MPTP. The results of 
the present study can be explained by the high likelihood that AADC in both DA and 
5-HT neurons were saturated by excessive amounts of L-DOPA given in these 
experiments, regardless of previous damage to DA pathways. This is supported by 
studies in normal rats where dual colour fluorescence showed previously unseen DA 
immunoreactivity localized in serotonergic fibers of the striatum and cell bodies of the 
midbrain raphe nuclei only after rats were treated with exogenous L-DOPA (Arai et al. 
1995). Using HPLC analysis, L-DOPA treatment in normal rats resulted in significant 
loss of 5-HT in many serotonergic and dopaminergic regions of the brain, especially 
the striatum, while striatal DA and DA turnover (Borah and Mohanakumar 2007) and 
enhancement of NA turnover in rat brain (Keller et al. 1974) were significantly higher. 
These findings are consistent with the present study. Furthermore, depression was 
Effects of L-DOPA on striatal monoamines in mice with L-DOPA-induced hyperactivity 
 117 
seen in L-DOPA-treated animals, as revealed in a forced swim test (Borah and 
Mohanakumar 2007), suggesting that L-DOPA-induced decreased 5-HT levels were 
partly responsible. In the 6- OHDA lesioned striatum of rats that received L-DOPA, 5-
HT levels were decreased (Carta et al. 2007) and DA was detected within increased 
numbers of serotonergic varicose fibers, suggesting that striatal serotonergic 
hyperinnervation may compensate for the lost function of dopaminergic neurons in 
this model (Maeda et al. 2005). Sprouting of serotonergic afferents into the striatum 
was also seen after MPTP exposure in C57 mice (Rozas et al. 1998). In the present 
study, striatal 5-HT levels were the lowest in dyskinetic animals, suggesting an 
additional depleting effect of both MPTP and L-DOPA. It was previously shown in 
C57 mice that MPTP alone had no significant effect on striatal 5-HT levels (Heikkila 
et al. 1984; Sundstrom et al. 1987), but the MPTP dosing schedules used in these 
prior experiments differed from the present study. In contrast to 5-HT, NA production 
and breakdown seemed to differ slightly in different brain locations. Since DA is a 
substrate for NA, it could be theorized that exogenous L-DOPA should cause 
universal increases in both DA and NA. Thus, L-DOPA first is converted to DA in the 
cytosol, since the DA-synthesizing enzyme AADC is found in this location. DA would 
then be packaged in vesicles and should be converted to NA in that location, since 
the NA-synthesizing enzyme DBH is bound to the insides of vesicular membranes. 
However, one surprising finding in the present study was that exogenous L-DOPA 
treatment actually tended to universally decrease NA levels, especially in the 
olfactory bulb, and this effect was seen regardless of motor activity or previous MPTP 
exposure. These results suggest that in animals treated with L-DOPA, the cytosolic 
pool of DA in these noradrenergic terminals is so high, that perhaps the increased 
production of synaptic vesicles happens so rapidly that DBH incorporation into these 
vesicles is lacking. This is consistent with previous studies in normal rodents showing 
that exogenous L-DOPA increased primarily the cytoplasmic pool of DA and that 
significant increases in vesicular DA required previous catecholamine depletion (Buu 
1989). However, in the striatum, NA production was not statistically different in 
normal acting animals, whether they previously received L-DOPA or not. Striatal NA 
levels were only lower in hyperactive animals, suggesting an MPTP-induced NA-
depleting effect that was previously reported (Nishi et al. 1991). Although there is a 
trend that L-DOPA treatment results in increased NA turnover, the present study 
demonstrates that the MHPG/NA ratio also differs slightly, depending upon the site 
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examined. In the olfactory bulb, L-DOPA-induced NA turnover is universally 
increased, similar to both DA and 5-HT turnover rates. However, the expected 
increased turnover of NA in the striatum is not seen in mice with L-DOPA-induced 
dyskinesia, suggesting that in these mice the small amounts of NA that are being 
produced are not being recycled as quickly, perhaps resulting in abnormally 
sustained NA-receptor activation. This hypothesis would concur with the findings that 
highly selective alpha-2 noradrenergic blocking agents such as idazoxan and 
fipamezole have been successfully used to counteract dyskinesia in the MPTP 
monkey model of L-DOPA-induced dyskinesia (Grondin et al. 2000; Henry et al. 
1999; Savola et al. 2003) and in human patients with these involuntary movements 
(Rascol et al. 2001) and that these receptors seem to be plentiful in the striatum 
(Nicholas et al. 1993; Rosin et al. 1996; Scheinin et al. 1994). Antidyskinetic effects 
utilizing serotonergic mechanisms have also been shown with various drugs in 
animal models and humans with L-DOPA-induced dyskinesia, although most of these 
agents also bind to other monoamine receptors as well (Nicholson and Brotchie 
2002). However, using more specific 5-HT receptor binding drugs, recent evidence 
suggests that in 6-OHDA rats, L-DOPA but not DA depletion results in up-regulation 
of striatal 5-HT1B receptors (Zhang et al. 2008) and an antidyskinetic effect can be 
obtained with 5-HT1A (Carta et al. 2007) and 5-HT1B agonists (Carta et al. 2007; 
Zhang et al. 2008), believed to be working at autoreceptors on serotonergic neuronal 
cell bodies/dendrites and terminals, respectively (Carta et al. 2007). The results of 
the present study suggest that exogenous L-DOPA can influence brain monoamine 
levels and metabolism regardless of animal activity; however, there is a unique 
monoamine profile in the striatum of dyskinetic animals in particular. Other motor 
brain areas in which monoamines are present should also similarly be examined in 
future studies, as well as other animal models of L-DOPA-induced dyskinesia to see 
if these trends are consistent. In any case, the present study suggests that in 
designing new drugs to treat PD patients with L-DOPA-induced dyskinesia, careful 
consideration should be made regarding choosing pharmacological profiles that 
would optimally affect these altered DA, 5-HT and NA brain pathways. 
 
This study was performed in collaboration with Prof. Anthony Nicholas (University of 
Alabama at Birmingham, USA), which conducted the in vivo part. My contribution was the 
development of the HPLC method as well as the preparation and HPLC-analysis of the 
tissue samples. 
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CHAPTER X 
Summary 
 
At present, several animal models mimicking L-3,4-dihydroxyphenylalanine (L-
DOPA)-induced dyskinesia are applied to investigate mechanisms underlying the 
induction and manifestation of dyskinesia as well as investigate potential drug targets 
for the alleviation of L-DOPA-induced dyskinesia. I used the 6-hydroxydopamine (6-
OHDA) dyskinesia model in rats, since it is a very robust and reliable model which is 
characterised by a clear behavioural outcome. The aim of my thesis was to 
investigate neurochemical and behavioural mechanisms underlying the expression of 
dyskinetic movements and thus characterise the rat L-DOPA dyskinesia model in 
depth. I shed light on various pathogenic factors, which are important for the 
manifestation of L-DOPA-induced dyskinesia, as well as tested novel drug targets to 
obtain new strategies for the treatment of L-DOPA-induced dyskinesia.  
One of the techniques I preferentially applied during my thesis is the technique of in 
vivo microdialysis. It is an invasive technique where neurotransmitter alterations as 
well as pharmacokinetic profiles of drugs in the brain extracellular fluid can be 
analysed. This bears the advantage to monitor neurotransmitter release and turnover 
not only under baseline conditions but also upon stimulation or inhibition with drugs 
since neurotransmitter or compound changes can be determined over time in the 
same animal resulting in fewer animal numbers per study. Additionally, behaviour 
can be observed in parallel and correlated to neurochemical changes. In vivo 
microdialysis can also be used reciprocally to administer compounds locally into 
various brain areas of interest, which is called reverse in vivo microdialysis. I 
frequently applied the technique of reverse in vivo microdialysis to assess different 
parameters, which may be important for the evocation of dyskinetic movements such 
as the choice of neurotransmitter as well as the factors lesion and brain area. 
Moreover, I used several behavioural tasks including the measurement of exploratory 
behaviour in an open-field system, the haloperidol-induced catalepsy test and the 
reserpine-induced akinesia test. In addition, monitoring of dyskinetic behaviour was 
one of the main behavioural tests I performed during my thesis. Furthermore, I used 
various chromatography techniques including high performance liquid 
chromatography (HPLC) combined with either electrochemical (ECD) or fluorescence 
Chapter X 
 120 
detection (FD) as well as liquid chromatography coupled to tandem mass 
spectrometry (LC-MS/MS) for the measurement of neurotransmitters and 
pharmacokinetics of compounds.  
The introduction comprises a review on the pathophysiology of L-DOPA-induced 
dyskinesia, in which the test strategy to assess the antidyskinetic effect in animal 
models as well as the translational aspect of preclinical and clinical studies is 
outlined. 
In the first study (chapter III: Intrastriatal inhibition of aromatic amino acid 
decarboxylase prevents L-DOPA-induced dyskinesia), I demonstrated that the 
increase of intrastriatal dopamine (DA) levels was instrumental for L-DOPA- and DA-
induced dyskinetic behaviour, whereas intrastriatal L-DOPA administration itself was 
not able to induce dyskinetic behaviour in the 6-OHDA rat model of dyskinesia. This 
result was obtained by striatal administration of benserazide via reverse in vivo 
microdialysis blocking the conversion of L-DOPA to DA. For the first time the striatal 
role of DA was clearly correlated with dyskinetic movements and a possible 
contribution of DA metabolites has been ruled out. In order to further investigate the 
downstream pathway of DA, I studied the effect of noradrenaline (NA) on the ability to 
provoke dyskinesia (chapter IV: Comparison of intrastriatal administration of 
noradrenaline and L-DOPA on dyskinetic movements). I clearly showed that NA 
is able to evoke dyskinesia in the same manner as L-DOPA. For the first time NA 
was discovered as dyskinesiogenic agent, which hypothesizes a novel form of 
dyskinesia, the “NA-induced” dyskinesia. Subsequently, I investigated the ability of 
different adrenoceptor antagonists to reduce dyskinetic movements induced by L-
DOPA (chapter V: The selective !1 adrenoceptor antagonist HEAT reduces L-
DOPA-induced dyskinesia in a rat model of Parkinson’s disease). I 
demonstrated that the selective !1 adrenoceptor antagonist HEAT, the !2 
adrenoceptor antagonist idazoxan as well as the non selective #1/#2 adrenoceptor 
antagonist propranolol alleviated L-DOPA-induced dyskinesia in a dose-related 
manner. For the first time, dyskinesia was reduced by administration of a !1 
adrenoceptor antagonist suggesting a novel treatment option for L-DOPA-induced 
dyskinesia. However, it remains unclear if !1 adrenoceptor antagonists at 
antidyskinetic doses might interfere with the cardiovascular system since some !1 
adrenoceptor antagonists are generally applied for the treatment of hypertension. In 
more detail, I investigated the mechanisms of the !2 adrenoceptor antagonist 
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idazoxan involved in the antidyskinetic effects. Particularly, I studied alterations of L-
DOPA-induced extracellular DA and L-DOPA levels in the lesioned as well as intact 
striatum using in vivo microdialysis (chapter VI: The !2 adrenoceptor antagonist 
idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal 
dopamine levels). I found that idazoxan at antidyskinetic doses reduced 
extracellular L-DOPA levels in the lesioned as well as in the intact striatum. 
Moreover, idazoxan at therapeutic doses led to a decrease in extracellular DA levels 
in the 6-OHDA-lesioned striatum. In contrast, no reduction of L-DOPA or DA levels 
was found when idazoxan was given at doses which did not alleviate dyskinetic 
movements. Thus, a reduction of L-DOPA and DA levels may contribute to the 
antidyskinetic effect of idazoxan. 
Another objective of my thesis was to focus on the role of the 
glutamatergic/GABAergic system in L-DOPA-induced dyskinesia. In the next study 
(chapter VII: Striatal L-DOPA but not GABA and glutamate is the crucial trigger 
to evoke dyskinetic movements in 6-OHDA-lesioned rats), I investigated the 
effects of GABA and glutamate on the ability to provoke dyskinesia in rats with 
already established dyskinetic history. Neither GABA nor glutamate did evoke 
dyskinesia after local administration in the striatum, GP as well as substantia nigra 
pars reticulata (SNr). In contrast, local L-DOPA administration in the lesioned 
striatum produced dyskinetic movements. I postulate a site specific action of L-DOPA 
since L-DOPA can provoke dyskinesia in the lesioned striatum but not after local 
administration into the GP or SNr.  
Another approach to reduce dyskinetic movements is based on the concept of 
continuous dopaminergic stimulation (CDS), which takes advantage of the fact that 
continuous stimulation of dopaminergic receptors may be less prone to induce 
dyskinesia. CDS can be achieved by administration of longer-lasting DA agonists, 
which prevent dramatic fluctuations of plasma and brain levels, and L-DOPA or DA 
agonist formulations, which extendedly release the drug. Moreover, CDS may also 
target alleviation of early morning akinesia because of a sustained stimulation of 
dopaminergic receptors during the night. In collaboration with colleagues, I assessed 
the CDS approach using a continuous release formulation of the non-ergoline DA 
agonist pramipexole (PPX) by investigating symptomatic effects of PPX-CR 
(continuous release) in two animal models of Parkinson´s disease (PD) (chapter VIII: 
Continuous dopaminergic stimulation by pramipexole is effective to treat early 
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morning akinesia in animal models of Parkinson’s disease: a pharmacokinetic-
pharmacodynamic study using in vivo microdialysis). I found that PPX-CR 
provides a higher therapeutic benefit than PPX-IR (immediate release) since PPX-CR 
significantly reduced early morning akinesia as well as constantly provided an 
anticataleptic response in vivo. 
Besides the 6-OHDA rat model of dyskinesia, various other rodent models of L-
DOPA-induced dyskinesia such as the L-DOPA-induced hyperactivity model 
following reserpine and transgenic mouse models including the regulator of G-protein 
signaling 9-2 (RGS9-2) knock-out mice and aphakia mice are available (please see 
chapter I for more details). Another mouse model for L-DOPA-induced dyskinesia 
relies on the dopaminergic degeneration using systemic 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP)-treatment followed by chronic administration of L-DOPA. 
Mouse models are more appreciated in the drug discovery process because of lower 
absolute amount of compounds needed. Moreover, mouse models may be more 
valuable for the investigation of basic mechanisms since transgenic mice 
overexpressing or lacking proteins involved in the disease can be used. In 
collaboration with Prof. Anthony Nicholas (University of Alabama at Birmingham; 
USA), the new mouse model of L-DOPA-induced dyskinesia was characterised by 
post mortem neurochemistry studies focusing on the monoamine neurotransmitters 
DA, serotonin (5-HT) and NA including metabolites (chapter IX: Effects of L-DOPA 
on striatal monoamines in mice with L-DOPA-induced hyperactivity). I found 
that there is a unique monoamine profile in the striatum of animals conducive to 
develop dyskinesia. 
Taken together, this thesis demonstrated that the 6-OHDA rat dyskinesia model is a 
valuable and reliable model for both investigating mechanisms underlying L-DOPA-
induced dyskinesia as well as identifying and validating novel drug targets. It is a well 
characterised model from the behavioural as well as molecular and biochemical side. 
The results from the present thesis demonstrate that 1) the neurotransmitter DA is 
instrumental for the manifestation of dyskinesia; 2) the DA-denervated striatum is the 
crucial brain area for L-DOPA-induced dyskinesia and 3) the noradrenergic systemic 
plays a role in dyskinesia, whilst NA can induce dyskinesia and anti-adrenergic drugs 
can alleviate L-DOPA-induced dyskinesia (for summary please see fig. 24). 
Numerous preclinical findings obtained in the 6-OHDA dyskinesia rat model have 
been successfully translated into the clinic (chapter I). However, testing potential drug 
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candidates in the model have to be critically evaluated regarding false 
positive/negative outcome since there are some confounding factors such as 
sedation, motor depressant effects, pharmacokinetic interactions as well as species-
related differences. Considering these issues, the model provides a reliable and good 
opportunity to gain insights into the behavioural and molecular mechanisms 
underlying L-DOPA-induced dyskinesia. At present no antidyskinetic compounds are 
in the market. Only the NMDA antagonist amantadine is off-label used by PD 
patients, but with controversial success. Thus, there is an unmet medical need for the 
treatment of dyskinesia in PD and it is indispensable to focus on the development of 
new therapeutic strategies to limit the burden on PD patients, their families and 
carers. In conclusion, validated animal models, which reliably predict clinical efficacy, 
are essential for the drug discovery process. 
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Fig. 24. Schematic drawing of presynaptic nigrostriatal neurons and postsynaptic GABAergic 
neurons in the healthy (A) and dyskinetic (B) brain.  
(A) In the healthy brain, L-DOPA is decarboxylated via the enzyme AADC to DA in dopaminergic 
nigrostriatal neurons. DA is then stored in synaptic vesicles and released into the extracellular space 
in an activity-dependent manner. DA acts on dopaminergic receptors, which are located on GABAergic 
neurons of the direct and indirect pathway of the basal ganglia loops. The direct pathway comprises 
the DA D1 receptor family consisting of DA D1 and DA D5 receptors. The DA D2 receptor family (D2, D3 
and D4 receptors) are located on GABAergic neurons of the indirect pathway. Release of DA can be 
regulated by DA D2 and D3 autoreceptors, which provide a negative feedback control. Additionally, DA 
can be metabolised by different enzymes such as MAO and COMT (not shown), which further reduce 
the level of DA in the synaptic cleft. 
(B) As PD progresses and L-DOPA-induced dyskinesia arises, dopaminergic neurons of the 
nigrostriatal pathway are more and more lost. Thus, fewer dopaminergic neurons remain to 
decarboxylate L-DOPA. Instead, L-DOPA is decarboxylated to DA in 5-HT neurons, which contain 
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the enzyme AADC as well. This results in an uncontrolled, excessive increase of extracellular DA in 
the DA denervated striatum, since the negative feedback control, normally provided by DA D2 and D3 
autoreceptors, is lost. In addition, 5-HT terminals are hyperactivated caused by depletion of 
endogenous 5-HT because of DA accumulating in the storage vesicles. It is suggested that this 
imbalance between the capacity of the 5-HT neurons to release DA derived by L-DOPA and the lack 
of feedback control mechanisms is the driving force for the induction of dyskinesia. In the present 
thesis, it was shown that dyskinesia can be alleviated by "1 antagonism, "2 antagonism, %1/%2 
antagonism as well as NMDA antagonism. Furthermore, it was demonstrated that local administration 
of L-DOPA, DA and NA delivered into the extracellular space of the striatum (abbreviation in the figure: 
[e]) can provoke dyskinesia. No dyskinesia was observed, when L-DOPA+benserazide was 
administered locally into the striatum, since the conversion of L-DOPA to DA was blocked. 
Furthermore, neither DA metabolites (DOPAC, HVA and 3-MT), GABA nor glutamate evoked 
dyskinetic behaviour. 
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APPENDIX 
Rapid analysis of GABA and glutamate in microdialysis samples using 
high performance liquid chromatography and tandem mass 
spectrometry 
 
ABSTRACT 
A LC-MS/MS method has been established for the rapid and reliable determination of 
GABA and glutamate in brain microdialysates. The microdialysis samples were 
analysed using a HILIC column, which is able to retain the polar amino acid 
neurotransmitters. The mobile phase consisted of a binary gradient elution profile 
comprising 0.1 % formic acid in water and acetonitrile. GABA, glutamate as well as 
the respective internal standards [D6]-GABA and [D5]-glutamate were detected by a 
triple quadrupole mass spectrometer in the positive ESI mode within a running time 
of 3 minutes. The linearity ranged from 1 nM to 10 #M for GABA and 10 nM to 10 #M 
for glutamate. The LOQ was found to be 1 nM for GABA and 10 nM for glutamate 
(injection volume 10 #l). The present LC-MS/MS method was compared to the 
classical method for analysis of GABA and glutamate using HPLC and fluorescence 
detection. Eventually, the feasibility of the LC-MS/MS method was demonstrated 
using in vivo microdialysis in rats by monitoring changes of the extracellular 
concentrations of GABA and glutamate in the GP following stimulation with 
potassium. 
 
 
INTRODUCTION 
GABA and glutamate are the most prominent amino acid neurotransmitters in the 
CNS. The inhibitory neurotransmitter GABA is widely distributed throughout the brain 
and is found in 30-40% of all synapses (van der Zeyden et al. 2008; van der Zeyden 
et al. 2008). GABA arises through decarboxylation of glutamate via the enzyme 
glutamic acid decarboxylase and regulates many neuronal processes. The excitatory 
neurotransmitter glutamate is released by approximately 40% of the synapses in the 
CNS (Coyle and Puttfarcken 1993) and is involved in many aspects of normal brain 
functioning including memory, learning (Hertz 2006) and synaptic plasticity of the 
CNS. Dysfunction of both GABAergic and glutamatergic neurotransmission can result 
in a variety of neurological disorders such as Alzheimer’s disease (Advokat and 
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Pellegrin 1992) and PD (Blandini et al. 1996; Chen and Yung 2004) as well as other 
CNS disorders (Chen and Yung 2004; Meldrum 1994). 
In PD, pathophysiological alterations in the neurotransmitter system of the basal 
ganglia circuits play a key role. The basal ganglia comprise the direct pathway 
projecting from the striatum to the GPi and the SNr as well as the indirect pathway 
connecting the striatum with the GPi/SNr via synaptic projections to the GPe and 
STN (Alexander and Crutcher 1990). In PD, the striatal DA depletion leads to an 
overactivation of the striatopallidal synapse, which contains GABA as a 
neurotransmitter. Our motivation to investigate amino acid neurotransmitters using in 
vivo microdialysis is to study neurochemical alterations in experimental models of 
PD. 
Changes of extracellular GABA and glutamate levels were studied extensively using 
in vivo microdialysis. In vivo microdialysis is a widely used technique to continuously 
monitor alterations of neurotransmitters in the extracellular fluid of the brain. The 
analytical standard technique to measure GABA and glutamate in microdialysates is 
HPLC coupled with fluorescence detection (HPLC-FD) (Ballini et al. 2008; Bianchi et 
al. 1999; Kehr 1998a; Kehr 1998b; Rea et al. 2005) or HPLC-ECD (Kehr 1998b; 
Macinnes and Duty 2008). Especially for the analysis of GABA in microdialysis 
samples, HPLC conditions are critical (Rea et al. 2005). It was observed that some 
unknown peaks of biological origin elute close to the GABA peak and that they 
sometimes cannot be separated from GABA unless keeping very stringent 
requirements as a very long running time of 60 minutes. In addition, some liquid 
chromatography/mass spectrometry (LC-MS) (Ma et al. 1999) and LC-MS/MS 
(Bourcier et al. 2006; Eckstein et al. 2008; Piraud et al. 2003; Song et al. 2005) 
methods have been developed for the analysis of GABA and glutamate in biological 
samples. However, the sensitivity of the latter methods would be insufficient to 
quantify GABA in microdialysates. 
Accordingly, the objective of the present study was to develop a rapid and reliable 
method for the simultaneous quantification of GABA and glutamate in microdialysis 
samples using LC-MS/MS. The linearity, LOQ, reproducibility and accuracy of the 
present method will be presented. Additionally, the present LC-MS/MS method was 
compared to the widely used HPLC-FD analysis of GABA and glutamate. In order to 
demonstrate the feasibility of the LC-MS/MS method we determined alterations of 
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extracellular GABA and glutamate levels in the GP following stimulation with 
potassium using in vivo microdialysis in rats. 
 
 
MATERIALS AND METHODS 
 
Animals 
Please see chapter II “General methodology” page 22. 
 
In vivo microdialysis surgery in the GP 
The in vivo microdialysis surgery in the GP was performed as described in chapter II 
“General methodology” page 23 with minor modifications of the type of guide cannula 
used as well as the coordinates. A intracerebral guide cannula was implanted aiming 
at the GP (MAB 4.9.IC, Microbiotech, Stockholm, Sweden) at the following 
coordinates relative to bregma: AP: - 1.2 mm, ML: + 3.0 mm, DV: - 5.2 mm (from 
skull).  
 
In vivo microdialysis procedure in the GP 
The in vivo microdialysis procedure in the GP was performed as described in chapter 
II “General methodology” page 24 with minor modifications of the type of probe used 
(MAB 4.9.2.Cu, 2 mm membrane length, Microbiotech, Stockholm, Sweden). n = 6 
rats were used for the experiment. The mean of fractions 1 to 4 (0 – 80 min) were 
used for calculation of the basal levels which were regarded as 100 %. During 
fraction 5 (80 -100 min) aCSF containing a high amount of potassium (49.7 mM 
NaCl, 100 mM KCl, 1.2 mM CaCl2, 0.85 mM MgCl2 and 1 mM Na2HPO4, pH 7.0-7.4) 
was perfused for 20 minutes into the GP. The sampling was then continued up to 
fraction 14 (100 – 280 min).  
 
Standard solutions 
As internal standards [D6]-GABA and [D5]-glutamate were used. The internal 
standard stock solutions as well as GABA and glutamate stock solutions were 
prepared separately by dissolving the compounds in LC-MS grade water at a 
concentration of 1 mM. All solutions were subsequently frozen at -80 °C. All further 
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standard and internal standard samples were obtained by diluting the stock solutions 
with aCSF and acetonitrile, respectively. 
 
Sample preparation procedure 
Ten #l of the microdialysis and standard sample, respectively, were diluted with 10 #l 
of internal standard solution (500 nM of [D6]-GABA and [D5]-glutamate in acetonitrile). 
Ten #l of this solution were injected into the LC-MS/MS. 
 
Gradient elution profile 
Mobile phase “A” and “B” consisted of 0.1 % formic acid in water (LC-MS grade) and 
acetonitrile (LC-MS grade), respectively. The gradient elution profile was chosen as 
follows: 0 min: 15 % A (1000 #l/min), 0.10 min: 15 % A (200 #l/min), 1.00 min: 80 % 
A (200 #l/min), 1.50 min: 80 % A (200 #l/min), 1.60 min: 15 % A (200 #l/min), 2.40 
min: 15 % A (200 #l/min), 2.50 min: 15% A (1000 #l/min), 3.00 min: 15 % A (1000 
#l/min). 
 
LC-MS/MS system 
Please see chapter II “General methodology” page 26. Chromatographic retention 
was obtained using a HILIC column (ZIC®-HILIC, 20 x 2.1 mm i.d., 3.5 #m, SeQuant 
AB, Umeå, Sweden) with a pre-microfilter (0.5 #m, Upchurch Scientific, Oak Harbor, 
WA, USA) at 20°C. The column switching valve was set at 0.00 minutes to the waste, 
at 0.70 minutes to the mass spectrometer and at 2.50 minutes to the waste again. 
 
Drugs and chemicals 
Please see chapter II “General methodology” page 26. 
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RESULTS AND DISCUSSION 
 
Optimisation of mass spectrometric conditions 
 
 
Fig. 25. ESI-MS/MS positive ion scanning 
spectra for (A) GABA and (B) glutamate. 
 
Positive ESI generates mostly 
protonated ions ([M+H+]) from molecules 
containing a functional group with the 
potential for ionisation. These ions are 
produced by applying a high voltage to a 
very fine spray of the analyte. GABA and 
glutamate are amino acids, which offer 
an ionisable amine function and can be 
protonated under the present conditions. 
The positive charged molecular ions m/z 
104 and 148 for GABA and glutamate 
were generated, respectively. Using the 
multiple reaction monitoring (MRM) 
mode, several fragment ions were 
generated (Fig. 25). For the 
determination of GABA and glutamate 
three transitions were measured, whilst 
one transition was used for quantification (Table 7). For the internal standards [D6]-
GABA and [D5]-glutamate one transition was selected. The compound specific 
parameters for each transition are shown in Table 7. Mass spectrometric conditions 
were optimised using the flow injection analysis (FIA) program provided by the 
“Quantitative Optimisation” function of the Analyst® software. 
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 Dwell time (ms) 
DP (V) CE (V) CXP (V) 
 
GABA 
    
 104.1-87.1 150 46 15 4 
 104.1-86.1 150 46 15 6 
 104.1-69.2 150 46 23 12 
 
glutamate 
    
 148.1-84.2 150 41 21 6 
 148.1-102.0 150 41 17 8 
 148.1-56.2 150 41 41 2 
 
[D6]-GABA 
    
 110.1-93.0 150 26 15 6 
 
[D5]-glutamate 
    
 153.1-88.1 150 46 23 6 
 
Table 7. Specific parameters of the API 4000™ triple quadrupole mass spectrometer for the 
measured transitions. The transition which is presented in bold was used for quantification. 
 
Due to the high amount of salts in the microdialysis samples, the ionisation source 
can be clogged. Therefore, a switching valve was used to avoid delivering of salts 
into the mass spectrometer and thus increase sensitivity.  
Stable deuterated internal standards for both amino acids were used. Hence, a 
compensation of potentially confounding matrix effects is obtained by using 
deuterated internal standards achieving a reliable quantification of the analytes. We 
chose the internal standards in a concentration range (500 nM), in which they do not 
interfere with the quantification of the analytes.  
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Optimisation of chromatographic conditions 
GABA and glutamate are not retainable in a simple fashion on reversed phased 
columns due to their high polarity. Classically, the retention time can be increased by 
using ion pairing reagents or derivatisation procedures. The usage of ion pairing 
reagents in LC-MS/MS methods is limited due to the fact that most of the reagents 
are not volatile. Therefore, we chose a HILIC column, which is suitable for the 
retention and separation of very polar and hydrophilic compounds. The zwitterionic 
sulfobetain ZIC®-HILIC stationary phase is covalently attached to porous silica. 
Within this stationary phase, water is bound in a liquid layer and the polar analyte is 
distributed in this water enriched compartment. Factors which are responsible for the 
retention of the analytes are both hydrogen bonding and dipole-dipole interactions. 
Hence, at least 3% water should be included in the mobile phase in order to hydrate 
the stationary phase sufficiently. Accordingly, a higher concentration of organic 
solvent in the mobile phase increases the retention time of the hydrophilic analytes. 
Using the HILIC column it was possible to develop a method for the analysis of 
GABA and glutamate without a derivatisation step. Furthermore, the mobile phase 
consisted only of the solvents 0.1 % formic acid in water and acetonitrile, which are 
commonly used for LC-MS/MS. 
During the method development, different flow rates were applied and it was found 
that especially the sensitivity of glutamate depends on the flow rate. The sensitivity 
was the higher, the lower the flow rate was. Therefore, we decided to use a low flow 
rate of 200 #l/min. However, we applied a higher flow rate of 1000 #l/min at the end 
of the run to equilibrate the system faster.  
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Linearity, LOQ, reproducibility and accuracy 
 
Fig. 26. Representative chromatograms of a standard sample: (A) GABA (1 nM); (B) [D6]-GABA 
(500 nM); (C) glutamate (10 nM) and (D) [D5]-glutamate (500 nM). 
 
Linearity was given in the tested range of 1 nM to 10 #M for GABA and 10 nM to 10 
#M for glutamate. The calibration curve was analysed with a weighting of 1/x2. Over 
the considered range of concentrations a correlation coefficient of 0.9981 for GABA 
and 0.9940 for glutamate was obtained. The LOQ for GABA and glutamate was 1 
and 10 nM (injection volume 10 #l), respectively, with a signal-to-noise ratio of 10:1 
(Fig. 26). The intra- and inter-batch reproducibility was measured using a GABA and 
glutamate concentration of 50 nM and 500 nM, respectively. The intra-batch 
reproducibility for 10 repeat injections was 2.7 % (R.SD) for GABA and 4.0 % (R.SD) 
for glutamate. The accuracy for GABA and glutamate was 112.2 ± 3.2 % (mean ± 
SD) and 102.7 ± 4.0 % (mean ± SD), respectively. The inter-batch reproducibility for 
10 repeat injections in 4 batches was found to be 5.0 % (R.SD) and 5.3 % (R.SD) for 
GABA and glutamate, respectively. 
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In vivo GABA and glutamate monitoring of microdialysis samples 
 
Fig. 27. Chromatograms of a basal microdialysis sample from the GP: (A) GABA (12.8 nM) and 
(B) glutamate (201.0 nM). 
 
In order to demonstrate the feasibility of the present LC-MS/MS method, GABA and 
glutamate levels were monitored via the in vivo microdialysis technique in freely 
moving rats. Alterations of extracellular GABA and glutamate levels were measured 
in the GP following stimulation with potassium to depolarize neurons and facilitate 
neurotransmitter release. Stimulation with a high concentration of potassium is known 
to primarily release amino acid neurotransmitters from neuronal tissue but also from 
non neuronal sources such as glia (Timmerman and Westerink 1997). Fig. 27 shows 
representative chromatograms of the basal levels of GABA and glutamate in the GP. 
The basal levels were found to be 12.72 ± 1.31 nM (mean ± SEM) and 189.02 ± 
14.76 nM (mean ± SEM) for GABA and glutamate, respectively. These results are 
consistent with previous studies, in which the basal levels of GABA and glutamate in 
the GP ranged from 12 to 48 nM and 100 to 650 nM, respectively (Mela et al. 2007; 
Windels et al. 2005; Ochi et al. 2004; Grimm and See 2000). Stimulation with 
potassium enriched aCSF resulted in a 14- and 8-fold increase in extracellular GABA 
and glutamate levels, respectively (Fig. 28). 
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Fig. 28. Time course of potassium-
evoked (A) GABA and (B) glutamate 
release in the GP (n = 6). From time 
point 80 – 100 min, the aCSF was 
switched to the potassium enriched aCSF 
to stimulate neurotransmitter release. 
Data are presented as mean ± SEM 
 
To date, the most common 
method for the detection of GABA 
and glutamate in microdialysates 
is HPLC-FD (Ballini et al. 2008; 
Bianchi et al. 1999; Kehr 1998a; 
Kehr 1998b; Rea et al. 2005) or 
more rarely HPLC-ECD (Kehr 
1998b; Macinnes and Duty 2008). 
Amino acids are polar molecules 
which offer low affinity for 
reversed phase columns. Its 
hydrophobic character and 
molecular size can be increased by a precolumn derivatisation mostly with the o-
phthaldialdehyde/mercaptoethanol (OPA) reagent (Lindroth and Mopper 1979; 
Tossman et al. 1983). Subsequently, the amino acid/OPA derivative can be analysed 
by FD or ECD. To verify the present LC-MS/MS method, a HPLC-FD method was 
applied for the analysis of GABA and glutamate (Fig. 29).  
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Fig. 29. Chromatograms of the same standard sample containing GABA (100 nM) and 
glutamate (100 nM) analysed with (A) HPLC-FD (mobile phase: binary gradient elution profile 
comprising 0.1 M sodium acetate buffer (pH 6.95) and methanol; flow rate : 1.0 ml/min; reversed-
phase column: Nucleosil 120 C18, 60 x 4.0 mm i.d., 5 #m, (MZ Analysentechnik, Mainz, Germany); 30 
°C), (B) LC-MS/MS (GABA) and (C) LC-MS/MS (glutamate). 
 
A chromatographic separation of GABA and glutamate in standard samples was 
achieved within 20 minutes. The LOQ of the HPLC-FD method was found to be 5 nM 
for both GABA and glutamate (injection volume 10#l), which is in the same range as 
the LOQ of the present LC-MS/MS method. However, the HPLC-FD method requires 
a precolumn derivatisation and is more time-consuming due to the 7-fold longer 
running time. Moreover, GABA in microdialysis samples of the GP could not be 
reliably analysed with the HPLC-FD since unknown peaks of biological origin coelute 
with GABA in some of the samples. Other groups have also demonstrated previously 
that HPLC conditions for the analysis of GABA in microdialysates are critical (Rea et 
al. 2005). They described that discrepancies concerning basal extracellular levels of 
GABA in the same brain region as well as effects of pharmacological compounds 
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may be due to the difficult chromatographic separation of GABA using HPLC. 
However, under optimised conditions as keeping an exact pH value of the mobile 
phase (5.26 ± 0.01) and extending the retention time up to 60 minutes, GABA can be 
reliably separated from unknown peaks of biological origin and subsequently 
quantified. The present LC-MS/MS method does not require such prerequisites, it is 
rather a rapid method, which allows detection of the analytes in a short running time 
of 3 minutes. Moreover, pre-treatment of the samples is not required due to the 
usage of HILIC columns which allows separating the polar analytes from the matrix. 
In addition, the LC-MS/MS technique provides superior selectivity. Indeed, a triple 
quadrupole MS operating in the MRM mode offers an additional dimension of 
selectivity due to the monitoring of specific fragments. Thus, the analytes are 
identified not only by the retention time but also by the interplay of characteristic 
product ions indicated by their molecular weight. 
An alternative method used for the analysis of GABA and glutamate out of 
microdialysates involves capillary electrophoresis with laser-induced fluorescence 
detection (Sauvinet et al. 2003). Neurotransmitters are tagged with the fluorogene 
agent naphthaline-2,3-dicarboxaldehyde and separated within 10 minutes by micellar 
electrokinetic chromatography followed by detection with laser-induced fluorescence. 
The limit of detection (LOD) was found to be 3 nM and 15 nM for GABA and 
glutamate, respectively.  
A new technique was developed for the detection of glutamate by implantation of 
ceramic-based multisite microelectrodes achieving a LOD of 500 nM (Burmeister et 
al. 2002). Recently, an enzyme-based microelectrode array with fast response time 
and low detection limits for glutamate has been developed (Hascup et al. 2008). 
Additionally, a novel biosensor based on quartz crystal microbalance for the analysis 
of GABA was designed with an LOD of 42 #M (Wang and Muthuswamy 2008). 
GABA and glutamate levels in biological samples have been measured previously 
using LC-MS (Ma et al. 1999) and LC-MS/MS (Bourcier et al. 2006; Eckstein et al. 
2008; Piraud et al. 2003; Song et al. 2005). However, most of these methods require 
ion-pairing or ion-exchange techniques or usage of derivatisation reagents, which 
display a complex and time-consuming procedure. These prerequisites are 
necessary since the amino acids are very hydrophilic and are retained poorly on a 
reversed phase column. Ma et al. (1999) investigated GABA and glutamate in rat 
brain tissue using atmospheric pressure chemical ionization LC-MS. Preparation of 
Appendix 
 138 
the sample was performed using a cation-exchange column and a subsequent 
evaporation step. The LOD for GABA and glutamate were 2.5 #g/ml (= 24 #M) and 
5.0 #g/ml (= 34 #M), respectively. Song et al. (2005) developed a capillary LC-
MS/MS method for quantification of GABA in human plasma and CSF. Prior to the 
separation, a time-consuming pre-treatment of the sample was performed by 
derivatisation with the reagent 7-fluoro-4-nitrobenzoxadiazole and a clean-up and 
concentration step on an extraction column. Using this method a LOD of 5 ng/ml (= 
48 nM) was achieved. Recently, Eckstein et al. (2008) analysed GABA and 
glutamate levels in CSF using positive ESI LC-MS/MS. In this study, 
heptafluorobutyric acid as ion-pairing agent was used. For both GABA and glutamate 
a LOQ of 7.8 ng/ml (= 75 nM for GABA, 53 nM for glutamate) was achieved. Zhang 
et al. (2007) developed a capillary LC-MS/MS method for the determination of 6 
neurotransmitters including GABA and glutamate in the extracellular brain fluid of 
monkeys obtained by the push-pull sampling method. Using a fused-silica capillary 
tubing (200 #m, i.d.) packed with polyhydroxyethyl aspartamide particles as HILIC 
stationary phase, a running time of 26 minutes including reconditioning was required. 
The LOD (signal-to-noise ratio 3:1) for GABA and glutamate was reported to be 4 nM 
and 20 nM, respectively, and the linearity ranged from 20 – 4000 nM for GABA and 
from 100 – 100000 nM for glutamate.  
Obviously, the latter methods are applicable for brain tissue, plasma, CSF and push-
pull samples, but insufficient to quantify basal GABA concentrations in microdialysis 
samples of the GP. In contrast, the LOQ (signal-to-noise ratio 10:1) in the LC-MS/MS 
method presented here was found to be 1 nM for GABA and 10 nM for glutamate 
requiring a volume of 10 #l of the microdialysate. Taking advantage of this method, a 
higher time resolution for the microdialysis experiment may be achieved due to the 
requirement of lower sample volumes and thus shorter sampling intervals are 
allowed. 
 
 
CONCLUSION 
A rapid and reliable LC-MS/MS method was developed for the simultaneous 
quantification of GABA and glutamate in brain microdialysates. The present method 
has several advantages compared to previously reported methods as it provides 
superior sensitivity, no sample pre-treatment and a very short running time of 3 
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minutes. Moreover, in comparison to the widely used HPLC-FD as well as the HPLC-
ECD analysis the selectivity is higher in the present LC-MS/MS method. The assay 
achieves a LOQ of 1 nM for GABA and 10 nM for glutamate (injection volume 10 #l), 
which is sensitive to quantify extracellular levels of GABA and glutamate in 
microdialysis samples of the GP. 
 
This study was performed together with Patrizia Voehringer. I developed the method and 
performed the in vivo studies. Patrizia Voehringer conducted reproducibility, accuracy and 
linearity measurements as well as helped with preparation of the manuscript. 
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LIST OF ABBREVIATIONS 
 
3-MT 3-methoxytyramine 
5-HIAA 5-hydroxyindoleacetic acid 
5-HT serotonin 
6-OHDA 6-hydroxydopamine 
AADC aromatic amino acid decarboxylase 
aCSF artificial cerebrospinal fluid 
ANOVA analysis of variance 
AUC area under the curve 
CD carbidopa 
CDS continuous dopaminergic stimulation 
CE collision energy 
COMT catechol-O-methyltransferase 
CR continuous release 
CSF Cerebrospinal fluid 
CXP cell exit potential 
DA dopamine 
DBH dopamine beta hydroxylase 
DBS deep brain stimulation 
DIMPEA 3,4-dimethoxyphenylethylamine 
DOPAC 3,4-dihydroxyphenylacetic acid 
DP declustering potential 
ECD electrochemical detection 
ESI electrospray ionisation 
FD fluorescence detection 
GABA gamma aminobutyric acid 
GP globus pallidus 
GPe globus pallidus externus 
GPi globus pallidus internus 
HEAT (2-[[#-(-4-hydroxyphenyl)ethyl]aminomethyl]-1-tetralone) 
HILIC hydrophilic interaction liquid chromatography 
HPLC high performance liquid chromatography 
HVA 4-hydroxy-3-methoxy-phenylacetic acid 
List of abbreviations 
 141 
IR immediate release 
LC-MS liquid chromatography/mass spectrometry 
LC-MS/MS liquid chromatography/tandem mass spectrometry 
L-DOPA L-3,4-dihydroxyphenylalanine 
LOD limit of detection 
LOQ limit of quantitation 
LPS lipopolysaccharide 
MAO monoaminoxidase 
MFB medial forebrain bundle 
MHPG 3-methoxy-4- hydroxyphenylglycol 
MPEP 2-methyl-6-(phenylethynyl)-pyridine 
MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
MRM multiple reaction monitoring 
MTEP 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine 
NA noradrenaline 
NMDA N-methyl-D-aspartate 
OPA o-phthaldialdehyde/mercaptoethanol 
PCA principal component analysis 
PD Parkinson’s disease 
PPX pramipexole 
rAAV recombinant adeno-associated viruses 
RGS9-2 regulator of G-protein signaling 9-2 
SNc substantia nigra pars compacta 
STN subthalamic nucleus 
UPDRS Unified Parkinson’s Disease Rating Scale 
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